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Major depressive disorder (MDD) is a growing health problem. Current treatment options 
are not always effective and take several weeks of regular administration before an 
improvement can be seen in symptoms. Sub-anaesthetic doses of ketamine have been found 
to have antidepressant effects in previously treatment-resistant MDD after just one dose. 
However, ketamine also produces short term psychosis-like side effects which are 
undesirable for MDD patients. Ketamine is known to be an NMDA receptor antagonist, 
binding within the channel pore to block ion flow, however the molecular mechanism(s) 
underlying its antidepressant and psychosis-like effects are still unclear.  
In this thesis several genetically modified mouse lines were used to probe the molecular 
events involved in ketamine’s actions. Firstly, a mouse line in which the c-terminal domain 
(CTD) of the NMDAR subtype GluN2B had been replaced with that of GluN2A, and a second 
line in which the opposite replacement had taken place, were used to investigate the role of 
the CTD in the NMDAR response to ketamine. It was found that the GluN2B CTD is required 
for the short-term psychosis-like response to a sub-anaesthetic dose of ketamine. This is 
interesting as the channel pore region, containing the binding site for ketamine, is unaltered 
in these mutants. Therefore, this finding implicates GluN2B CTD specific intracellular 
signalling molecules in this action of ketamine and raises the question of whether the CTD 
itself is able to respond to ketamine binding within the pore to induce signalling changes, 
perhaps via a conformational change.  
Secondly, a mouse line, in which the activity-regulated synaptic protein Arc has been tagged 
with a fluorescent marker, was used to investigate the response of synapses to both 
anaesthetic and sub-anaesthetic doses of ketamine. In this experiment tagged Arc protein 
was visible as punctate accumulations at synapses. A novel method termed ‘synaptome 
mapping’ was used to image these accumulations across entire coronal sections and to 
quantify their number, size and intensity. Using this method alterations to the Arc synaptome 
map were detected 1h, 6h and 24h following ketamine administration. The two doses used 
produced different changes to this map, with the sub-anaesthetic antidepressant dose 
inducing increases in Arc puncta number across many brain regions, whereas the anaesthetic 
dose induced short term (1h) increases followed by longer term decreases in Arc puncta 
number. This finding links long-term increases in Arc at the synapse with an antidepressant 






Depression is an illness that affects many people across the globe. Unfortunately, the current 
treatments are not effective for everyone, they also take several weeks of repeat dosing 
before they begin to work. Ketamine has been found to have antidepressant effects in these 
previously treatment resistant patients and is effective after just one dose. Ketamine is an 
anaesthetic used for various surgical procedures, however, it is specifically low sub-
anaesthetic doses which have an antidepressant effect. Ketamine has undesirable psychosis-
like side effects which make it unsuitable for use in depressed patients. Therefore, it is 
important to understand exactly how ketamine is acting on the brain to produce these 
different effects, in order to design drugs which can be antidepressant without the harmful 
side effects. The experiments described in this thesis identified two new aspects of 
ketamine’s action at the connections between brain cells (synapses), which may be helpful 
for this future drug development. The first of these is that low antidepressant doses of 
ketamine induce increases in the amount of a protein called Arc at synapses. However, high 
non-antidepressant doses induce a reduction in Arc. This suggests that Arc may contribute to 
the antidepressant response, and that in the long-term targeting Arc may be a way to induce 
an antidepressant response. Ketamine is known to bind to and block a receptor, called the 
NMDA receptor, which is present at synapses. However, it is unclear how ketamine binding 
to this receptor is able to induce an antidepressant response. The experiments described in 
this thesis also found that a specific part of that receptor is responsible for the psychosis-like 
effects of ketamine. This is the part of the receptor which is responsible for linking to 
signalling inside the cell. The next step for this research will be to find out if the same part of 
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Chapter 1 Introduction  
 6 
1.1 The Glutamatergic synapse and the NMDA receptor  
1.1.1 Synaptic transmission 
The human brain contains approximately 86 billion neurons (Azevedo et al., 2009) that 
communicate with each other via many more synaptic connections to form large, complex 
networks. Anatomically, the synapse consists of an axonal terminal of a pre-synaptic neuron, 
juxtaposed with a dendritic spine of a post-synaptic neuron. The two are separated by a gap 
of ~20nm (Brady et al., 2005), known as the synaptic cleft. When an electrical impulse 
travelling along the axon reaches the pre-synaptic terminal it induces the release of 
neurotransmitters, which travel across the synaptic cleft and bind to receptors on the post-
synaptic membrane. The binding of these neurotransmitters either increases (excitatory 
synapses) or decreases (inhibitory synapses) the likelihood of an action potential firing in the 
post-synaptic cell, depending on the identity of the neurotransmitters involved. The area of 
the post-synaptic plasma membrane bordering the synaptic cleft is specialised for the 
purpose of responding to these neurotransmitters and contains a concentration of 
scaffolding, signalling and receptor molecules, forming an electron dense area termed the 
post-synaptic density (PSD). Glutamate is the most common excitatory neurotransmitter in 
the nervous system. Levels of glutamate are constitutively low in the extracellular space due 
to the precise regulation of release and reuptake. Release of glutamate from the pre-synaptic 
terminal, in response to depolarisation, results in a rapid increase in glutamate concentration 
in the synaptic cleft (Herman & Jahr, 2007; Herman et al., 2011). This glutamate binds to 
ionotropic glutamate receptors, such as the N-methyl-D-aspartate (NMDA) receptor and α-
amino-3-hydroxy-5-methyl-4-isoxzoleproponic acid (AMPA) receptor, positioned on the 
post-synaptic membrane. The subsequent opening of these ion channels allows an influx of 
cations into the cell, resulting in the temporary depolarisation of post synaptic membrane 
potential. These excitatory postsynaptic potentials (EPSPs) increase the probability that the 
postsynaptic cell will fire an action potential.  
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Figure 1 - The glutamatergic synapse  
A synapse is the connection between neurons in which the axon terminal of a pre-synaptic 
neuron (blue) is proximal to the dendritic spine of a post-synaptic neuron (grey). At a 
glutamatergic synapse the neurotransmitter glutamate is released from the pre-synaptic 
terminal in response to the arrival of an action potential at the axon terminal. Glutamate then 
binds to AMPA and NMDA receptors present on the post-synaptic membrane to increase ion 
flow leading to depolarisation of the post-synaptic neuron. The post-synaptic density (dark 
grey) borders the synaptic cleft.   
1.1.2 Synaptic plasticity  
The strength of synaptic connections is highly dynamic. A short period of high frequency 
stimulation has been found to induce a sustained (hours to days) increase in synaptic 
strength (Bliss & Lomo, 1973). This is termed long-term potentiation (LTP) and is now known 
to result from an increase in AMPA receptor delivery to the postsynaptic membrane, 
alongside structural changes to the dendritic spine, which both increase the probability that 
the postsynaptic cell will fire an action potential in response to glutamate signalling. 
Conversely, it was found that a period of low frequency stimulation can induce a long-term 
depression (LTD) of synaptic strength. Since the identification of these forms of synaptic 
plasticity, a popular view has been that this relative strengthening and weakening of synaptic 
connections drives the modification of neuronal networks underlying learning and memory 
processes. The maintenance of both LTP and LTD requires synthesis of new proteins (Stanton 
& Sarvey, 1984; Frey et al., 1988; Kauderer & Kandel, 2000), and although many candidate 
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effector molecules have been identified, many of the mechanisms underlying synaptic 
plasticity are still to be elucidated.  
1.1.3 The NMDA receptor  
As mentioned in section 1.1.1, the N-Methyl-D-aspartate receptor (NMDAR) is a glutamate-
gated cation channel essential for synaptic transmission at excitatory glutamatergic 
synapses. A unique characteristic of the NMDA receptor is the presence of a voltage-
dependent Mg2+ block which must be removed by membrane depolarisation of sufficient 
amplitude and duration before channel opening can take place (Mayer et al., 1984; Nowak 
et al., 1984). This means that NMDA receptors do not contribute significantly to an EPSP 
evoked by a single impulse, as the amplitude and duration of depolarisation is not usually 
significant enough to remove the Mg+ block, that kind of fast synaptic transmission is 
mediated by AMPA receptors. Although there is at least one report of single synaptic events 
being sufficient to open the NMDAR (Emptage et al., 1999). Multiple impulses in quick 
succession can increase the amplitude and duration of depolarisation and thus the likelihood 
of NMDAR activation. Therefore, the NMDAR has been considered a molecular ‘coincidence 
detector’, activating only if glutamate is released from a pre-synaptic terminal when there is 
also sufficient activation of the post-synaptic cell to remove the Mg+ block. NMDA receptors 
also require the binding of a co-agonist Glycine, along with Glutamate, for activation 
(Johnson & Ascher, 1987; Patneau & Mayer, 1990; Clements & Westbrook, 1991). This 
‘coincidence detector’ characteristic of NMDAR action forms the molecular basis for the 
paradigm of LTP at synapses. The high Ca2+ permeability of NMDARs, as compared with AMPA 
and kainite receptors (Mayer & Westbrook, 1987),  means that channel opening induces an 
increase in subcellular calcium levels. This activates a host of intracellular signalling cascades, 
one result of which is LTP-related enhancement of AMPA receptor phosphorylation and 
trafficking to the postsynaptic membrane. In addition to this, an NMDAR-dependent form of 
LTD has also been observed (Thiels et al., 1996).  
1.1.4 NMDA receptor structure 
The NMDAR is a heteromer with subunits consisting of four domains, illustrated in figure 2. 
The n-terminal domain (NTD) contributes to the assembly of subunits and allosteric 
regulation through interactions with molecules such as Zn2+ (Paoletti et al., 2000) or 
ifenprodil (Williams, 1993). The ligand binding domain (LBD) is proximal to the membrane 
and contains binding sites for either Glycine, or Glutamate depending on the subunit type 
(discussed in section 1.1.5). The transmembrane domain (TMD) forms the ion channel pore 
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and consists of three transmembrane helices and a re-entrant loop which lines the pore itself. 
This loop contains asparagine residues that are essential for Ca2+ selectivity and Mg+ block 
(Burnashev et al., 1992). The c-terminal domain (CTD) is involved in guiding receptor 
trafficking and coupling receptors to specific intracellular signalling and scaffolding molecules 
(Ryan et al., 2008; Horak & Wenthold, 2009; Frank et al., 2016).  
 
Figure 2 - Structural domains of the NMDA receptor.  
NTD = N-terminal domain; LBD = Ligand-binding domain; TMD = Transmembrane domain; 
CTD = C-terminal domain; Gly = Glycine; Glu = Glutamate.  
1.1.5 NMDA receptor subtypes  
There are different subtypes of NMDA receptor subunits, which contribute different 
functional characteristics to the assembled receptor, these are discussed below and 
summarised in table 1. The presence of a GluN1 subunit is essential for receptor assembly 
and these can combine with either GluN2A-D or GluN3A-B subunits to form a heteromer. The 
GluN1 subunit family is encoded by a single gene, which can be alternatively spliced to create 
up to 8 variants (Sugihara et al., 1992; Laurie & Seeburg, 1994; Zukin & Bennett, 1995). The 
obligatory GluN1 subunit contains the glycine binding site and is essential for receptor 
assembly and function (Ishii et al., 1993; Scott et al., 2001). There are four GluN2 subunit 
subtypes (A-D), which contain glutamate binding sites (Laube et al., 1997; Anson et al., 1998). 
These subtypes arise from separate genes (Monyer et al., 1992) and their identity has a 
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critical effect on the functional properties of the receptor. Each of the four different GluN2 
subtypes has a distinct regional expression pattern within the adult brain. GluN2A is 
ubiquitously expressed across all brain regions, whereas GluN2B expression is restricted to 
forebrain only. GluN2C is only found in cerebellum and olfactory bulbs. GluN2D is expressed 
at low levels, mainly in the diencephalon and telencephalon. (Watanabe et al., 1992; Ishii et 
al., 1993; Monyer et al., 1994). The canonical NMDAR contains two GluN1 subunits and two 
GluN2 subunits, most commonly GluN2A or GluN2B. However, tri-heterometic receptors 
containing two different subtypes of GluN2 have also been identified at the synapse in vivo 
(Tovar et al., 2013; Hansen et al., 2014). In the adult brain the GluN2A and 2B subtypes are 
the most widely and highly expressed (Watanabe et al., 1992), and have therefore been the 
most thoroughly studied to date. The CTD is the most divergent domain between the 
different GluN2 subtypes (Ryan et al., 2008), enabling them to interact with discrete sets of 
intracellular signalling molecules. This includes the subtype-specific interactions between the 
GluN2B CTD and CaMKII, RasGFR1 and SynGAP (Leonard et al., 1999; Strack et al., 2000; 
Krapivinsky et al., 2003; Kim et al., 2005). All three of these molecules are Ca2+ sensitive and 
are involved in plasticity-related changes (Lu et al., 2010; Kristensen et al., 2011). This 
interaction between CaMKII and GluN2B CTD is essential for LTP, suggesting that proximity 
Figure 3 – Dotplot showing sequence homology between GluN2A and GluN2B subunits.  
The amino acid sequences of the GluN2A subunit and the GluN2B subunit are compared 
along the vertical and horizontal axis, respectively. Areas of sequence similarity are denoted 
by dots. The same amino acid in the same position in both subunits appears as a dot along 
a diagonal line stretching from top left to bottom right of the dotplot. High levels of sequence 
homology between GluN2A and GluN2B can be observed in the extracellular domain and the 
membrane spanning region, in contrast there is divergence between the two subtypes in the 
cytoplasmic tail region. Figure courtesy of Dr Noboru Komiyama, reproduced with 
permission.  
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to the NMDAR is important for CaMKII activation (Sanhueza et al., 2011). There are also 
differences between the NTDs of GluN2 subtypes, allowing a degree of subtype specific 
allosteric modulation, which has been used experimentally. For example the ifenprodil family 
of molecules are selective antagonists at GluN2B-containing receptors (Williams, 1993). 
GluN2A subunits on the other hand, are much more sensitive to blockade of extracellular 
Zn2+ than GluN2B-containing receptors (Paoletti et al., 1997). In addition to this, GluN2 
subtypes have differing channel conductance properties. GluN2A and 2B display high 
conductance channel openings (50pS) with a high Ca2+ permeability and sensitivity to Mg+, 
whereas GluN2C and 2D have a lower conductance (20/40pS), Ca2+ permeability and Mg+ 
sensitivity (Monyer et al., 1992; Kuner & Schoepfer, 1996; Schneggenburger, 1996). Subtypes 
also differ in deactivation speed, with the GluN2A subtype having much faster deactivation 
than GluN2B, 2C and 2D (Vicini et al., 1998; Wyllie et al., 1998; Gray et al., 2011).  
 GluN2A GluN2B GluN2C GluN2D 
Expression 
pattern 
Ubiquitous  Forebrain  Cerebellum and 





Conductance  high high low low 
Ca2+ 
permeability  
high high low low 




Table 1 - Summary of characteristics of NMDA receptor subtypes. 
Given these differing properties it can be assumed that different GluN2 subtypes may be 
involved in different cellular functions. For example, selective blockade of GluN2B-containing 
receptors with ifenprodil or Ro 25-6981 has been found to abolish induction of LTD but not 
LTP, suggesting that LTP may be mediated specifically by GluN2A-containing receptors (Liu et 
al., 2004; Massey et al., 2004). Indeed, there is evidence that the c-terminal domain of 
GluN2A is required for LTP (Kohr et al., 2003). However, another report found no impairment 
of LTP by GluN2B- or GluN2A- specific antagonists (Berberich et al., 2005). In addition, 
GluN2B upregulation has been found to enhance LTP (Tang et al., 1999), and intact LTP has 
been observed in GluN2A knockout mice, although this could be a compensatory action 
(Kiyama et al., 1998; Weitlauf et al., 2005). The potential GluN2 subtype-specificity of LTP 
therefore remains an area of debate, with some concerns about the validity of the 
pharmacological tools being used to selectively block subtypes (Neyton & Paoletti, 2006).  
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A popular view has been that GluN2A-containing receptors are localised at synapses, 
whereas GuN2B-containing receptors are more likely to be found at extra-synaptic sites. This 
is based on experiments in cultured neurons, in which EPSCs were taken as a measure of 
synaptic receptor activity, and whole cell currents used to measure activity of extrasynaptic 
receptors. It was found that block of EPSCs by the GluN2B-specific antagonist ifenprodil was 
less than the block of whole cell currents. This suggests that the extrasynaptic receptor 
population is enriched with GluN2B-containing receptors (Tovar & Westbrook, 1999; Martel 
et al., 2009). Similar findings have been reported in rat cortical slices (Stocca & Vicini, 1998). 
However, the idea of GluN2B receptors being restricted to extrasynaptic sites is an 
oversimplification, as there is significant evidence to suggest a functional population of 
GluN2B receptors at the synapse (Thomas et al., 2006; Harris & Pettit, 2007; Gray et al., 2011; 
Rauner & Kohr, 2011). For example, when defining synaptic and extrasynaptic NMDAR 
populations as those that do, or do not, respond to low frequency (0.1Hz) synaptic events 
respectively, no enrichment of GluN2B receptors in the extracellular compartment was 
observed (Chen & Diamond, 2002; Clark & Cull-Candy, 2002; Harris & Pettit, 2007). In 
addition to this, ESPCs are intact in neurons expressing only GluN1/GluN2B-containing 
receptors (Thomas et al., 2006). There is also a third family of GluN3 NMDA receptor 
subunits, which consists of the GluN3A & 3B subtypes (Ciabarra et al., 1995; Chatterton et 
al., 2002). Although these are much rarer than GluN1 & 2, there is a growing body of work 
investigating their influence on synaptic maturation and pruning (Perez-Otano et al., 2016).  
1.1.6 Putative metabotropic action of the NMDAR 
The importance of the CTD in NMDA receptor function is highlighted by the finding that 
animals with a truncation of the GluN2A, 2B or 2C CTD have an identical phenotype to 
animals with complete deletion of the corresponding subunit, despite the ability to form 
synaptically activated NMDAR channels being preserved (Sprengel et al., 1998). It is clear that 
the CTD provides specific binding sites for signalling molecules responding to the influx of 
Ca2+ following channel opening, however, there is also some evidence to suggest that the 
CTD itself may respond to agonist binding by changing conformation. This would suggest the 
NMDAR has the potential for metabotropic function. Evidence for this comes from the 
observation that LTD is still inducible by low-frequency stimulation (LFS) during blockade of 
the NMDAR ion channel by MK-801. Whereas preventing binding of Glutamate with D-APV 
prevented induction of LTD (Nabavi et al., 2013). Ion flux-independent NMDAR-dependent 
LTD has also been described elsewhere (Stein et al., 2015; Carter & Jahr, 2016). In addition 
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to this, alterations in FRET efficiency between the CTDs of two GluN1 subunits, indicates that 
in the absence of ion flux there is conformational change of the CTD in response to agonist 
binding (Dore et al., 2015; Ferreira et al., 2017).  
1.1.7 The post-synaptic density and NMDA receptor supercomplexes 
It is important to remember that the NMDA receptor is not acting alone at the post-synaptic 
membrane but that it is interacting with many intracellular signalling and scaffolding 
molecules within the post-synaptic density (PSD) (Husi et al., 2000; Husi & Grant, 2001). The 
PSD appears as an electron dense region of plasma membrane situated at the post-synaptic 
side of the synaptic cleft (Gray, 1959). It is thought to facilitate postsynaptic signalling by 
regulating receptor localisation such that specific receptors and intracellular interactors are 
present at the plasma membrane and aligned with the presynaptic active zone, from which 
neurotransmitters are released (Tang et al., 2016). Mutations in PSD proteins cause over 100 
brain diseases (Bayes et al., 2011), highlighting the importance of this structure for normal 
brain function.  Although postsynaptic specialisations are present at both excitatory and 
inhibitory synapses, the PSD of excitatory synapses is particularly complex. Mass 
spectrometry of purified PSD preparations has identified between ~400 and ~2000 different 
proteins present in this structure (Peng et al., 2004; Yoshimura et al., 2004; Collins et al., 
2006; Trinidad et al., 2008; Bayes et al., 2011). These include a diverse range of different 
molecules including scaffolding proteins, receptors and channels, cytoskeletal elements, cell 
adhesion molecules and intracellular signalling enzymes (Peng et al., 2004). The most 
abundant of these are CaMKIIa and CaMKIIB, followed by members of the PSD-95 MAGUK 
family of scaffold molecules and SynGAP, which binds to PSD95. There is also a significant 
population of glutamate receptors present, with NMDA receptors being more abundant than 
AMPA receptors (Cheng et al., 2006). It is now known that there are many different subtypes 
of synapse, containing different combinations of these PSD proteins. Given the sheer number 
of proteins present at the PSD this raises the potential for a huge number of different synapse 
types with varying signalling properties. Recent work has confirmed this with large-scale 
mapping of the scaffold proteins PSD95 and SAP102, identifying a huge diversity in synapse 
subtypes across previously defined brain regions. In addition to this, new levels of 
organisation at the level of synapse type were identified within brain regions previously 
thought to be homogenous (Zhu et al., 2018).  
The NMDA receptor is a key structural and functional component of the PSD. The large 
number of other PSD proteins interacting with the NMDA receptor first became apparent in 
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the early 2000s (Husi et al., 2000; Husi & Grant, 2001). NMDA receptor activation also 
changes the phosphorylation status of 127 proteins and 189 phosphopeptides (Coba et al., 
2009). Further work has now demonstrated that NMDA receptors are present at the synapse 
as part of complexes of either ~840kDa or ~1.5MDa. PSD95 and Arc are present in these 
~1.5MDa complexes, which also contain other scaffold proteins, ion channels, trans-synaptic 
adhesion molecules and signalling proteins (Frank et al., 2016). The assembly of these NMDA 
receptor supercomplexes requires the presence of an intact GluN2B CTD in addition to both 
PSD95 and PSD93 (Frank et al., 2016). This is strong evidence that proteins at the PSD are 
assembled into discrete super molecular complexes, rather than one large complex or a more 
diffuse distributed network. Indeed, as part of the same study 60 different proteins were 
probed in mouse forebrain synaptoneurosomes and found to be assembled into complexes 
and supercomplexes of varying sizes, just 13 were also detected in their monomeric form 
(Frank et al., 2016). Further to this, super resolution imaging methods have enabled the 
visualisation of discrete ‘nanoclusters’ of PSD95 molecules assembled within the dendritic 
spine (Broadhead et al., 2016). A contradictory view had been suggested by previous electron 
microscopy (EM) work which identified vertical filaments, thought to be PSD95 family 
molecules, evenly spaced throughout the PSD (Chen et al., 2008). However, in that EM study 
PSD95 family molecules were identified by their general shape rather than specific labelling.  
1.1.8 PSD95 & PSD93 
As mentioned, PSD95 and PSD93 are both essential components of the NMDA receptor 
~1.5MDa complex, present at the PSD. They are both members of the MAGUK family of 
scaffold proteins and interact with numerous synaptic proteins including other MAGUK 
proteins, NMDA receptor subunits, potassium channels and cytoskeletal proteins (Fernandez 
et al., 2009; Guo et al., 2012). The presence of PSD95 is essential for normal synaptic plasticity 
and learning and memory function, as PSD95 mutant mice exhibit enhanced LTP and 
disruption of LTD (Migaud et al., 1998; Carlisle et al., 2008) as well as deficits in spatial 
learning (Migaud et al., 1998). Interestingly, in these animals NMDA receptors are still 
localised to the synapse, suggesting that PSD95 is important for the coupling of the NMDA 
receptor to pathways that control synaptic plasticity, rather than receptor localisation. 
Mutations in the genes for PSD95 (DLG4) and PSD93 (DLG2) have been associated with an 
increased risk of schizophrenia and autism spectrum disorder (Cheng et al., 2006; Walsh et 
al., 2008; Xing et al., 2016). Interestingly, although there is a large degree of homology 
between PSD95 and PSD93, they have distinct roles in cognitive processes. PSD95 is essential 
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even for simple forms of learning, whereas PSD93 is required for more complex cognitive 
processes (Nithianantharajah et al., 2013).   
1.1.9 Summary 
The NMDA receptor acts as a ‘coincidence detector’ at glutamatergic synapses, allowing 
influx of Ca2+ in response to release of glutamate from the pre-synaptic terminal and 
sufficient depolarisation of the post-synaptic membrane. The post-synaptic density is a highly 
complex molecular machine composed of complexes and supercomplexes of many different 
proteins, with many different combinations of these possible. The NMDA receptor is a key 
element of this machine, assembling large supermolecular complexes via the c-terminal 
domain of the GluN2B subunit. These complexes contain many signalling molecules that are 
able to respond to the influx of Ca2+ resulting from glutamatergic signalling at the synapse.   
1.2 Activity-Regulated Cytoskeleton-Associated Protein (ARC/ARG3.1) 
Activity-Regulated Cytoskeleton-Associated protein (Arc), also known as Arg3.1, (hereafter 
referred to as Arc) is a particularly interesting member of the 1.5MDa complexes described 
in section 1.1.8 as it is the product of an immediate early gene, and as such is highly activity-
regulated. The Arc gene is located on chromosome 8 in the human, chromosome 15 in the 
mouse, and is conserved across vertebrate species (Lyford et al., 1995). Arc is expressed 
predominantly in the brain (Link et al., 1995) and is most commonly observed in CaMKII-
positive principal neurons (Vazdarjanova et al., 2006), however Arc protein has also been 
detected in glial cells in the hippocampus (Rodriguez et al., 2008). Its most abundant 
interacting protein is PSD95 (Frank et al., 2016) and the presence of PSD95 seems to be 
essential for the synaptic targeting of Arc protein (Fernandez et.al., 2017). There is evidence 
that Arc mRNA and protein can be specifically targeted to recently-activated synapses 
(Steward et al., 1998). This provides a method by which composition of the PSD can be 
specifically altered in response to highly localised changes in activity. At the synapse Arc is 
thought to alter AMPA receptor endocytosis and F-actin stabilisation, both processes which 
are involved in synaptic plasticity.   
1.2.1 Arc transcription and mRNA transport  
First described in 1995 by two independent research groups, Arc expression was found to be 
dramatically increased in brain following electroconvulsive seizure. This activity-induced 
upregulation was rapid and transient, observed from 30 min to 8 hr post-seizure, and was 
found to be protein synthesis independent (Link et al., 1995; Lyford et al., 1995; Larsen et al., 
2005). These characteristics place Arc as a member of the immediate early gene (IEG) family. 
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This is a group of genes, including c-fos and zif268, which are activated rapidly and transiently 
as a ‘first response’ to many different cellular stimuli (Sheng & Greenberg, 1990). Although, 
in contrast to most IEG products Arc is not a transcription factor and can be classed as an 
‘effector’ IEG, as its product acts directly to induce a cellular response, see section 1.2.3 for 
more information on Arc function. Since those initial seizure experiments carried out in 1995, 
Arc expression has been induced experimentally by a wide variety of stimuli which involve an 
increase in synaptic activity. These include application of bicuculline or removal of TTX in vitro 
(Shepherd et al., 2006), high frequency stimulation (HFS) of the perforant path input into the 
hippocampus (Link et al., 1995), microinfusion of BDNF (Ying et al., 2002) and novel 
environment exploration in vivo (Chawla et al., 2005). The complex sequence of events 
linking synaptic activity to Arc expression is still under investigation. However, Arc 
transcription is induced by activation of NMDARs (Link et al., 1995; Bloomer et al., 2008), 
mGluRs (Waung et al., 2008), and TrkB receptors (Yasuda et al., 2007). Interestingly, 
inhibition of AMPARs is also able to increase the degree of Arc expression induced by BDNF 
(Rao et al., 2006). Downstream of these receptors, activation of the extracellular signal-
regulated kinase (ERK) pathway is required for Arc transcription (Bluthgen et al., 2017), and 
this appears to be a key pathway linking synaptic activity with the activation of transcription 
factors such as CREB and SRF. Several promoter regions, containing response elements for 
activity-induced transcription factors, have been identified upstream of the Arc open reading 
frame (ORF). These include a synaptic activity response element (SARE), located ~7kb 
upstream of Arc, which contains binding sites for the transcription factors serum response 
factor (SRF), myocyte enhancer factor 2 (MEF2) and Ca2+/cAMP-response element binding 
protein (CREB) (Kawashima et al., 2009; Pintchovski et al., 2009). The presence of this SARE 
is both necessary and sufficient for synaptic activity-induced transcription of the Arc gene 
(Kawashima et al., 2009). Activation of CREB, MEF2 and SRF is downstream of Ca2+ influx, via 
ERK signalling in the case of SRF (Esnault et al., 2017), and they have been previously 
identified as neuronal activity sensors (Robertson et al., 1995; Bito et al., 1996; Flavell & 
Greenberg, 2008). There is also a “Zeste-like” element at ~1.4kb upstream of the Arc 
transcription initiation site, which mediates activity-induced transcription in a PKA- and ERK-
dependent manner (Pintchovski et al., 2009). There are an additional two serum response 
elements (SREs) at ~1.5kb and ~0.9kb upstream, respectively. These elements were, in fact, 
the first to be identified, however they were not found to be essential for induction of Arc 
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transcription by calcium and cAMP (Waltereit et al., 2001). See figure 4A for a summary of 
these promoter regions.  
 
Figure 4 - Schematic diagrams of the Arc gene, mRNA and protein domains of interest. 
A. Arc gene showing regulatory elements upstream of the Arc open reading frame (ORF). CRE 
= cAMP response element; MEF2 = ; A2RE = A2 response element (Gao et al., 2008); DTE = 
dendritic targeting element; B. Arc mRNA showing identified functional regions. DTE = 
Dendritic targeting element; C. Arc protein showing key regions. Arc protein is 396aa in size. 
NRS = nuclear retention sequence; NES = nuclear export sequence; NLS = nuclear localisation 
sequence. Adapted from (Bramham et al., 2010). 
Transcription of the Arc gene results in the production of mRNA which is transported out of 
the nucleus and targeted to the dendrites (Link et al., 1995; Lyford et al., 1995; Steward et 
al., 1998; Wallace et al., 1998), this dendritic transport makes Arc unusual amongst IEGs. Two 
dendritic targeting elements (DTEs) have been identified within the Arc 3’ UTR, which are 
required for this process (Kobayashi et al., 2005). Within the Arc coding region an A2 
response element has been identified. This element is the binding site for heterogeneous 
nuclear ribonucleoprotein (hnRNP), and this binding appears to be required for Arc mRNA 
transport to dendrites (Gao et al., 2008). See figure 4B. What is particularly interesting about 
Arc is that this transport appears to be not only induced, but specifically guided by recent 
synaptic activity. This is demonstrated by selective stimulation of the inputs to specific layers 
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of the dentate gyrus (DG), which is able to induce accumulation of newly synthesised Arc 
mRNA specifically within the stimulated portion of the dendritic tree (Steward et al., 1998; 
Shannon et al., 2014). This seems to take place alongside targeted degradation of Arc mRNA 
in inactive dendritic regions (Farris & Steward, 2010). There is evidence from electron 
microscopy that this new Arc mRNA is targeted to dendritic spines within the activated layer  
(Rodriguez et al., 2005). This Arc induction is protein synthesis independent and rapid, with 
upregulation in the dendrites detected after 1h of stimulation. Interestingly, only high 
frequency LTP-inducing trains of stimulation are able to induce upregulation of Arc mRNA 
(Lyford et al., 1995; Steward et al., 1998). This redistribution is dependent upon NMDA 
receptor activity (Steward & Worley, 2001). Arc mRNA is a target of nonsense-mediated 
decay (NMD), which limits the number of times a single mRNA can be translated. This process 
results in a half-life of Arc mRNA in culture of just 47 min (Rao et al., 2006; Giorgi et al., 2007), 
which enables tight control of Arc protein levels in response to activity. Two introns present 
in the 3’UTR of the Arc gene make it a target for this kind of regulation (Giorgi et al., 2007).  
1.2.1 Arc translation and protein transport 
Following transcription, the translation of Arc mRNA is also controlled in an activity-
dependent manner. There is evidence that, following HFS, Arc translation can be induced by 
ERK activation via formation of the eIF4F translation-initiation complex (Panja et al., 2009). 
mGluR activation is able to induce rapid local translation of pre-existing Arc mRNA in 
dendrites, which appears to be via phosphorylation of eEF2 (Park et al., 2008; Waung et al., 
2008; Bramham et al., 2010). Following targeted stimulation of specific layers of dentate 
gyrus Arc protein follows the same distribution pattern as mRNA, also showing targeting to 
activated layers following 2h of stimulation (Steward et al., 1998; Farris & Steward, 2010). 
Local translation of Arc in dendrites within 15s of glutamate stimulation has since been 
observed in real time (Na et al., 2016). At the synapse Arc interacts with PSD95 (Fernandez 
et al., 2009) to form part of the ~1.5MDa NMDAR super complexes previously described 
(Frank et al., 2016). The interaction of Arc with PSD95 seems to be essential for Arc’s 
presence at the synapse (Fernandez et al., 2017). Although Arc protein is considered to be 
present predominantly at the post synaptic side of the synapse, there are reports from 
electron microscopy of Arc labelling in axon terminals (Rodriguez et al., 2005). Although Arc 
is an ‘effector’ IEG rather than a transcription factor, localisation of Arc protein to the nucleus 
has also been observed in vivo and in vitro (Irie et al., 2000; Bloomer et al., 2007; Korb et al., 
2013). It seems that Arc localisation to the nucleus can be induced by activity, such as that 
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induced in the hippocampus by novel environment exploration. A Pat7 nuclear localisation 
signal (NLS) was identified at amino acids 331-335 of the Arc protein, which appears to be 
responsible for the active targeting of Arc to the nucleus. A region towards the n terminus, 
between amino acids 29 and 68, was also identified as a nuclear retention signal (NRS), 
keeping Arc in the nucleus. In the absence of this NLS a nuclear export signal (NES), identified  
between amino acids 121 and 154, appears to induce export out of the nucleus into the 
cytoplasm (Korb et al., 2013). These regions are illustrated in figure 4C. Recently, a study, in 
which purified Arc preparations were analysed with EM, found evidence that Arc protein 
forms oligomeric structures similar to virus-like capsids (Pastuzyn et al., 2018). Although it is 
not known whether this takes place in neurons. Further to this, recent evidence also suggests 
that Arc protein and mRNA can be released by neurons in extracellular vesicles in response 
to activity and can then be taken up by other neighbouring cells (Pastuzyn et al., 2018).  
1.2.2 Arc function  
This precise activity-regulated control of Arc levels, coupled with its targeting to recently-
activated synapses, suggests a potential role in the process of synaptic plasticity thought to 
underlie memory formation. Accordingly, knockout of Arc has been reported to result in the 
inability to form long term memory in fear conditioning, conditioned taste aversion and long-
term object-recognition tasks (Plath et al., 2006; Ploski et al., 2008). Interestingly Arc 
knockout did not seem to affect task acquisition or short term memory (Plath et al., 2006). 
Infusion of Arc antisense oligodeoxynucleotides (ODNs) into the hippocampus prior to, or 
immediately after, training in a Morris water maze task can inhibit recall 2 days later. 
However, infusion at 8h post-training did not affect recall, suggesting a critical period during 
which Arc is required for memory consolidation (Guzowski et al., 2000). This does not seem 
to be specific to the hippocampus as infusion of Arc antisense ODNs into the lateral amygdala  
prior to fear conditioning training can impair recall at 24h (Ploski et al., 2008). Knockout or 
knockdown of Arc has also been found to impair synaptic plasticity responses. Arc knockout 
mice display an enhanced early phase but an impaired late phase of LTP in the Dentate Gyrus. 
These mice also had an impaired maintenance of LTD (Plath et al., 2006). These effects were 
not specific to the hippocampus, as cerebellar Purkinje cell cultures from Arc knockout 
animals also display a block of late phase LTD (Smith-Hicks et al., 2010). Block of Arc 
expression specifically in the hippocampus with the use of Arc antisense ODNs produced 
similar results, LTP maintenance was blocked without affecting induction (Guzowski et al., 
2000). Interestingly, infusion of Arc antisense ODNs 2h but not 4h after HFS was able to 
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reverse ongoing LTP, suggesting a critical window of Arc involvement in LTP consolidation. 
Arc AS treatment in the absence of HFS had no effect on basal synaptic transmission 
(Messaoudi et al., 2007). The exact way in which Arc is involved in these two opposing forms 
of synaptic potentiation is unclear. The highly-regulated, rapid targeting of Arc protein to 
recently-activated synapses indicates that it could be acting as a short-term tag, marking 
synapses for modification by other effector molecules (Frey & Morris, 1997; Okuno et al., 
2012). Arc does interact with the Actin cytoskeleton, this was reported as early as 1995 when 
it was found that Arc co-sediments with F-Actin (Lyford et al., 1995). Consolidation of LTP is 
thought to involve expansion of the PSD and dendritic spine, mediated at least in part by 
Actin polymerisation (Fukazawa et al., 2003; Matsuzaki et al., 2004). Infusion of Arc AS ODNs 
2 h post-HFS of the MPP prevented the increase in phallodin staining in the DG usually 
associated with LTP-induced increase in F-actin stabilisation at spines. Application of an F-
actin stabiliser prevented Arc AS ODNs from inhibiting LTP maintenance, suggesting that Arc 
may be acting via F-actin to promote LTP consolidation (Messaoudi et al., 2007).  
There is also considerable evidence that Arc is able to modulate surface AMPA receptor levels 
to alter synaptic strength. Arc expression reduces surface levels of GluR1, which is dependent 
upon Arc binding to the endocytic proteins Dynamin and Endophilin (Chowdhury et al., 2006; 
Rial Verde et al., 2006). Binding domains for endophilin 3 and dynamin 2 have been identified 
in the Arc protein sequence, see figure 4C (Chowdhury et al., 2006). Arc knockout animals 
display a ~2-fold increase in surface GluR1 and rate of endocytosis is also lower than that of 
wild-type, despite such large surface numbers. This can be rescued by transfection of Arc 
(Chowdhury et al., 2006). Knockdown of Arc expression in cultured hippocampal neurons 
also produced a slight increase in surface GluR1 levels, which was accompanied by increased 
mEPSC amplitude (Waung et al., 2008). This suggests that increases in Arc protein can reduce 
synaptic strength by increasing AMPA receptor endocytosis. In these experiments total GluR1 
levels were also decreased, suggesting Arc is able to affect transcription, translation or 
degradation of GluR1 more globally. This was not a general reduction of all glutamate 
receptors as NR1 levels actually increased slightly following Arc expression (Chowdhury et 
al., 2006). This effect of Arc on AMPA receptor levels has been suggested as a mechanism by 
which Arc may affect LTD. In fact, induction of mGluR-dependent LTD appears to require local 
translation of Arc in the dendrites. This increase in dendritic Arc levels is rapid and is 
detectable <10 min after mGluR activation (Park et al., 2008; Waung et al., 2008; Jakkamsetti 
et al., 2013).  
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It has been suggested that Arc levels provide a marker of activity at the level of the neuron 
to guide homeostatic scaling responses. Homeostatic scaling is the process by which synaptic 
strength is globally reduced or increased across the cell, in a manner which preserves the 
relative differences in strength between individual synapses. This process is induced by 
chronic activity or inactivity and is thought to prevent extreme strengthening or weakening 
of synapses, which could saturate a neuron’s capacity for synaptic plasticity (Moser et al., 
1998; O'Brien et al., 1998; Turrigiano et al., 1998). Chronic blockade (TTX) or stimulation 
(Bicuculline) of activity in hippocampal neuronal cultures induces a decrease or increase in 
Arc protein expression, respectively. Arc knockout blocks the homeostatic scaling of surface 
GluR1 and synaptic strength by both chronic TTX and chronic Bicuculline. Arc overexpression 
was also found to block the homeostatic upregulation of GluR1 usually observed  following 
chronic inactivity (Shepherd et al., 2006). This suggests a simple system in which Arc levels 
provide a marker of the recent state of activity in a neuron and results in the global up- or 
down-scaling of synaptic strength in response.  
The specific function of Arc in the nucleus is still unclear, as it has no known DNA binding 
regions. However, one line of evidence has shown that nuclear Arc is able to decrease GluA1 
transcription via an indirect action on the cyclic AMP response elements (CREs) in its 
promoter (Korb et al., 2013).  Arc forms discrete puncta in the nuclei of hippocampal neurons, 
which co-localise with PML-nuclear bodies (Bloomer et al., 2007). Interestingly, Arc 
expression in response to activity upregulates PML expression and this upregulation is both 
essential for GluA1 transcriptional repression, but also sufficient to induce it in the absence 
of any change in Arc (Korb et al., 2013). This suggests that Arc may act indirectly via 
upregulation of PML to reduce GluA1 levels in response to activity, this could form part of 
the homeostatic response already described.  
1.2.3 Arc as a marker of neuronal activity 
The activity-regulated nature of Arc expression has led to its use as a marker of recently 
activated neurons. Fluorescent constructs placed under the control of the Arc promoter have 
been used to identify neurons activated during fear conditioning (Vousden et al., 2015; Cho 
et al., 2016), novel environment exposure (Jakkamsetti et al., 2013), motor (rotarod) learning 
(Cao et al., 2015) and light deprivation/exposure (Wang et al., 2006). In-situ hybridisation 
and immunohistochemistry have also identified increases in endogenous Arc mRNA and 
protein respectively, following a vast array of behavioural stimulation protocols. This includes 
an immediate increase in Arc mRNA in the hippocampus following 5 min of novel 
 22 
environment exposure (Guzowski et al., 1999; Chawla et al., 2005), followed by an increase 
in protein levels as early as 30min post-exploration (Ramirez-Amaya et al., 2005).  
1.2.4 Arc Summary 
In summary, Arc is a highly dynamic, activity-regulated member of the NMDAR supercomplex 
present at the PSD. It is both targeted to recently-activated synapses, and able to modify the 
strength of those synapses via increasing AMPA receptor endocytosis or interactions with 
the cytoskeleton. Arc is also present in the nucleus and can influence GluA1 transcription. 
Precise control of Arc levels is important for maintenance of LTP, LTD and long-term memory. 
However, several aspects of Arc regulation and function still remain to be elucidated, 
including the molecular mechanism by which it is able to facilitate opposing forms of synaptic 
plasticity.   
1.3 Ketamine  
1.3.1 Ketamine-induced psychological effects  
Ketamine was synthesised in 1962 and was intended as a safer derivative of the anaesthetic 
Phencyclidine (PCP) which produces severe hallucinogenic side effects. A subsequent study 
on volunteer prisoners found ketamine to have similar pharmacologic effects to PCP but with 
shorter duration (Domino, 1984). Ketamine can be described as a dissociative anaesthetic 
and still produces some of the adverse reactions reported with PCP including hallucinations, 
blurred vision, delirium, floating sensations, and vivid dreams, although with less frequency 
(Domino, 1984; Frohlich & Van Horn, 2014). It is this hallucinogenic ability that has led to 
ketamine’s use as a drug of abuse (Dotson et al., 1995). However, it is still used worldwide in 
clinical practice as it has several beneficial characteristics as an anaesthetic, including a 
reduced risk of airway collapse or cardiovascular depression (Haas & Harper, 1992).  
1.3.1.1 Psychotomimetic effects of ketamine in humans  
The effect of sub-anaesthetic doses of ketamine on mental state has been the subject of 
several studies, the results of which are summarised in table 2. The picture emerging from 
this body of work is that at low doses ketamine is often able to induce perceptual distortions, 
but that the complex hallucinations associated with emergence from anaesthesia are less 
common. Also frequently observed, is an increased score on the clinician-reported Brief 
Psychiatric Rating Scale (BPRS) and the Clinician Administered Dissociative States Scale 
(CADSS). These scales provide a measure of symptoms including hallucinations, 
suspiciousness, hostility and dissociative states. Many of the symptoms reported in these 
studies mimic those of schizophrenic patients, in fact ketamine has been used previously as 
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an experimental model of schizophrenia (Frohlich & Van Horn, 2014) and exacerbates pre-
existing positive symptoms when given to schizophrenia patients (Lahti et al., 1995). Several 
studies have found these ketamine-induced symptoms to be sensitive to the actions of the 
antipsychotics Haloperidol (Krystal et al., 1999), LY354740 (Krystal et al., 2005) and Clozapine 
(Malhotra et al., 1997). Effects on cognitive ability and memory function have also been 
reported (table 2). All of the reported psychosis-like effects are detectable soon after 
commencement of ketamine infusion and last only briefly (<15 min) after cessation of 
infusion. Given the serum half-life of ketamine, which is ~11 min in the human (Wieber et al., 
1975) it appears that these psychotomimetic effects are an acute response to the presence 
of the drug and are not a sign of lasting alterations to mental state. Although there is some 
evidence that long-term recreational use can increase incidence of dissociative and 
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Table 2 - Summary of current literature on effect of sub-anaesthetic doses of ketamine on 
mental state in healthy volunteers. 
↑ = sig. increase, ↓ = sig. decrease, - = no change from placebo control. BPRS = Brief 
Psychiatric Rating Scale. SANS = Scale for the Assessment of Negative Symptoms. CADSS = 




1.3.1.2 Antidepressant effects of ketamine in humans  
Further to its anaesthetic and psychotomimetic effects, there is now evidence that at low 
doses ketamine can produce an antidepressant effect in patients with treatment-resistant 
Major Depressive Disorder (MDD). Several studies have found 0.5 mg/kg ketamine infusion 
to significantly reduce scores on the Hamilton (HDRS) and Montgomery-Asberg Depression 
Rating Scales (MADRS), as compared with placebo. Please see table 3 for a summary of the 
literature. What is interesting is that the time of onset of this antidepressant effect of 
ketamine is usually later than the psychotomimetic effects described above. In fact, many 
studies into the antidepressant effects of ketamine also assessed psychosis-like symptoms 
with the BPRS, CADSS or VAS (Berman et al., 2000; Zarate et al., 2006; aan het Rot et al., 
2010). In these studies, psychosis-like symptoms were transiently increased during infusion 
but returned to baseline soon after cessation, whereas an antidepressant effect was not 
detected until ~3-4 h post-infusion. This is with the exception of (Diazgranados et al., 2010) 
in which the onset of antidepressant effects was more rapid (at cessation of infusion), 
however this study also involved concomitant use of lithium or valproate. The picture from 
studies administering ketamine alone suggests that, rather than being a direct result of the 
presence of ketamine in the brain, these delayed antidepressant effects may be produced by 
a downstream alteration in brain function. Conventional antidepressant drugs, such as SSRIs 
are not effective after one dose and can take weeks of daily administration before an 
improvement in symptoms can be seen. This relatively rapid-onset, but long-lasting, effect of 
a single dose of ketamine is therefore a promising observation in the search for more optimal 
antidepressant treatments.  
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 Ketamine dose Clinician administered 
tests 
Time point of 
change (post-
infusion start) 
(Berman et al., 2000) 0.5 mg/kg over 40 
min 
↓HDRS score 240 min – 72 h  
↑BPRS score* 
↑VAS “high” score* 
10 & 40 min 
(Zarate et al., 2006) 0.5 mg/kg over 40 
min 




40 min  
(aan het Rot et al., 
2010) 




4 h  
↑CADSS score* 0-40 min 
(Diazgranados et al., 
2010)a 
 
0.5 mg/kg over 40 
min 
(N.B concomitant 










(Murrough et al., 
2013) 




24 h  
Table 3 - Summary of current literature on antidepressant effect of sub-anaesthetic doses 
of ketamine in MDD patients. 
↑ = sig. increase, ↓ = sig. decrease from placebo control. * = test for psychosis-like 
symptoms. Three studies were excluded from this summary on the basis that they were open-
label with no placebo (Price et al., 2009; DiazGranados et al., 2010; Ibrahim et al., 2011). 
HDRS = Hamilton Depression Rating Scale. MADRS = Montgomery-Asberg Depression Rating 
Scale. QIDS-SR = Quick Inventory of Depressive Symptoms. BPRS = Brief Psychiatric Rating 




1.3.2 Ketamine-induced behaviour in mice  
Given the promising antidepressant effects, and worrying psychotomimetic effects, of 
ketamine observed in humans it has become increasingly important to understand the 
underlying molecular changes involved. Therefore, much work has focussed on modelling 
ketamine-induced psychotomimetic and antidepressant effects in laboratory animals. Here I 
discuss the current evidence for ketamine’s effect on rodent behavioural measures, intended 
to model the described human responses. Interestingly, much of our current knowledge 
comes from investigations into the possible use of ketamine as an animal model for 
schizophrenia research.  
1.3.2.1  ‘Psychotomimetic’ effects of ketamine in rodents  
Sub-anaesthetic doses of ketamine induce increased locomotion in mice, as measured by 
recording the distance travelled by the animals in an open field arena (Irifune et al., 1991; 
Imre et al., 2006; Chatterjee et al., 2011). Ketamine-induced hyper-locomotion can be 
attenuated by antipsychotic drugs (Irifune et al., 1991; Chatterjee et al., 2011) therefore, this 
measure has been taken as having translational relevance to the ketamine-induced 
schizophrenia-like effects described in section 1.3.1.1. This effect is short-lived, for example 
administration of 10mg/kg ketamine induces an increase in locomotion at 10 & 20 min post-
administration but returns to control levels by 30 min (Irifune et al., 1991). The serum half-
life of ketamine in laboratory mice is ~13 min (Maxwell et al., 2006) and a 30mg/kg dose has 
been found to clear from the brain in <1h (Lord et al., 2013). This timing suggests that, as 
with the psychosis-like symptoms in humans, ketamine-induced hyper-locomotion is an 
acute response to the presence of ketamine rather than a more permanent alteration to 
behaviour. The hyper-locomotive response to ketamine is dose-dependent, with higher 
doses producing a longer-lasting increase in locomotion (Irifune et al., 1991; Danysz et al., 
1994).  
1.3.2.2  ‘Antidepressant’ effects of ketamine in rodents  
Several different kinds of tests have been developed to assess depressive-like phenotypes in 
rodents. The most commonly used are the Tail Suspension Test (TST) and Forced Swim Test 
(FST). These tests are designed to measure the degree of ‘behavioural despair’ of an animal 
when it is placed in an uncomfortable situation which it cannot escape from. The amount of 
time spent not trying to escape from that situation, defined by a lack of movement 
(immobility time), is taken as a measure of ‘behavioural despair’. An increased immobility 
time is an indicator of reduced attempts to escape from that situation and is considered a 
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depressive phenotype. In the novelty-supressed feeding test (NSFT) a food pellet is placed in 
the centre of a novel environment and the latency of the animal to begin feeding on that 
pellet is recorded. Increased latency to feed is considered a sign of increased anxiety. In the 
sucrose preference test (SPT) the innate preference of rodents for sucrose water over regular 
water is used. Absence of that preference is considered an indicator of anhedonia. A 
depressive phenotype in any of these tests can be rescued by various different 
antidepressant medications, which are themselves effective in depressed patients (Bodnoff 
et al., 1988; Cryan et al., 2005; Pollak et al., 2010; Powell et al., 2012  ). 
Table 4 summarises the current literature on the effect of different doses of ketamine on the 
outcomes of these tests. The picture that emerges from these studies is that sub anaesthetic 
doses of ketamine are able to induce an antidepressant-like effect which has been reported 
as early as 30min and can last up to 7 days post-administration. This rapid onset is interesting 
given the repeated dosing required for SSRIs to become effective. Indeed, several studies 
have directly compared SSRI and ketamine efficacy in rodent models, confirming the absence 
of an acute antidepressant effect of SSRIs (Autry et al., 2011; Zanos et al., 2016). Given the 
~13 min half-life of ketamine (Maxwell et al., 2006), it is clear that antidepressant effects are 
lasting beyond the presence of the drug in the brain. This suggests that the transient 
presence of ketamine is sufficient to induce lasting changes in brain function. What is 
particularly interesting is the dose-response relationship that emerges from this large body 
of data. It seems that an antidepressant response to ketamine is restricted to low, sub-
anaesthetic doses, with the same effect not observed following higher doses. For example in 
rats 10mg/kg, but not 80mg/kg, ketamine was able to induce a decrease in FST immobility 
time (Li et al., 2010). Similar results have been reported by others (Zanos et al., 2016).  
However, there are some limitations to the current literature on this topic. There is the 
possibility that the short term hyper-locomotive response to ketamine, described in section 
1.3.2.1, could affect the early measurements of immobility in the FST and TST. However, 
most papers included data showing that general locomotion was not altered at the dose and 
time point at which the TST or FST was carried out. Those which report an effect in the FST 
or TST at a dose and time point when hyper-locomotion would be expected (Irifune et al., 
1991), but did not specifically test for it,  have been highlighted with an asterisk in table 4. 
Regardless of the exact onset time it is clear that the antidepressant effect of ketamine in 
rodents is more rapid than that of SSRIs. Questions have been raised over the relevance of 
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‘antidepressant’ responses in rodent models to clinical outcomes in human patients (Pollak 
et al., 2010). However, in this case there is supporting data from patient studies, so this is 
not a significant concern. Several published reports failed to find an effect of ketamine in the 
FST at doses and time-points previously reported to be effective, in general negative results 
are less likely to be published, suggesting a potential lack of reproducibility (Popik et al., 2008; 
Bechtholt-Gompf et al., 2011; Chatterjee et al., 2011). This is not uncommon with rodent 
tests of depressive phenotypes, as these tests can be affected by various biological factors 
which complicate comparison across studies (Bogdanova et al., 2013). Again, when viewed 
alongside the patient data this variability is less of a concern.  
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et al., 2003) 
Ms/Male Swiss  0.1mg/kg ↓ immobility 
time FST 
30 min 
(Rosa et al., 
2003) 
Ms/Swiss 5mg/kg ↓ immobility 
time FST 
30 min*  
(Hayase et 
al., 2006) 
Ms/ICR 30 & 100mg/kg ↑ time until 
immobility FST 
No change in 
activity FST 
60 & 120 min  
(Garcia et al., 
2008) 
Rt/Male Wistar 5, 10 & 
15mg/kg 
↓ immobility 
time FST (10 & 
15 mg/kg only) 
60 min  




1.25, 2.5, 5 10, 
50, 160mg/kg 




40 min*, 1 
week &  2 
weeks  
(Cruz et al., 
2009) 












Ms/Male NMRI 2 & 5 mg/kg  














(Autry et al., 
2011) 
Ms/C57BL/6 3 mg/kg ↓ immobility 
time FST 
30min – 7 days 
(Bechtholt-




0.5, 2.5, 12.5, 
40, 80, 160 
mg/kg 




1h* & 7 days 
(Beurel et al., 
2011) 





Ms/Male Swiss 100mg/kg No effect in FST  
(↑ immobility 
after 10 x daily 
100mg/kg) 
24 h  
(Koike et al., 
2011) 
Ms/Male ICR 30mg/kg  




30 min & 72 h 




0.5, 2.5, & 5 
mg/kg 
↓ immobility 
time FST (2.5 & 
5 mg/kg only @ 
30 min, 5 only 
@ 7 days) 
30 min & 7days  
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30mg/kg  ↓ immobility 
time TST, ↓ 
latency to feed 
NSFT 
30 min & 24 h 





6mg/kg  ↓ immobility 
time FST, ↑ 
sucrose 
preference SPT 
18 h & 28 h  
(Zhou et al., 
2014) 
Rt/Male Wistar 10mg/kg ↓ immobility 
time FST 
30 min* 
(Wang et al., 
2015) 
Rt/Male Wistar 10mg/kg ↓ immobility 
time FST 
↓ latency to 
feed NSFT 
0.5h-4h 
(Zanos et al., 
2016) 
 1, 3, 10, 30, 50 
mg/kg 
↓ immobility 
time FST (10 & 
30 mg/kg @ 1h, 
10mg/kg @ 24h) 
30 min & 24h 
Table 4 – Summary of current literature on antidepressant-like effect of ketamine in 
mouse.  
TST = Tail Suspension Test; NSFT = Novelty Supressed Feeding Test; FST = Forced Swim Test; 
SPT = Sucrose Preference Test; * = lack of locomotion test when reduction in immobility 
reported within potential hyper-locomotion window.  
1.3.3 Effect of ketamine on memory performance  
In addition to its psychosis-like and antidepressant effects, acute low-dose ketamine 
administration has been found to impair both the encoding and retrieval of episodic memory 
in humans (Ghoneim et al., 1985; Krystal et al., 1994; Newcomer et al., 1999; Hetem et al., 
2000). In rodents 1mg/kg and 3mg/kg doses of ketamine, administered 20 min prior to or 
immediately after a ‘training’ session were able to impair novel object recognition during 
testing 60 min later (Pitsikas & Boultadakis, 2009). Ketamine was also found to impair 
retrieval of a social recognition memory at 10mg/kg (Gao et al., 2009). The literature on the 
effect of ketamine administration on working memory in humans is inconsistent (Morgan & 
Curran, 2006). However, in rodents a deficit in working memory has been observed 
immediately (~5 min) following low dose (>10mg/kg) ketamine administration (Smith et al., 
2011).  
1.3.4 Molecular mechanism of ketamine   
1.3.4.1 Ketamine as an NMDA receptor antagonist 
The primary action of ketamine is as a non-competitive NMDA receptor antagonist. This 
action is common to dissociative anaesthetic agents including nitrous oxide, 
dextromethorphan, and PCP (Absalom & Menon, 2010). Ketamine binds within the NMDA 
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receptor channel pore to block ion flux. This blockade requires an open channel to allow 
ketamine access to the binding site (Macdonald et al., 1987; Zeilhofer et al., 1992). NMDAR 
blockade by ketamine is also voltage dependent, increasing with membrane depolarisation 
(Halliwell et al., 1989; Zeilhofer et al., 1992). Although ketamine’s action at the NMDA 
receptor has been well documented, and is considered to be responsible for the acute 
anaesthetic effect that ketamine has (Anis et al., 1983; Daniell, 1990; Sato et al., 2004), the 
molecular mechanisms downstream from receptor blockade are still under investigation. 
This is particularly important when it comes to understanding the long-lasting antidepressant 
effects of ketamine, which are known to continue long after the drug has been metabolised. 
What is interesting to note, is that the psychological effects of ketamine take place at sub-
anaesthetic doses, where it is estimated that brain concentrations of the drug would be in 
the low micromolecular range (Hartvig et al., 1995; Zorumski et al., 2016). At this 
concentration ketamine is likely to be inhibiting <50% of NMDA receptors, leaving a 
significant portion unaffected (Dravid et al., 2007; Kotermanski et al., 2009; Zorumski et al., 
2016) . There is still debate over whether different NMDA receptor subtypes have different 
sensitivities to ketamine blockade. An initial study in Xenopus oocytes found similar 
sensitivity to ketamine blockade across subtypes (Yamakura et al., 1993). However, following 
this, a study in HEK cells found that at physiological levels of Mg2+ differing sensitivities to 
ketamine are detectable between the subtypes. In this experiment the most sensitive 
subtype was GluN2C, followed by GluN2D, GluN2A and GluN2B were the least sensitive and 
were almost indistinguishable from one another (Kotermanski & Johnson, 2009). The impact 
in vivo of any preference of ketamine to block one NMDAR subtype over another will be 
highly dependent upon the extracellular concentration of ketamine present in the brain 
following administration. This can be a difficult value to calculate with accuracy and has led 
to some debate over the likely contribution of individual NMDAR subtypes to behavioural 
outcomes of ketamine action (Khlestova et al., 2016).  
1.3.4.2 Ketamine increases synaptic protein levels 
Sub-anaesthetic doses of ketamine have been found to induce long term increases in synaptic 
protein levels. 10mg/kg ketamine is able to increase levels of Synapsin I, PSD95 and GluR1 in 
synaptoneurosomes of prefrontal cortex (PFC). This increase was observed at 2 - 72h post-
administration, a timeline which coordinates with the antidepressant effects of this dose of 
ketamine. An increase in Arc was also observed in this preparation but this effect was only 
detectable at 1 - 2h post-administration, making it more rapid and relatively transient. 
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Another study replicated this increase in Arc and found it to be sensitive to treatment with 
the protein synthesis blocker anisomycin (Autry et al., 2011). An increase in spine density in 
the PFC at 24h post ketamine administration was also observed (Li et al., 2010). Similar 
increases in Synapsin I, PSD95 and GluR1 have been observed after administration of 
30mg/kg ketamine (Tang et al., 2015). Rapid new protein synthesis is required for both the 
rapid (30 min) and long-lasting (24h) antidepressant effect of ketamine, as both can be 
blocked by a single administration of anisomycin 30min prior to ketamine administration 
(Autry et al., 2011). 
1.3.4.3 Ketamine activates mTOR signalling  
Prior to this synaptic effect, a transient increase in members of the mTOR signalling cascade 
has been observed. 30min - 1h following 10mg/kg ketamine administration, levels of p4E-
BP1, pmTOR and pp70S6K are elevated in PFC synaptoneurosome preparations (Li et al., 
2010). A separate report found increased leves of p4E-BP1 and pp70S6K 2 days after a 
30mg/kg dose of ketamine, pmTOR levels were unaltered at this timepoint (Tang et al., 2015). 
Activation of mTOR signalling positively controls protein synthesis, and blockade of mTOR 
activity with rapamycin prevents ketamine-induced upregulation of synaptic proteins as well 
as the antidepressant response (Laplante & Sabatini, 2009; Li et al., 2010). Interestingly, the 
increase in mTOR signalling is not observed following a higher dose (80mg/kg). This dose-
dependency correlates with that of the antidepressant effect of ketamine which was also 
detected at 10mg/kg, but not 80mg/kg (Li et al., 2010). The increase in p70S6K 
phosphorylation is not specific to the PFC, as a similar result was observed in western blot 
from hippocampus (Harraz et al., 2016). Levels of the GTP binding protein Rheb, an upstream 
regulator of mTOR activity, are also increased following ketamine administration. 
Interestingly, the GluN2B selective inhibitor CERC301 was able to mimic the effects of 
ketamine on both Rheb and pp70S6K levels but the NMDA receptor antagonist memantine 
had no effect  (Harraz et al., 2016). Upstream of mTOR signalling, ketamine is able to reverse 
CMS-induced reductions in pAKT and pERK (Tang et al., 2015). This seems to be required for 
ketamine action as inhibitors of ERK are able to prevent the ketamine-induced 
antidepressant response (Li et al., 2010; Reus et al., 2014). Further upstream of ERK, BDNF 
signalling via TrkB receptors has also been implicated in ketamine action. BDNF knockout 
mice do not display an antidepressant response to ketamine or MK801, the same result was 
seen in TrkB knockout mice. Both BDNF levels and TrkB activation are transiently increased 
after ketamine administration (Autry et al., 2011). BDNF is released from the postsynaptic 
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membrane in response to neuronal activity and acts via surface TrkB receptors to stimulate 
signalling cascades including ERK (Numakawa et al., 2010). Overall, it is clear that 
upregulation of synaptic proteins, triggered by activation of ERK/mTOR is taking place in 
response to sub anaesthetic doses of ketamine. This kind of cellular response usually takes 
place following increases in neuronal activity (Ghosh & Greenberg, 1995; Sweatt, 2001; 
Krapivinsky et al., 2003).  
1.3.4.4 Ketamine induces glutamate release 
There is evidence that subanaesthetic doses of ketamine are able to induce glutamate 
release and increase neuronal activity in the PFC. 10, 20 & 30mg/kg ketamine all increase 
glutamate outflow in the PFC. This effect was observed 40-100min post-administration with 
30mg/kg producing the longest lasting increase. However, an anaesthetic dose (200mg/kg) 
actually decreased glutamate outflow 20 – 80 min post-administration. An intermediate dose 
(50mg/kg) had no lasting effect (Moghaddam et al., 1997). Similar results have been reported 
by others (Chowdhury et al., 2012; Stone et al., 2012). This is interesting given the similar 
lack of antidepressant effects at anaesthetic doses. Glutamate  increase seems to be 
functionally required for ketamine-induced psychotomimetic effects in humans, and the 
severity of psychotomimetic symptoms is positively correlated with glutamate levels (Anand 
et al., 2000; Krystal et al., 2005; Stone et al., 2012). An increase in neuronal activity as 
measured by c-fos levels has also been observed in several brain regions (Imre et al., 2006).  
1.3.4.5 The indirect ‘disinhibition’ hypothesis of ketamine action  
It is still unclear how ketamine is able to boost neuronal activity given its NMDAr antagonist 
properties, however, several hypotheses have recently been proposed. These include the 
suggestion that at low doses ketamine could act preferentially at NMDARs on inhibitory 
interneurons, thus releasing primary glutamatergic neurons from that inhibition and leading 
to increased activity. This has been termed the disinhibition hypothesis of ketamine action, 
and has been discussed in several review articles (Seamans, 2008; Miller et al., 2016; Wohleb 
et al., 2017). One line of evidence supporting this hypothesis is the observation that 30mg/kg 
ketamine administration is able to preferentially reduce the firing rate of a subpopulation of 
putative inhibitory interneurons in the orbitofrontal cortex (Quirk et al., 2009). In this study 
neuronal populations were defined by their extracellular waveform and spike train 
characteristics. In culture ketamine was able to decrease GAD67, the enzyme responsible for 
the majority of GABA synthesis, in Parvalbumin positive interneurons (Kinney et al., 2006). 
These results have been replicated in the PFC of rats following 2 days of ketamine injection, 
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in addition to a reduction in GAD67 immunoreactivity, there was a 20% reduction in mIPSCs 
which were confirmed as GABA mediated currents via blockade with bicuculline (Zhang et 
al., 2008). However, a requirement for this reduction in inhibitory activity for antidepressant 
responses has yet to be established. Neither knockout of NMDArs in interneurons nor 
administration of GABA antagonists has been able to mimic and/or occlude the 
antidepressant response of ketamine (Autry et al., 2011; Pozzi et al., 2014). This 
‘disinhibition’ hypothesis does go some way towards explaining the unusual dose-
dependency of the ketamine response, as at high (anaesthetic) doses any preference for 
ketamine to bind to certain subpopulations of NMDARs would likely be inconsequential.  
1.3.4.6 GluN2B specific actions of ketamine    
There is growing evidence that ketamine’s antidepressant effects may be mediated 
specifically by GluN2B containing NMDA receptors. Administration GluN2B-selective 
antagonists are able to mimic both the antidepressant actions of ketamine in humans and 
rodents, and the increases in mTOR signalling and synaptic protein synthesis (Preskorn et al., 
2008; Li et al., 2010; Lima-Ojeda et al., 2013; Miller et al., 2014). This seems to be via a direct 
effect on pyramidal neurons, as removal of NMDA receptors from inhibitory interneurons did 
not alter the behavioural response to GluN2B-specific antagonist Ro 25-6981 (Kiselycznyk et 
al., 2015). This is interesting as GluN2B is considered to play a role in homeostatic plasticity 
via its specific interactions with CAMKII and SynGAP. Blockade of action potentials with TTX 
induces a homeostatic response in which mTOR signalling and protein synthesis are 
upregulated and mEPSC amplitude is increased. This acute homeostatic response was 
mimicked and occluded in a mouse line in which GluN2B subunits have been replaced with 
GluN2A, leaving total surface NMDAr levels unchanged (Wang et al., 2011). A preferential 
action of ketamine on pyramidal cell GluN2B-containing NMDArs could therefore elicit a 
homeostatic-like response including mTOR signalling, synaptic protein synthesis and 
synaptogenesis. Again this could explain the dose dependent nature of ketamine action, as 
at high doses this preference may be inconsequential. The most compelling evidence for this 
hypothesis so far comes from a mouse line in which GluN2B has been selectively removed 
from the principal neurons of the neocortex. Ketamine-induced antidepressant effects, 
increased excitatory synaptic transmission and increased protein synthesis are all mimicked 
and occluded in these mice (Miller et al., 2014). Ketamine does not bind preferentially to 
GluN2B-containing receptors over the other NMDAR subtypes (Kotermanski & Johnson, 
2009), so it is unclear how a specific GluN2B action would arise. Again, a high dose of 
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ketamine would be likely to mask any preferential action via GluN2B, fitting with the 
previously-described dose-response relationship.  
1.3.4.7 NMDAr blockade-induced protein translation via eEF2 
dephosphorylation  
eEF2 is a signalling molecule thought to act as a biochemical sensor. Action potential-
mediated network activity maintains eEF2 in a relatively dephosphorylated (active) state, 
whereas the spontaneous activity promotes phosphorylation (inactivation) (Sutton et al., 
2007). Dephosphorylation of eEF2 has been found to augment protein synthesis  (Sutton et 
al., 2007). It has been suggested that ketamine would block this resting NMDAr activity, 
attenuating phosphorylation of eEF2 and promoting local protein translation (Autry et al., 
2011). In support of this hypothesis ketamine is able to decrease NMDA-mEPSCs and eEF2 
phosphorylation in vitro. Decreased eEF2 phosphorylation was also detected 30 min post-
ketamine administration in vivo in hippocampus, but not in cortex (Autry et al., 2011). 
Interestingly, ambient glutamate has been found to produce a tonic current via GluN2B-
containing NMDA receptors (Miller et al., 2014). This suggests that part of the GluN2B specific 
ketamine action described in section 1.3.4.6 could be due to reduced phosphorylation of 
eEF2 in response to blockade of this tonic current (Miller et al., 2016).  
1.3.4.8 Ketamine metabolites as effectors of the antidepressant response 
A recent hypothesis suggests that it is not ketamine, but one of its metabolic products that 
is inducing an antidepressant effect. This is interesting given that the onset of antidepressant 
action seems to be taking place after ketamine metabolism. Most metabolites of ketamine, 
other than norketamine, do not induce anaesthesia and have therefore been previously 
considered clinically inactive (Leung & Baillie, 1986). However, recent evidence has shown 
that administration of the (2R,6R)-hydroxynorketamine (HNK) metabolite induces a potent 
antidepressant action. In addition to this, a form of ketamine with inhibited metabolism to 
(2S,6S;2R,6R)-HNK failed to induce antidepressant effects in the FST or LH (Zanos et al., 2016). 
This challenges the widely-held view that NMDAr antagonism underlies ketamine action, as 
(2R,6R)-HNK does not bind or inhibit NMDA receptors. Indeed, the antidepressant action of 
(2R,6R)-HNK required the acute activation of AMPA receptors. The effects of (2R,6R)-HNK 
lasted beyond the presence of detectable levels in brain, and both ketamine and (2R,6R)-HNK 
increased AMPA receptor levels 24h post-administration (Zanos et al., 2016). This suggests 
again that the brief presence of the drug is able to initiate long lasting alterations in synaptic 
strength and/or number. Interestingly, (2R,6R)-HNK seems to lack the dissociative side 
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effects of ketamine as it has no anaesthetic properties, and does not affect locomotion or 
coordination in rodents (Leung & Baillie, 1986; Zanos et al., 2016). These new findings are 
exciting, but considering the evidence described in section 1.3.4.6 detailing the importance 
of the GluN2B-containing NMDAR, it may be too soon to rule out a role of the NMDA action 
of ketamine in its antidepressant effects, as some have suggested. Several recent letters and 
reviews discuss these two hypotheses in detail (Miller et al., 2016; Collingridge et al., 2017; 
Zanos et al., 2017).  
1.3.4.9 Non-NMDAr targets of ketamine  
The idea that ketamine may be acting via targets other than the NMDA receptor is not new. 
A finding often cited in support of a non-NMDAr target is that (S)-ketamine is a more potent 
inhibitor of NMDARs, but (R)-ketamine has a more potent antidepressant effect. However, 
as described in sections 1.3.2 & 1.3.4.3, it may be that a low level of NMDAr antagonism is 
required for antidepressant action rather than widespread blockade. Further to this, MK801, 
an NMDAr antagonist which lacks ketamine’s additional targets, also lacks a long term 
antidepressant action although it is able to induce a short term effect (Maeng et al., 2008). 
However, MK801 also has a different affinity for NMDA receptors which could also account 
for this discrepancy (Wong et al., 1986; Berman & Murray, 1996).  
Several other receptor targets for ketamine have been identified. At high doses it is able to 
inhibit nicotinic and muscarinic acetylcholine receptors, however, its affinity for these 
receptors is much lower than that for the NMDAr (Durieux, 1995; Yamakura et al., 2000). 
Ketamine is also able to bind opioid (Smith et al., 1987), dopamine D2 and serotonin 5-HT2 
receptors (Yamakura et al., 2000; Kapur & Seeman, 2002; Seeman et al., 2005). There is 
evidence that ketamine can block voltage-gated sodium channels, and that this results in a 
local anaesthetic effect (Wagner et al., 2001). The identification of these other receptor 
targets certainly highlights the complexity of ketamine’s pharmacological profile and should 
inform the interpretation of future investigations into its molecular mechanism of action.  
1.3.5 Summary 
It is clear that there is now a large body of work detailing the effects of ketamine on both 
human and rodent measures of psychosis and depression. The picture that emerges from 
this work is one of a short-term psychotomimetic response to sub-anaesthetic ketamine 
doses, followed by a long-lasting antidepressant response. This antidepressant response 
outlasts the presence of ketamine in the brain and therefore is likely caused by a downstream 
effect of transient ketamine action. It also appears to be specifically triggered by low, sub-
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anaesthetic, doses. However, despite much effort, the mechanism of action of these distinct 
psychological responses is still largely unknown. There is evidence for a specific role of the 
GluN2B subtype of the NMDAR, and the suggestion that ketamine could be acting primarily 
on inhibitory interneurons to indirectly increase activity of principal excitatory neurons. 
Ketamine is able to induce increases in glutamate release, activation of mTOR and ERK 
signalling, and upregulation of synaptic proteins. Both the glutamate release and activation 
of intracellular signalling is specific to low sub-anaesthetic doses, similar to the dose-
response of ketamine’s antidepressant effect. Understanding better the molecular events 
underlying ketamine’s different psychological effects will be crucial piece of the puzzle to 
complete if we are to harness the powerful antidepressant properties of this drug in a safe 
manner.  
1.4 Summary and thesis aims  
In conclusion, there are several outstanding questions regarding the molecular mechanism 
of ketamine’s action which the work in this thesis aims to address. As explained above, there 
is evidence that the antidepressant effect of ketamine is mediated specifically by the GluN2B 
NMDAR subunit, however, there is no reported specificity of ketamine binding to that 
subunit. The first aim of this thesis is to investigate this question by establishing which part 
of the GluN2B subunit is responsible for mediating ketamine’s action, is it the channel pore 
region of GluN2B which is required? Or is it the intracellular c-terminal domain? Further to 
this, low dose ketamine has been found to induce upregulation of synaptic proteins including 
Arc and PSD95. However, it is not yet clear whether this is specific to sub-anaesthetic doses, 
as is the case with ketamine’s antidepressant effect. Additionally, a detailed investigation 
into which brain regions are involved in this synaptic response has not yet been carried out. 
Therefore, the second aim of this thesis is to investigate the changes in Arc and PSD95 levels 
at the synapse following sub-anaesthetic and anaesthetic doses of ketamine, across multiple 
brain regions.   
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All experiments were carried out in accordance with UK animals (Scientific Procedures) Act, 
1986 and all procedures were approved by the British home office inspectorate.  
2.1.1 The ArcVENUS mouse line 
The Arc-venus mouse line was engineered by Dr. Fei Zhu under the supervision of Dr. Noboru 
H. Komiyama and Prof. Seth G.N. Grant. Full details of the generation and characterisation of 
this line can be found in her PhD thesis. Briefly, a targeting vector was generated, containing 
the coding sequence for the Venus form of the yellow fluorescent protein flanked by two 
homology arms for the Arc gene. This vector was designed to insert the Venus sequence into 
the Arc open reading frame and before its stop codon. Mouse embryonic stem cells were 
targeted with this vector, correctly targeted ES cells were injected into mouse blastocysts to 
create chimeric mice. F1 generation heterozygotes were crossed with a cre-deleter mouse to 
remove the LoxP flanked neo cassette. Progeny were backcrossed on to C57BL/6J mice to 
establish a working colony, which was bred to homozygosity.  
 
Figure 5 - Generation of Arc-Venus mouse line.  
Schematic illustrations of the targeted genomic Arc locus. The Arc allele was targeted with 
the Venus (YFP) sequence inserted into its open reading frame and before its stop codon by 
homologous recombination. neor: neomycin-resistance gene. * = stop codon of the coding 
sequence. Figure and legend reproduced, with permission, from (Fernandez et al., 2017). 
2.1.2 PSD95-eGFP line 
The PSD95-eGFP mouse line was engineered by Dr. Fei Zhu under the supervision of Dr. 
Noboru H. Komiyama and Prof. Seth G.N. Grant. Full details of the generation and 
characterisation of this line can be found in her PhD thesis and now published (Zhu et al., 
2018). Briefly, a targeting vector was generated, containing the enhanced green fluorescent 
protein (eGFP) coding sequence flanked by two homology arms for the gene encoding the 
PSD95 protein (Dlg4). Mouse embryonic stem cells were targeted with this vector, correctly 
targeted ES cells were injected into mouse blastocysts to create chimeric mice. F1 generation 
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heterozygotes were crossed with a cre-deleter mouse to remove the LoxP flanked neo 
cassette. Progeny were backcrossed on to C57BL/6J mice to establish a working colony, which 
was bred to homozygosity.  
 
Figure 6 - Generation of PSD95-eGFP mouse line. 
Schematic illustrations of the targeted genomic PSD-95 locus. The PSD-95 allele was targeted 
with the EGFP sequence inserted into its open reading frame and before its stop codon by 
homologous recombination. Recombination events are shown by dashed lines. neor: 
neomycin-resistance gene; DTA: diphtheria toxin gene. Figure and legend reproduced, with 
permission, from Dr. Fei Zhu PhD thesis. 
2.1.3 GluN2B-2A and GluN2A-2B swap lines  
These two complementary mouse lines were engineered by Dr. Noboru H. Komiyama and 
have been previously published (Ryan et al., 2013). In summary, the exons encoding the c-
terminal domains (CTDs) of the GluN2A and GluN2B NMDA receptor subunits were 
exchanged. The CTDs of GluN2A and GluN2B are encoded by the terminal exons of their 
respective genes and the initial amino acid sequence encoded by these terminal exons is 
identical. For the GluN2A2B(CTR) line a targeting construct was designed to replace GluN2A 
exon 12 with that of GluN2B. For the GluN2B2A(CTD) line a targeting construct was designed to 
replace GluN2B exon 12 with that of GluN2A. Mouse embryonic stem cells were targeted 
with these vectors, correctly targeted ES cells were injected into mouse blastocysts to create 
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chimeric mice. F1 progeny were backcrossed on to C57BL/6J mice to establish a working 
colony, which was bred to homozygosity.  
 
Figure 7 – Generation of GluN2A2B(CTR) and GluN2B2A(CTR) mouse lines. 
The GluN2A2B(CTR) allele encodes a chimeric GluN2A subunit consisting of GluN2A extracellular 
and transmembrane regions and the GluN2B CTD. The terminal GluN2A exon that encodes 
the CTD was replaced with the paralogous sequence from GluN2B (target 1). The FRT-
flanked Neo selection cassette was placed in the GluN2A 3ʹ UTR and was removed by 
crossing GluN2A2B(CTR)/+ mice with CAG-FLP recombinase transgenic mice (target 2). B. 
The GluN2B2A(CTR) allele encodes a chimeric GluN2B subunit consisting of a GluN2B 
extracellular and transmembrane regions and the GluN2A CTD. The terminal GluN2B exon 
that encodes the CTD was replaced with the paralogous sequence from GluN2A (target 1). 
The loxP-flanked Neo selection cassette was placed in the GluN2B 3ʹ UTR and was removed 
by crossing GluN2B2A(CTR)/+ mice with CMV-Cre recombinase transgenic mice (target 2). A & B 
and corresponding legend reproduced, with permission, from (Ryan et al., 2013) 
2.1.4 PSD93 knockout line 
The PSD93 knockout line of mice was generated by the laboratory of David Bredt and has 
been previously published (McGee et al., 2001). Details of the characterisation of this line 
can also be found on the genes2cognition.org database. Briefly, a targeting construct was 
designed to replace the exon containing most of the second PDZ domain of PSD93 with 
neomycin, this construct was flanked on two sides by a total of 8.5kb genomic DNA. Mouse 
embryonic stem cells were targeted with this vector. Correctly targeted ES cells were injected 
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into mouse blastocysts to create chimeric mice. These mice were then bred to produce 
animals homozygous mutant animals which lack the PSD93 protein (McGee et al., 2001). 
 
Figure 8 - Targeted disruption of PSD93. 
Restriction maps of the pTK/NEO targeting vector, the native PSD-93 gene, and the properly 
targeted deletion locus are shown. Recombination (shown as large Xs) between the targeting 
vector and the wild-type locus produced the targeted allele. A BamHI site was engineered into 
the 3 end of the Neo cassette of the targeting vector to facilitate genotyping. B, BamHI; H, 
HindIII; N, NheI; P, PstI; S, SacI; X, XbaI. Figure and legend from (McGee et al., 2001). 
2.1.5 PSD95 knockout line 
The PSD95 knockout line of mice was generated by Margaret Arbuckle and Seth Grant and 
has been previously published (Yao et al., 2004; Abbas et al., 2009). Details of the generation 
and characterisation of this line can also be found on the genes2cognition.org database. 
Mouse embryonic stem cells were targeted with a vector containing 5.2kb and 5kb of flanking 
genomic DNA. This was inserted in frame into exon 13 of the PSD95 encoding gene (Dlg4) 
with neomycin/tk cassette. Correctly targeted ES cells were injected into C57BL/6 blastocysts 
to create chimeric mice. F1 progeny were backcrossed on to C57BL/6J mice to establish a 
working colony, which was bred to homozygosity. This insertion of a premature stop codon 
resulted in the deletion of the area coding for the GK domain of the protein. This caused a 
near complete absence of PSD95 mRNA and no detectable levels of PSD95 protein in 
homozygous animals (Yao et al., 2004). 
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Figure 9 - Targeted mutation of the PSD95 gene.  
PSD-95 genomic DNA with restriction enzyme sites (EI, EcoRI; EV, EcoRV; Sp, SpeI; Xb, XbaI; 
Xh, XhoI.); boxes, exons. With integrated targeting vector (middle) and targeted locus 
(bottom). tk, thymidine kinase gene; neo, neomycin resistance gene; HA, haemaglutinin 
epitope tag; STOP, stop codon; arrowheads, loxP sites; DT-A, Diptheria toxin A based 
vector. Figure and legend reproduced, with permission, from genes2cognition.org 
database. 
2.2 Behavioural paradigms 
2.2.1 Open-field testing of ketamine behaviour 
For all open-field experiments described below an empty arena of 50cm x 50cm x 25cm was 
used. At the beginning of each exploration session mice were placed into the centre of the 
arena and allowed to move freely with the experimenter hidden from their view for the 
duration of the recording. Movement of the animal was tracked by a ceiling-mounted camera 
connected to a computer with AnyMaze software (Stoelting Co.). Distance travelled by the 
animal per 5 min testing period was exported from this software and used for analysis.  
2.2.2 Pilot study – Wild-type animals 
All mice were 3-month-old C57BL6J males sourced from Charles River (Margate, Kent, UK). 
Mice were given 7 days to habituate to the animal facility and were then handled by the 
experimenter briefly once a day for 3 days prior to the start of the experiment. Mice were 
tested in groups of 4-5 per day in a rolling schedule. On day 1 of this protocol mice were 
brought into the testing room in home cages and given 30 minutes to acclimatize to the new 
environment. Mice were then individually placed in the open field (OF) arena and allowed to 
freely explore for 10 minutes. Mice were then placed back in their home cage and remained 
in the testing room for an hour before being placed back in the OF for another 10-minute 
habituation session. Mice were then placed back in their home cage and returned to their 
housing room. On day 2 of the protocol, mice were brought into the same testing room and 
again given 30 minutes to acclimatise. Each mouse was then placed back in the same OF 
arena for 5 minutes of baseline measurements to be taken, before being removed from the 
OF and given a subcutaneous (SC) injection of either sterile saline or 10mg/kg ketamine 
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(Vetalar) administered at 10ml/kg or brief handling (naïve control), before being placed 
immediately back in the OF for a further 55 minutes. Throughout this thesis, Ketamine refers 
to Vetalar, a ketamine hydrochloride injection manufactured by Boehringer Ingelheim and 
used regularly in veterinary practice. This is provided in sterile vials at a concentration of 
100mg/ml and was diluted in sterile physiological saline (Sodium Chloride 0.9%, provided in 
vials from Hameln Pharmaceuticals). Please see figure 10 for a timeline of this protocol, and 
table 5 for group sizes.  Experimenter was blinded to treatment, with the exception of the 
naïve control. Animals were culled after removal from the arena.  
 
Figure 10 - Timeline of ketamine locomotion pilot study protocol. 
Empty boxes represent time spent in home cage in testing room filled boxes represent time 
spent in open field arena. 
2.2.2.1 Main study – GluN2B-2A, GluN2A-2B, PSD95KO & PSD93KO mutants 
Mice were briefly handled by the experimenter for 3 (GluN2A-2B, PSD93KO) or 6 days (all 
other cohorts) prior to experimental day and were tested in groups of 3-4 per day in a rolling 
schedule. On day 1 of this protocol mice were brought into the testing room and given 30 
minutes to acclimatize to the new environment. Mice were then individually placed in the 
open field (OF) arena and allowed to freely explore for 10 minutes. Mice were then placed 
back in their home cage and kept in the testing room for an hour before each being placed 
back in the OF for another 10 min habituation session. Mice were then placed back in their 
home cage and returned to their housing room. On day 2 of the protocol, mice were brought 
into the same testing room and given 30 minutes to acclimatise to the room. Each mouse 
was then placed back in the same OF arena for 15 minutes of baseline measurements to be 
taken, the mouse was then removed from the OF and given a subcutaneous (SC) injection of 
either sterile saline or 10mg/kg Vetalar administered at 10ml/kg, before being placed 
immediately back in the OF for a further 45 minutes. Please see figure 11 for summary of 
protocol and table 5 for information on group sizes.  
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Figure 11 - Timeline of ketamine locomotion mutant study protocol 
Empty boxes represent time spent in home cage in testing room filled boxes represent time 
spent in open field arena. 
 Pilot GluN2B2A(CTR) GluN2A2B(CTR) PSD-93 KO PSD-95 KO 
 WT WT HOM WT HOM WT HOM WT HET HOM 
Saline 6 6 6   5 6    
Ketamine 6 9 9 12 12 7 7 11 8 11 
Naïve  6          
Table 5 - Animal numbers per genotype and treatment group in ketamine locomotion 
experiments. 
WT = wild-type animal, HET = animal heterozygous for knockout or swap mutation, HOM = 
animal homozygous for knockout or swap mutation. Grey boxes indicate that a group was 
omitted from this experiment. Saline control groups were omitted in the case of the GluN2A-
2B and PSD-95 knockout experiments, this was due to limited availability of animals of the 
correct genotype. 
2.2.2.2 Forced-swim testing of ketamine behaviour 
6 mice (3m,3f) were treated with 10mg/kg ketamine administered as 10ml/kg SC. A further 
6 mice (3m,3f) were treated with saline as a control, administered at 10ml/kg SC (table 6). 
24 hours later mice were tested in the forced swim test. Mice were C57/BL6, 4-5mo. FST 
apparatus consisted of two plastic cylinders 25.5cm tall with a diameter of 14cm, containing 
water to a depth of 10cm and maintained at a temperature of 23-25°C (figure 12). Two 
animals were tested simultaneously and were separated from each other and the 
experimenter by opaque dividers. Each pair consisted of one saline and one ketamine-
treated mouse. The test was carried out on one day in a quiet room with consistent light 
levels. The experimenter performing the FST was blinded to the treatments received. Mice 
were placed in the water for 6min and videos were recorded for scoring later. Only the last 
4 min of each video was used for scoring. The videos were randomised and the experimenter 
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was blinded to the identity of each video. The criteria for immobility scoring was defined as 
the mouse remaining completely still, other than slight twitching or small involuntary 
movements as required to remain upright.  
 
 
2.3 Synaptome mapping  
For the basal Arc synaptome map described in section 4.3 ArcVENUS/VENUS mice were taken from 
their home cages and culled and processed as is described in section 2.3.1 onwards. For the 
ketamine Arc and PSD95 synaptome mapping described in sections 4.4-4.5 groups of animals 
were treated with either 100mg/kg ketamine (high dose) 10mg/kg ketamine (low dose) or 
sterile saline, all administered via a subcutaneous route at 10ml/kg. Mice were returned to 
their home cages following administration. At 1h, 6h or 24h animals were sacrificed and 
brains processed as described in section 2.3.1 onwards. Please see table 7 for group sizes. 
Ketamine treatment, perfusion and brain freezing for ketamine synaptome mapping was 
carried out by Dr Jess Nithianantharajah.  
 1h 6h 24h 
saline Low  High saline Low High saline Low High 
Arc-Venus 5 4 4 5 5 4 5 5 5 
PSD95-eGFP       5 4 4 
Table 7 - Animal numbers per treatment group and time point in ketamine synaptome 
mapping experiments. 
2.3.1 Transcardial perfusion and freezing of samples 
Mice were anaesthetised in by intraperitoneal (IP) injection of 0.1 mL of 20% pentobarbital 
sodium (Euthatal, Merial animal health Ltd.) Animals were placed back in their cage until 
unconscious, after which they were transported in the cage to a procedure room for 
Table 6 – Summary of animal 
numbers used in the FST pilot 
experiments. 
 Pilot Pilot 2 
 WT WT 
Saline 6 3 
Ketamine 6 3 
Figure 12 - Diagram of 
forced swim test 
apparatus. 
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perfusion. When no responses were observed from pinching toes or tail, two tail samples 
were taken for PCR genotyping. The mouse was then pinned down on a cork surface and the 
thorax was opened to expose the heart. A small incision was made in the right atrium and 
10mL of cold phosphate buffered saline (PBS, Fisher Scientific), followed by 10mL of cold 4% 
paraformaldehyde (PFZ, Alfa Aesar 16%, diluted 1:4 in PBS), was injected into the left 
ventricle. The brain was then dissected out and post-fixed in 4% PFA at 4°C for 3-4h. Brains 
were cryoprotected by incubation in 30% sucrose (VWR chemicals, w/v in PBS) at 4°C for 72h. 
Brains were then prepared for embedding by incubation in a 50:50 solution of optimal cutting 
temperature (OCT) medium (VWR international) and 30% sucrose for 1h at 4°C. Following 
this, brains were embedded in a plastic mould (Sigma-aldrich) containing OCT and 
immediately frozen in a container of isopentane (Sigma-Aldrich) placed in liquid nitrogen. 
Once frozen, brains were stored at -80°C. Brains were protected from the light as much as 
possible throughout the processing steps detailed above. 
2.3.2 Cryosectioning   
18µm thick coronal sections were cut with a cryostat (NX70 Thermo Fisher) and directly 
mounted on glass superfrost plus microscopy slides (Thermo Scientific). A drop of PBS was 
applied to each slide before collection of the section. The atlas used to guide sectioning was 
‘The Mouse Brain in Stereotaxic coordinates’ by G. Paxinos and K. B. J. Franklin. Slides were 
then left to dry overnight at room temperature, during which time they were protected from 
light. Slides were then stored at -80°C. Some PSD95-eGFP samples were sectioned by Jamie 
Rose and Ellie Tuck.  
2.3.3 Immunohistochemistry 
Brain sections were first rinsed for 5 min in PBS. A PAP pen was then used to form a 
hydrophobic barrier encircling each brain section. For each incubation 50µl of solution was 
applied to each section, sections were kept in a dark, damp chamber throughout. Sections 
were incubated with blocking solution consisting of tris buffered saline (TBS, Fisher Scientific) 
containing 5% bovine serum albumin (BSA, Sigma-Aldrich) and 0.2% triton-X (Sigma-Aldrich) 
for 2 hours. Sections were then incubated with the same blocking solution containing a 
primary antibody against VGlut1 (cat no. 75-066, Neuromab), at a concentration of 1:250, 
overnight at 4°C. This was followed by 3x 10min washes with TBS containing 0.2% triton-X. 
Sections were then incubated with blocking solution containing an anti-mouse IGg1 Alexa 
Fluor 555 secondary antibody (cat no. A21127, ThermoFisher Scientific) at a concentration of 
1:500, and 4’,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) at a concentration of 1:1000, 
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for 1 hour at room temperature. This was followed by 3x 10 min washes of TBS containing 
0.2% triton-X, a final 10 min wash of TBS only was then carried out and coverslips were 
applied as described in section 2.4.5.  
2.3.4 Preparation of Mowiol mounting medium  
Mowiol was prepared by dissolving 96g of glycerol (Sigma-Aldrich, BioXtra >99%) and 38.4g 
Mowiol (Calbiochem) into 192 mL 0.2M Tris buffer (pH8.5) and 96 mL milliQ water (18.2MΩ) 
by heating to 50°C until clear. This solution was then centrifuged at 8,500 rpm for 15 min at 
4°C, supernatant was collected and 2.5% DABCO (1,4-Diazabicyclo[2.2.2]octane, Sigma-
Aldrich) added to prevent photobleaching. 
2.3.5 Application of coverslips 
Slides were removed from the freezer and allowed to dry for 1hr at room temperature, in 
the dark. Slides were then rinsed in PBS for 5 min, following which 10µl of Mowiol mounting 
media (see 2.6.3) was applied to each brain section. Each section was covered with a 13mm 
diameter round cover glass, thickness No. 1,5 (VWR International). Slides were left overnight 
at room temperature, in the dark, to allow the mounting media to ‘cure’.  
2.3.6 Spinning disk confocal Imaging  
For synaptome mapping whole coronal sections were imaged with the Revolution XDi 
spinning disk microscopy (SDM) system from Andor technology. The use of this system for 
synaptome mapping was pioneered by Dr. Melissa Cizeron and full details can be found in 
her PhD thesis. Briefly the Revolution XDi system uses CSU-X1 which has a 50µm pinhole, and 
an Andor iXon Ultra monochrome back-illuminated EMCCD camera for detection. Images 
generated by this system are 16 bit depth and 512 x 512 pixels. Pixel size is 84nm. An Olympus 
uPlanSAPO 100X oil immersion lens (NA 1.4) was used for all image acquisition. Please see 















Arc-Venus basal map 515nm 40% 120ms 540/30 2 250 
Arc-Venus ketamine 488nm 10% 70ms 525/50 4 250 
PSD-95 eGFP 
ketamine 
488nm 60% 50ms 525/50 2 250 
Arc-Venus with 
VGlut1 staining  
515nm  40% 120ms 540/30 2 250 
561nm 40% 55ms  2 250 
Arc-Venus with DAPI 
staining 
488nm 40% 120ms 525/50 2 250 
405nm 18% 55ms 452/45 2 250 
Table 8 - Spinning disk confocal microscope aquisition settings used for synaptome 
mapping datasets. 
For synaptome mapping the SDM was set up to acquire sequential images across a 
rectangular grid with 0% overlap between adjacent tiles. The grid was defined by the user 
and covered the whole brain section. A small number (~4) of reference focus points were 
applied to the grid manually to create a map, from which the optimal focal plane for the 
intermediate tiles was calculated by the system and automatically applied during image 
acquisition. No z stack was taken. For imaging of VGlut1 and DAPI staining the SDM was used 
to take individual tile images. Three images were taken per target brain region per mouse.  
2.3.7 Image analysis and quantification  
The Ensemble method of puncta segmentation and quantification, which was applied to the 
Arc-Venus and PSD95-eGFP synaptome mapping datasets described in this thesis, was 
developed by Dr. Zhen Qiu and Melissa Cizeron. It is not related to the Ensembl Genome 
Browser. Full details and validation of the method can be found in Melissa’s thesis and the 
first data generated using this method was recently published (Zhu et al., 2018). All of the 
below puncta detection, characterisation and mapping functions were carried out by code 
written by Dr Zhen Qiu in either Matlab or Python, which was run either by Dr Zhen Qiu or 
Sarah Lemprière. Credit also goes to Alistair Tullo for work on earlier versions of the 
synaptome mapping pipeline.  
2.3.7.1 Delineations 
The grid of tiled images acquired by the SDM was manually segmented into defined 
anatomical regions of interest to enable informative analysis of the puncta detection data. 
First, a Matlab script written by Dr. Zhen Qiu was used to produce a low resolution overview 
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of each acquired grid, generated by downsizing the individual tile images by a factor of 16. 
These TIFFs were then stitched together using the grid dimensions present in the metadata 
(see appendix 9 for Matlab script). These overview stitched images were then opened in 
Fiji/ImageJ. Image J is a public domain image processing program and can be downloaded for 
free (https://imagej.nih.gov/ij/download.html). Fiji is a version of ImageJ which comes pre-
loaded with plugins for scientific image analysis and is also freely available 
(https://imagej.net/Fiji/Downloads). The ‘polygon selection’ tool was then used to delineate 
the borders of individual anatomical regions contained in the brain section as defined by the 
Allen Mouse Brain Atlas (http://mouse.brain-map.org). Each region was then added as a 
region of interest in the Fiji ROI manager and all regions for one brain section were saved as 
a zip file for use in generation of the synapse maps. 
2.3.7.2 Generation of training set and manual punctum counting  
The Ensemble method first requires the generation of a training set of images, which are a 
subset of the total dataset to be analysed. These were randomly selected by Dr Zhen Qiu, 
from a combination of brain regions and sections representative of the range of synaptic 
characteristics present in the dataset as a whole. This was carried out separately for the Arc-
Venus dataset and the PSD95-eGFP dataset.  The ‘Cell Counter’ plugin for Fiji, built by Kurt 
De Vos (https://imagej.nih.gov/ij/plugins/cell-counter.html), was used to record the 
coordinates of puncta within each of the training set images, as defined by the individual 
observer. The Arc-Venus basal training set was counted independently by 4 individuals, these 
were Dimitra Koukaroudi, Malik Yousuf, Alexander Gunn and Sarah Lemprière. The Arc-Venus 
ketamine training set was counted independently by 3 individuals, these were Ellie Tuck, Jess 
Nithianantharajah and Sarah Lemprière. The PSD95-eGFP training set (288 images) was 
counted by Dr Melissa Cizeron, Vlad Anto and Andreii Kolesnyk. 
2.3.7.3 Generation of Synaptic puncta detection parameters 
This set of training images, with their accompanying puncta coordinates, were then used to 
train an algorithm designed to select a set of puncta detection parameters. This method 
differs from previously used image analysis methods in that it uses several different filters or 
thresholds and intelligently combines the thousands of detection results. The combination 
of thresholds/filters and other parameters are trained automatically by a machine learning 
algorithm, called ensemble learning, to produce a detection result as close as possible to the 
manual detection carried out on the training image set. This method of parameter selection 
was designed and carried out by Dr Zhen Qiu. One set of parameters was chosen for each 
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Arc-Venus training set (488nm and 515nm acquisition) and one for the PSD95-eGFP training 
set. The PSD95-eGFP parameters were determined from a training set drawn from Dr Melissa 
Cizeron’s data and had previously been used to analyse the data in her thesis and in the 
recent publication (Zhu et al., 2018). Those, and the chosen Arc-Venus parameters, were then 
used to detect puncta in the datasets presented in this thesis, using the pipeline described 
below. 
2.3.7.4 Generation of synapse maps   
The puncta detection parameters determined by the manual counting described above were 
then applied to entire SDM datasets using code written by Dr Zhen Qiu. This code also 
segmented puncta and determined their mean pixel intensity and overall size. The steps 
involved in this process are summarised below and in figure 13.  
Step 1: Puncta segmentation 
Prior to segmentation the 512 x 512 pixel tiles acquired by the SDM were each split up into 
4 smaller tiles of 256 x 256 pixels. The puncta detection parameters were then applied to 
each tile and the characteristics of the detected fluorescent puncta, such as their size, shape 
and fluorescence intensity were quantified. In order to do this the 9 pixels with the highest 
intensity were identified for each punctum, an average intensity of these 9 was calculated 
and the edge of the punctum was defined by the first pixels to fall below a certain percentage 
of that maximum intensity level. For the datasets presented here that percentage was 15%. 
Once the boundaries of each punctum were defined, the mean intensity and the size of each 
punctum was calculated. The mean intensity value is the average intensity of all pixels 
contained within the punctum. The size value is the number of pixels contained within the 
punctum. A text file containing the coordinates of each individual punctum along with its 
characteristics was generated for each 256 x 256 pixel sub tile.  
Step 2: Generation of a 3D array ‘Stat_Sum’ image  
The text files generated in step 1 were then translated into a 3D array in which each pixel 
represents one sub-tile. In this array x and y are the coordinates of the sub-tile and each 
measurement (Puncta number, size and intensity) is represented at a different z level. The 
value for the pixels within this array are determined by the sum of the given measurement 
for all puncta within the sub-tile represented. The mean value per sub-tile was then 
calculated by dividing this sum by the number of puncta detected within that sub-tile.  
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Step 3: Generation of binary masks  
The .zip files containing the manually delineated regions were then converted into a set of 
binary masks, one per region.  
Step 4: Generation of the regional values ‘Stat_Region’ 
The binary masks were then applied to the ‘Stat_Sum’ array to determine which sub-tiles 
were contained within a given region. A median value was then calculated for each 
measurement, for each delineated region. These were exported as a Microsoft Excel file and 
used for analysis. 
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2.3.7.5 Analysis of VGlut1 and DAPI staining  
For VGlut1 and DAPI staining images synaptome mapping was not carried out. One of three 
mice imaged was selected as representative of the group, representative images were 
selected from that mouse for visual presentation in this thesis. 
Figure 13 - Schematic diagram of image analysis pipeline 
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2.4 Statistical analysis 
2.4.1 Analysis of behavioural testing data  
Each behavioural testing dataset consisted of two or more treatment/genotype groups and 
16 time periods. In order to compare between treatment/genotype groups at each individual 
time period ordinary two-way ANOVAs were used. These were followed by the appropriate 
post-hoc multiple comparisons testing for the number of treatment/genotype groups being 
compared. For a two-group comparison (e.g. figure 17A) Sidak’s multiple comparisons test 
was used, for more than two groups (e.g. figure 16A) Tukey’s multiple comparisons test was 
used. In the case of multiple groups being compared to one control group (e.g. figure 18A) 
Dunnett’s multiple comparisons test was used.  
In addition to this comparison of all 16 time periods, the total distance travelled during the 
first 15 min post-administration was compared between treatment/genotype groups. All 
datasets were found to be normally distributed with the Shapiro-Wilk test of normality. For 
datasets with only two treatment/genotype groups an unpaired t-test was carried out. For 
datasets with more than two treatment/genotype groups an ordinary one-way ANOVA was 
carried out, followed by Tukey’s multiple comparisons test. All tests were carried out using 
the Prism statistical package (GraphPad Software, San Diego). 
2.4.2 Analysis of synaptome mapping data  
For the basal Arc synaptome map presented in section 4.4 of this thesis a two-way ANOVA, 
followed by Sidak’s multiple comparisons was used to test for a significant difference 
between the left and right hemispheres in the 7 main anatomical regions. As no significant 
difference in puncta density, size or intensity was identified between hemispheres in the 
basal Arc map, for the ketamine synaptome mapping data an average value of both 
hemispheres was calculated for each of the anatomical regions in each mouse.  
For the ketamine synaptome mapping experiments, presented in sections 4.6 & 4.7, multiple 
t-tests, one per brain region, were used to compare the saline group to each of the treatment 
groups. In this analysis no correction for multiple comparisons was used, therefore increasing 
the likelihood of false positives. However, a form of correction was implemented in the 
interpretation of these results by focusing on clusters of significantly-affected regions within 
a common anatomical area. If several related regions are changing together this reduces the 
chance of the individual results being false positives. A common form of correction for 
multiple comparisons is the Bonferroni correction, in order to reduce the likelihood of false 
positives this correction is carried out by testing each individual hypothesis with a higher 
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significance threshold. The corrected threshold is calculated by dividing the original threshold 
(usually p<0.05) by the number of comparisons, in the case of the synaptome data this is 86, 
one comparison per brain regions. Applying the Bonferroni correction to this data would 
change the critical p value from the usual p<0.05 to p<0.00056. Therefore, regions with p 
values of >0.00056 and not surrounded by significant changes in one or more anatomically-
related regions will not be discussed.  
The Cohen’s d effect size of the change in synaptome map properties from saline control, to 
either the high- or low- ketamine dose groups was calculated for each region using the 
equation below:  
 
Where x is the mean and s, the pooled standard deviation, is defined as: 
  
This gives a number based on the number of standard deviations which separate the means 
of the two groups. The more SDs between the means, the larger the Cohen’s d value. A 
positive value is an increase from the control group and a negative value is a decrease from 
the control group. For the ketamine synaptome data these Cohen’s d values were presented 
on a colour scale with positive values on a white-red scale and negative values on a white-
blue scale. Please see appendix 17 for visual examples of the spread of data points resulting 
in different effect size values.  
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Chapter 3 Ketamine-induced behaviour in PSD 





Ketamine has both short-term psychotomimetic, and long-term antidepressant, effects in 
humans and in rodent models. In rodent models, the short-term psychotomimetic effects 
have been studied by observing the behaviour of animals in an open field arena immediately 
after ketamine administration. Transient hyper-locomotion following administration of a 
sub-anaesthetic dose of ketamine has been reported (Irifune et al., 1991) and this response 
is reduced by treatment with antipsychotic medication (Irifune et al., 1998; Chatterjee et al., 
2011). The hyper-locomotive response in rodents is thought to be a correlate of the short-
term psychotomimetic response observed in human subjects (Zarate et al., 2006), which can 
include psychomotor agitation (Domino, 1984). The long-term antidepressant effects of 
ketamine have been frequently assessed in rodents using behavioural despair paradigms 
(Rosa et al., 2003; Autry et al., 2011), in which an animal is placed in an uncomfortable 
situation and the time spent immobile, or not trying to escape, is recorded. Decreased 
immobility time is taken as evidence of antidepressant action and can be induced by existing 
antidepressant medications (Cryan et al., 2005; Pollak et al., 2010). In the case of sub-
anaesthetic does of ketamine, a reduction in immobility time has been reported from 30 min 
to 7 days post-administration (Autry et al., 2011; Tizabi et al., 2012).  
Although its primary action is thought to be NMDA receptor antagonism, the molecular 
mechanism(s) underlying ketamine’s effects are still unclear. Recent evidence has strongly 
implicated GluN2B-containing NMDA receptors in ketamine’s antidepressant action (Miller 
et al., 2014). However, ketamine appears to bind to both GluN2A- and GluN2B-containing 
receptors with the same affinity (Yamakura et al., 1993; Kotermanski & Johnson, 2009), it is 
therefore unclear how this specificity is arising. The amino acid sequences of the GluN2A and 
2B subunits are highly similar, with the exception of the c-terminal domain (CTD) (Ryan et al., 
2008). The sequence divergence in the CTD of these two subunits results in a specific set of 
intracellular interactors for each. For example, the GluN2B CTD interacts specifically with 
CaMKII, RasGFR1 and SynGAP (Leonard et al., 1999; Strack et al., 2000; Krapivinsky et al., 
2003; Kim et al., 2005). The GluN2B CTD is also specifically required, in combination with 
PSD95 and PSD93, for assembly of the 1.5MDa supercomplexes found at the PSD. Absence 
of any one of these three elements prevents formation of the supercomplex (Frank et al., 
2016). Several members of the NMDAR supercomplex have also been found to be 
upregulated following ketamine administration, these include PSD95 and Arc (Li et al., 2010). 
This divergence of the CTD between GluN2A and 2B, and the specific role of the GluN2B CTD 
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in forming supercomplexes, raises the question of whether the reported GluN2B specificity 
of the ketamine response could be explained by a specific action of its CTD.  The aim of the 
experiments described in this chapter therefore, was to establish whether the CTD of the 
GluN2B subunit is functionally important for the action of ketamine, and whether this is 
due to its role in assembling the 1.5MDa supercomplex at the PSD. In order to achieve this, 
the short-term hyper-locomotive response to ketamine was assessed in several mouse lines, 
each containing mutations in one of the proteins of interest.  
3.2 Summary of methods used in this chapter  
3.2.1 Animals  
In order to dissect out the role of the GluN2B c-terminal domain in ketamine action, 
independent from that of its ligand-binding or transmembrane domains, two complementary 
mutant mouse lines were used. The GluN2B2A(CTR) line contains a replacement of the GluN2B 
CTD with the CTD of the GluN2A subunit. The GluN2A2B(CTR) line contains the inverse: a 
replacement of the GluN2A CTD with that of the GluN2B subunit. This genetic manipulation 
leaves the remaining domains of the receptor unchanged. These animals show no alteration 
in total amount of the modified subunit and display normal synaptic NMDA current and 
AMPA/NMDA ratio, suggesting that synaptic localisation of these receptors is not altered by 
the CTD replacement (Martel et al., 2012; Ryan et al., 2013).  
 
Figure 14 - Schematic diagram showing the replacement of c-terminal domains in 
GluN2A2B(CTR) and GluN2B2a(CTR) mutants. 
In order to investigate the roles of PSD95 and PSD93 in the action of ketamine, two knockout 
mouse lines were used. The PSD95 knockout line contains a deletion of the part of the gene 
encoding the GK domain of the protein. This results in near complete absence of PSD95 
mRNA, through nonsense-mediated decay, and no detectable protein in homozygous 
animals (Yao et al., 2004; Abbas et al., 2009). In the PSD93 knockout line the exon containing 
PDZ domain 2 has been removed, this results in disruption of the gene and the absence of 
PSD93 protein in homozygous animals (McGee et al., 2001).  
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3.2.2 Ketamine-induced hyper-locomotion 
For the pilot open-field locomotion study 3-month-old C57BL6J males were sourced from 
Charles River (Margate, Kent, UK). Animals were habituated to the open field (OF) arena 
during two 10 min exploration sessions the day before the experimental day. On the 
experimental day animals were given a 5-minute acclimatisation period in the arena. 
Ketamine (10mg/kg at 10ml/kg) or saline (10mg/kg) was administered via subcutaneous (SC) 
injection and animals were immediately placed back in the arena for a 55 min testing period. 
A naïve control group was also included, animals in this group were briefly removed from the 
open field arena after the acclimatisation period before being placed back in for the testing 
period. All groups in the pilot study contained 6 animals. For the subsequent open-field 
locomotion experiments GluN2B2A(CTR), GluN2A2B(CTR), PSD95 knockout and PSD93 knockout 
animals were bred to homozygosity. For the PSD95 knockout experiment a group of animals 
heterozygous for the mutation were also used. Wild-type controls were also sourced from 
the same colonies. These experiments followed a similar format to the pilot study: two 
habituation sessions of 10 min each were carried out the day before the experiment. 
However, on the experimental day the acclimatisation period was extended to 15 min. As 
before, ketamine (10mg/kg at 10ml/kg) or saline (10ml/kg) was then administered via SC 
injection. The testing period began immediately after injection and lasted 45 min. During all 
periods in the open-field arena movement of the animal was tracked by a ceiling-mounted 
camera connected to a computer with AnyMaze software (Stoelting Co.). Distance travelled 
by the animal per 5 min testing period was exported from this software and used for analysis. 
For this study the group sizes varied depending on the mutant line, for PSD95 knockout and 
GluN2A2B(CTR) swap animals a saline control group was omitted due to lack of available animals 
see table 5 in chapter 2.  
3.2.3 Ketamine-induced ‘antidepressant effects’ 
For the first forced swim test pilot study, 4-5-month-old wild-type C57BL6J mice were 
sourced from an in-house colony. 10mg/kg ketamine or saline was administered at a volume 
of 10ml/kg via SC injection; 6 animals were included in each treatment group. Animals were 
briefly handled for several days prior to the experimental day to acclimatise them to the 
experimenter. 24h following administration animals were placed in a plastic cylinder 
containing water to a depth of 10cm, meaning they could not reach the base of the cylinder 
and had to float or swim. Mice remained in the water for 6 min, during which their behaviour 
was recorded with a fixed camera. The last 4 mins of each video was scored in a blinded 
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fashion for time spent immobile. For the second pilot study the protocol was adapted as 
follows. Injection volume was reduced to 5ml/kg maintaining final dosage at 10mg/kg, this 
was with the aim of increasing the efficiency of dose delivery. The depth of water was 
increased to 20cm. Steps were also taken to decrease the stress of the animals by handling 
them more frequently prior to the experimental day. This second pilot study was carried out 
by Victoria Hohendorf, an undergraduate student, under the supervision of Dr Szu-Han Wang 
and Sarah Lemprière.  
3.2.4 Statistical analyses 
The statistical tests used varied depending upon the nature of the dataset and are described 
in the legend of each figure. All tests were carried out using the Prism statistical package 
(GraphPad Software, San Diego).  
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Figure 15 - Summary diagram of ketamine behavioural testing apparatus and protocols. 
(Continued on following page) A. Open-field apparatus used for ketamine-induced hyper-
locomotion testing. Open-field arena measured 50cm x 50cm and the walls were 25cm high. 
Movement of mice was tracked by a ceiling mounted camera. Coat colour of all mice was 
black, open field arena was constructed from white plexiglass. B. Forced-swim test apparatus 
used for testing of ketamine-induced antidepressant effects. Animals were placed in a clear 
cylinder filled with water to a depth of 10cm, kept at a temperature of 23-25°C. Movement of 
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the animals was recorded by a tripod mounted camera recording a side view of the cylinder. 
C. Pilot open-field ketamine protocol. Day one contained two 10 min habituation sessions in 
the open field arena, separated by 1h rest in the home cage. Day 2 contained one 5 min 
baseline recording session, followed immediately by SC administration of ketamine of saline, 
and a further 55 min recording session. D. Final open-field ketamine protocol. Day 1 contained 
two 10 min habituation sessions in the open field arena, separated by a 1h rest period in the 
home cage. Day 2 contained one 15 min baseline recording session, followed immediately by 
SC administration of ketamine or saline, and a further 45 min testing session. E. Forced-swim 
test ketamine protocol. Administration of ketamine or saline was carried out on day 1. On day 
2, 24h post-administration, animals were tested in the forced-swim test for 6 min. The last 4 
min of the testing session was used for scoring. 
3.3 Ketamine-induced hyper-locomotion results 
3.3.1 Pilot study 
In this protocol two habituation sessions were used to enable the animal to acclimatise to 
the OF arena prior to the testing day. During these two habituation sessions the average 
distance travelled by all groups gradually decreased as mice became more familiar with the 
environment and reduced their exploratory behaviour. Mean distance travelled decreased 
significantly from 18.55m during the first 5 min of to 10.34m during the final 5 min of 
habituation (p<0.0001, figure 16B). This response to repeated OF exposures is well 
documented (Bolivar et al., 2000). In the ketamine-treated group there is then a significant 
increase in distance travelled at 5, 10 and 15 min post-administration, as compared with 
either the saline-treated or naïve groups (figure 16A. KET vs SAL: 5 min p<0.0001, 10 min 
p<0.0001, 15 min p<0.0001). This reaches a peak during the 5-10 min post-administration at 
which point there is a 137% increase in mean distance travelled from the 5 min ‘baseline’ 
period immediately preceding ketamine administration (BL = 12.87m, 5-10 min post-
administration = 30.54m). This time course of hyper-locomotion is consistent with published 
findings, where 10mg/kg ketamine induced an increase in locomotion during the 0-10 min 
post-administration, but was close to baseline during the 10-20 min  period (Irifune et al., 
1991). Based upon this evidence, for the remaining open-field experiments presented here I 
have defined the ‘ketamine response window’ as the 15 min immediately following ketamine 
administration. Figure 16C shows a significant increase in total distance travelled during the 
ketamine response window in the ketamine-treated group (KET v SAL p = 0.0002, KET v NAÏVE 





Figure 16 - Ketamine-induced changes in locomotion in wild-type C57BL6 mice. 
A. Distance travelled in open-field arena per 5 min segment across all open field sessions. 
Data points = mean, error bars = standard error of the mean (SEM). * = p<0.0001 KET vs SAL, 
+ = p<0.0001 KET vs NAÏVE, two-way ANOVA with Tukey’s multiple comparisons test.  B. 
distance travelled by individual mice per 5 min during habituation and baseline sessions. Data 
points = individual animals. All treatment groups pooled. ns = p>0.05, ** = p<0.01, one-way 
ANOVA with Bonferroni multiple comparisons test C. Distance travelled in open-field arena 
during the 15 min immediately following ketamine administration. Data points = individual 
animals, error bars = SEM. *** = p<0.001, one-way ANOVA with Tukey’s multiple comparisons 
test. N = 6 animals per group. HAB = habituation session, BL = Baseline session. 
3.3.2 GluN2B-2A & GluN2B-2A swap mutants  
Here, two complementary genetically modified mouse lines were used, in the first of which 
(GluN2B2A(CTR)) the CTD of the GluN2B NMDA receptor subunit has been replaced with that of 
the GluN2A subunit, leaving the other receptor domains unchanged. GluN2B2A(CTR) animals 
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travelled further than wild-type during the second habituation session, and the first 10 min 
of the baseline session (GDL vs WT: HAB2 0-5 min p = 0.0005, HAB2 5-10 min p = 0.04, BL 0-
5 min p < 0.0001, BL 5-10 min p = 0.0158). Indeed, when total distance travelled during the 
entire habituation time is compared, GluN2B 2A(CTR) mutants travelled significantly further 
than wild-type controls (appendix 2). This suggests a baseline level of increased locomotion, 
which could be interpreted as this mutation mimicking the effects of sub-anaesthetic 
ketamine. However, there was no significant difference between GluN2B2A(CTD) and wild-type 
during the 5 minutes immediately preceding ketamine administration, suggesting that 
GluN2B(2ACTR) mutant animals are able to be habituated to an environment and no-longer 
exhibit unusual levels of locomotion when the open field arena is familiar to them. From 
figure 17A it is clear that the wild-type animals are responding to ketamine in a similar way 
to those in the pilot study, displaying a significantly greater amount of locomotion than the 
saline group at 0-5 (p = 0.0016), 5-10 (p < 0.0001) and 10-15 min (p = 0.0198) post-
administration. Again, the peak distance travelled by wild type animals was reached during 
the 5-10 min post ketamine administration and this was a 136% increase from the final 5 min 
of baseline recording (BL = 8.74m, 5-10 min = 20.86m). However, no such ketamine-induced 
increase was seen in the GluN2B2A(CTD) group. There was no difference between saline- and 
ketamine- treated GluN2B2A(CTD) animals at any time point during the protocol. In fact, at the 
time point when wild-type animals are exhibiting their peak ketamine-induced hyper-
locomotion, the distance travelled by the GluN2B2A(CTD) group shows a 33% reduction from 
baseline level (BL = 12.29m, 5-10 min = 8.23m). This lack of a response to ketamine in the 
GluN2B2A(CTD) group is clear when total distance travelled during the 15 min ‘response 
window’ is compared (Figure 17C). There is a significant increase in the wild-type ketamine 
group (mean distance 48.09m KET, 16.13 SAL, p = 0.0070) but no significant difference in 
distance travelled between the ketamine- and saline-treated GluN2B2A(CTD) animals (mean 
distance 26.16 KET, 24.62 SAL, p = 0.9981). This shows that in the absence of the GluN2B CTD 
animals do not respond to ketamine by exhibiting short-term hyper-locomotion. 
In the second of these complementary mouse lines (GluN2A2B(CTD)) the reverse swap has 
taken place, to replace the GluN2A CTD with that of the GluN2B subtype. In this case a saline 
control group was omitted due to limited numbers of mutant animals available. Following 
ketamine administration wild-type animals exhibited a peak 60% increase in distance 
travelled from baseline level (BL = 11.15m, 5-10 min post-administration = 17.84m) 
suggesting that ketamine is acting to increase locomotion, although to a lesser degree than 
 66 
in the previous two control groups (previously 137% and 136%). The GluN2A2B(CTD) mutant 
group displayed a significantly greater level of locomotion in the 15 min following ketamine 
administration than wild-type (figure 17D, mean distance 46.32m WT, 70.59m GluN2A-2B, p 
= 0.0019). There is also a trend towards increased locomotion in these mutants during some 
of the habituation and baseline recording sessions, prior to ketamine administration, this 
does not reach significance in the sidak’s multiple comparisons test for any individual 5 min 
time period. However, there is a significant increase in the sum distance travelled during all 
habituation periods in the GluN2A2B(CTR) group (appendix 2). Therefore, it will be essential to 
repeat this experiment with saline control groups to ensure that the increased ketamine-
induced locomotion is indeed an exaggerated response to ketamine and not a reflection of 
increased background levels of locomotion in these mutants (see section 3.6). However, the 
percentage change in locomotion from baseline to the peak of ketamine effect in the mutant 
group is 128%, considerably larger than the 60% displayed by the wild type group. This 
suggests that in the absence of the GluN2A CTD, and in the presence of additional GluN2B 
CTDs, there is an exaggerated hyper-locomotive response to ketamine. This provides further 






Figure 17 – Effect of GluN2 c-terminal domain swap mutations on ketamine-induced 
hyper-locomotion (following page).  
A. Distance travelled by GluN2B2A(CTR) mutant and wild-type animals per 5 min across all open 
field exploration sessions. Asterisks represent a significant difference between the saline- and 
ketamine- treated wild-type groups (* = p<0.05). There were no significant differences 
detected between the saline- and ketamine- treated GluN2B2A(CTR) groups. 2-way ANOVA with 
Sidak’s multiple comparisons test. B. Distance travelled by GluN2A2B(CTR) mutant and wild-type 
animals per 5 min across all open-field exploration sessions. * = p<0.05 GluN2A2B(CTR KET vs 
WT KET, 2-way ANOVA with Sidak’s multiple comparisons test. C. Effect of GluN2B2A(CTR) 
mutation on distance travelled during ketamine response window. ns = p>0.05, * = p<0.05, 
** = p<0.01, one-way ANOVA with Tukey’s multiple comparisons test. D. Effect of 
GluN2A2B(CTR) mutation on distance travelled during ketamine response window. ** = p<0.01, 
unpaired t-test. A & B data points = mean, error bars = SEM. C & D data points = individual 
animals, error bars = SEM. 
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3.3.3 PSD-95 knockout mutants 
PSD95-/- animals displayed reduced levels of locomotion as compared with wild type controls 
at two time points during the habituation sessions (figure 18A PSD95-/- vs WT: HAB1 0-5 min 
p = 0.0356, HAB2 5-10min p = 0.0320). However, during the baseline recording session no 
such differences were detected, there was also no significant difference in the sum distance 
travelled during all habituation periods (see appendix 2). Again, for this experiment a saline 
control group was omitted to enable a large enough n number for useful comparisons. 
However, in the wild-type group there was a 103% increase in locomotion at 5-10 mi post-
administration, as compared with the 5 min preceding administration (BL = 7.45m, 5-10 min 
post-administration = 15.19m). This suggests that ketamine is having the expected effect. 
The PSD95-/- group had a significantly lower level of activity during this 5-10 min post-
administration (figure 18C WT = 15.19m, PSD95-/- = 9.64m, p = 0.0307). This suggests that, 
similarly as with the GluN2B2A(CTD) mutants, the ketamine hyper-locomotive response is 
diminished in the absence of PSD95. However, when the total distance travelled during the 
15 min ‘ketamine response’ window was compared, there was no significant difference 
between wild-type and PSD-95-/- or PSD-95-/+ animals (WT = 36.61m, PSD95-/- = 24.58, p = 
0.2349. WT = 36.61m, PSD95-/+ = 43.57m, p = 0.6540). Therefore, although there is a similar 
trend, the effect of the PSD95-/- mutation is less pronounced than that of the GluN2B2A(CTD) 
swap, only reaching significance at one 5 min time point.  
3.3.4 PSD-93 knockout mutants 
PSD93-/- animals displayed reduced levels of locomotion as compared with the control group 
during the first 5 min of habituation to the open field (PSD93-/- vs WT: HAB1 0-5 min p = 
<0.0001). However, total distance travelled during all habituation sessions was not 
significantly altered (see appendix 2). Following ketamine administration both the wild-type 
and PSD93-/- groups show increased locomotion as compared with saline controls, this is 
significant at 0-5, 5-10 and 10-15 min post-administration (see figure 18B). This ketamine 
response is even more obvious when you compare the total distance travelled in the first 15 
min following ketamine administration, as in figure 18D, where there is a highly significant 
difference between saline and ketamine groups (mean distance 12.82m WT SAL, 48.98 WT 
KET, p = <0.0001. mean distance 13.98m PSD93-/- SAL, 48.93m PSD93-/- KET, p = <0.0001), but 
no significant difference between wild-type and PSD93-/- (WT KET v PSD93-/- KET p = >0.9999, 
WT SAL v PSD93-/- SAL p = 0.9957). This shows that loss of PSD93-/- does not diminish the 
short-term hyper-locomotive response to ketamine. There does, however seem to be an 
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increase in the duration of that hyper-locomotion as the ketamine PSD93-/- group maintained 
a significant increase in distance travelled over the corresponding saline control group until 
the 20-25 min time point (PSD93-/- KET = 15.18, PSD93-/- SAL = 50.1, p = 0.0398), which is 10 











Figure 18 - Effect of PSD95 & PSD93 protein knockout on ketamine-induced hyper-
locomotion (continued on following page). 
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A. Distance travelled by homozygous PSD95 knockout, heterozygous PSD95 knockout and 
wild-type animals per 5 min across all open field exploration sessions. * = p<0.05 PSD95-/- KET 
vs WT KET, + = p<0.05 PSD95-/+ KET vs WT KET, two-way ANOVA with Dunnett’s multiple 
comparisons. n = 11(PSD95-/-), 8(PSD95-/+), 11(WT). B. Distance travelled by homozygous 
PSD93 knockout and wild-type animals per 5 min across all open field exploration sessions. * 
= p<0.05 WT KET vs WT SAL, + = p<0.05 PSD93-/-KET vs PSD93-/- SAL, two-way ANOVA with 
Tukey’s multiple comparisons. N = 5(WT SAL), 7(WT KET), 6(PSD93-/- SAL), 7(PSD93-/- KET). C. 
Effect of PSD95 knockout mutation on distance travelled during ketamine response window. 
ns = p>0.05, one-way ANOVA with Tukey’s multiple comparisons. D. Effect of PSD93 knockout 
mutation on distance travelled during ketamine response window. ns = p>0.05, *** = 
p<0.001, one-way ANOVA with Tukey’s multiple comparisons. A & B data points = mean, error 
bars = SEM. C & D data points = individual animals, error bars = SEM. 
 
3.4 Ketamine-induced ‘antidepressant’ effects 
A reduction in immobility time in the forced-swim test (FST) has been reported 24hr after a 
10mg/kg dose of ketamine (Zanos et al. 2016, Ma et al. 2013, Liu et al. 2012). The aim of 
these experiments was to replicate these published findings, with a view to then testing the 
4 mutant lines for ketamine-induced ‘antidepressant’ effects. Two pilot studies were carried 
out, the first found no significant difference in mean immobility time between ketamine- and 
saline-treated groups (KET = 61.25% & SAL = 67.66%, p = 0.653). There was, however, an 
increase in the spread of data points in the ketamine group, as can be observed in figure 19A. 
In particular, there are two animals in the ketamine group with immobility times considerably 
lower than the saline group cluster, suggesting that a subset of animals may be responding 
in the expected way to ketamine treatment. A repeat pilot study was then carried out with 
modifications to the protocol aimed at increasing the efficiency of ketamine dose delivery 
and decreasing the stress of the animals on the testing day. This second pilot study also 
scored three different behaviours related to the animals’ attempts to escape: swimming, 
paddling and immobility. With swimming being the strongest attempt at escape and 
immobility being the absence of an attempt. A significant increase in the percentage of time 
spent swimming was observed in the ketamine treated group (SAL=36.3%, KET=57.78%, 
p=0.018). There was also a trend towards decreased immobility in the ketamine treated 
group, visible in figure 19B, although this did not reach significance (SAL=22.22%, KET=2.13%, 
p=0.084). This indicates that ketamine treatment is increasing the drive of the animals to 
escape, and thus is inducing an ‘antidepressant’ phenotype. There was no significant 
difference in time spent paddling (SAL=41.48%, KET=40.09%, p=0.86). A third pilot study has 
since been carried out following small modifications of the protocol including increased 
handling of animals prior to the experimental day, increased familiarisation of animals with 
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testing room, and adaptation of FST apparatus to reduce the ability of animals to view other 
objects in the room during the test. This final pilot study found a significant reduction in 
immobility time in the ketamine treated group, confirming the findings from the second pilot 
study and demonstrating that it is possible to replicate the reported ‘antidepressant’ effects 
of 10mg/kg ketamine in mice. Results from this third pilot study will be reported in the 
undergraduate dissertation of Samuel Bates (BMedSci, University of Edinburgh).  
 
Figure 19 - Effect of ketamine on immobility time of wild-type animals in forced swim test. 
A. Initial pilot study. Percentage of 4 min scoring period spent immobile (s), per mouse, in 
both ketamine and saline treated groups. No significant difference between saline and 
ketamine treated groups (p=0.6533) Unpaired t-test. N = 6 per group. B. Second pilot study. 
Protocol modifications included increased handling prior to experimental day, delivery of 
ketamine solution in smaller volume (5ml/kg) and scoring of three different behavioural 
states. Significant increase in time spent swimming in ketamine group (p=0.0381). No 
difference in other behavioural measures (Paddling p=0.9969, Immobile p=0.0538). Two way 
ANOVA with Sidak’s multiple comparisons. Second pilot study was carried out by Victoria 
Hohendorf, an undergraduate student, under the supervision of Dr Szu-Han Wang and Sarah 
Lemprière. 
3.5 Chapter discussion 
3.5.1 Wild-type hyper-locomotive response to ketamine administration 
In humans, sub-anaesthetic doses of ketamine produce two phases of response. These are a 
short-term dissociation, charactertised by perceptual distortions, and a long-term 
antidepressant effect. The short-term hyper-locomotive response of wild-type animals to 
administration of a sub-anaesthetic dose of ketamine described here is consistent with the 
existing literature (Irifune et al., 1991; Imre et al., 2006; Chatterjee et al., 2011) and is 
considered to be translationally relevant to the short-term dissociative effects seen in 
humans. This translational relevance comes partly from the short duration of response. 
Although plasma concentration of ketamine was not analysed in the experiments presented 
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here, it has a short half-life in mice of ~13 min (Maxwell et al., 2006; Li et al., 2015; Zanos et 
al., 2016). This suggests that the short term hyper-locomotion observed here is taking place 
only during the presence of relatively high concentrations of ketamine, which is in stark 
contrast to the antidepressant effects which are still detectable up to 7 days post-
administration (Autry et al., 2011). Similarly, psychotic-like effects of sub-anaesthetic doses 
of ketamine in humans have been reported during infusion and for a short time (<40min) 
following infusion (Krystal et al., 1994). The hyper-locomotive response of wild type animals 
to ketamine administration was consistently observed throughout all the experiments 
presented here, which were carried out across a period of over 12 months. This highlights 
the utility and the reliability of this model as a measure of short-term ketamine response. 
There was also no difference in wild type hyper-locomotive ketamine response between 
male and female animals (see appendix 1), this was consistent with the literature (Zanos et 
al., 2016).  
3.5.2 The importance of the GluN2B c-terminal domain for ketamine-induced hyper-
locomotion 
The most striking observation from the set of experiments presented here is the absence of 
a ketamine-induced hyper-locomotive effect in the GluN2B2A(CTD) animals and an exaggerated 
response in the GluN2A2B(CTD) mutants. Taken together these observations suggest that the 
GluN2B c-terminal domain is important for this short-term behavioural response to 
ketamine. Although there is evidence that the truncation or removal of CTDs from the 
NMDAR can have an effect on channel conductance properties (Maki et al., 2012), 
replacement of one CTD with that of another subtype is able to rescue that phenotype 
(Berberich et al., 2005). This suggests that the presence of a GluN2 CTD is important for 
channel function, but the replacement of the GluN2B CTD with that of GluN2A would leave 
the GluN2B subtype specific channel properties unaltered. Indeed, NMDA-evoked unitary 
currents from GluN2B2A(CTR) cultured neurons are no different from those in wild type 
neurons, both being approximately 50pS which is typical for GluN2B-containing NMDARs 
(Martel et al., 2012). Therefore, it is unlikely that the absence of ketamine effect seen here 
with the CTD swap mutation is caused by alteration in ion channel properties. There has been 
evidence to suggest that GluN2A-containing receptors are more likely to be synaptic, with 
GluN2B-containing receptors more likely to be found at extrasynaptic sites (Martel et al., 
2009). As the CTD is the receptor domain considered important for this trafficking, there is 
the possibility that the replacement of the GluN2A CTD with that of GluN2B could reduce the 
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number of NMDARs present at synaptic sites. However, NMDAR-mediated EPSCs in 
GluN2B2A(CTR) and GluN2A2B(CTR) mutants are no different from control (Ryan et al., 2013). 
Furthermore, neuronal cultures from GluN2B2A(CTR) animals do not differ from wild type 
cultures in the  proportion of NMDARs that are extrasynaptic, as determined by the quantal 
activation-mediated blockade of synaptic NMDARs using MK-801 followed by the recording 
of whole cell currents (Martel et al., 2012). Finally, there is no difference in the amount of 
GluN2B in PSD-enriched or non-PSD enriched fractions of hippocampal preparations from 
wild type and GluN2B2A(CTR) animals (Martel et al., 2012). This suggests that a reduction in 
trafficking of NMDARs to the synapse is unlikely to account for the ketamine response 
phenotype seen in GluN2B2A(CTD) animals. Even so, an electron microscopy experiment to 
confirm synaptic vs extra-synaptic NMDAR ratios in these mutants is planned, see section 
3.6.1. The replacement mutation also does not alter the total amount of either subunit when 
probed with an antibody against the n-terminal domain in total forebrain extract (Martel et 
al., 2012; Frank et al., 2016). Ketamine is known to bind within the channel pore region 
therefore, as this is region unaltered by the CTD swap mutation, ketamine should be able to 
block GluN2B2A(CTR) and GluN2A2B(CTR) receptors to the same degree as wild-type receptors. 
This is a reasonable assumption to make based on the existing data showing no alteration of 
ion channel properties in the chimeric receptors (Martel et al., 2012). However, an 
experiment to specifically test the blockade of NMDA currents by ketamine in these mutants 
is planned (see section 3.6.1). 
The main role of GluN2 CTDs is to couple to intracellular signalling cascades by binding to a 
diverse range of signalling proteins (Sprengel et al., 1998; Traynelis et al., 2010). The different 
GluN2 subtypes have been found to bind to different sets of signalling proteins, thus enabling 
them to modulate intracellular signalling in a specific way (Krapivinsky et al., 2003; Barria & 
Malinow, 2005; Martel et al., 2012). Taken together, this suggests that a likely explanation 
for the disruption of the ketamine response observed in the GluN2B2A(CTR) mutants is that 
modulation of a GluN2B CTD-specific intracellular signalling event is required for the 
ketamine response. This implies that it is not simple blockade of ion flow, which should take 
place as normal in GluN2B2A(CTR) animals, which is responsible for its psychotomimetic effects, 
but that a specific action of the CTD is involved. This is not the first time GluN2B has been 
implicated in the ketamine response. In  vivo deletion of GluN2B only from principal cortical 
neurons mimics and occludes ketamine’s antidepressant effects (Miller et al., 2014). 
However, the results presented here build on that evidence in two ways. Firstly they show a 
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similar GluN2B specificity of the short-term ‘psychotomimetic’ response of ketamine and 
secondly, they narrow down that specific requirement to the CTD of the subunit. As the 
intracellular signalling function of the CTD is the most likely to be involved here, we can 
therefore look to specific GluN2B CTD interactors for hypotheses as to the molecular 
mechanism underlying short-term ketamine action.  
There are several proteins known to interact specifically with the GluN2B CTD, over that of 
the other GluN2 subtypes. These include the Ras GTPase-activating protein SynGAP (Wang 
et al., 2013), the guanine nucleotide exchange factor Ras-GRF1 (Krapivinsky et al., 2003), and 
Ca2+/calmodulin-dependent protein kinase II (Leonard et al., 1999; Strack et al., 2000; Barria 
& Malinow, 2005; El Gaamouch et al., 2012). These are connected functionally, as well as by 
their association with GluN2B. Upon NMDAR activation there is an influx of Ca2+ which 
triggers the phosphorylation of CaMKII, which in turn phosphorylates SynGAP. When 
phosphorylated, SynGAP exerts a greater inhibitory action on Ras and thus suppresses ERK 
activation (Komiyama et al., 2002; Wang et al., 2013). Ras-GRF1 on the other had responds 
to NMDAR activity by promoting activation of Ras, and thus ERK activation (Krapivinsky et al., 
2003). The interaction between Ras-GFR1 and GluN2B was found to be essential for NMDAR-
dependent ERK activation in neuronal cultures (Krapivinsky et al., 2003). Thus, the nature of 
Ras and ERK signalling resulting from NMDAR activation is controlled by the relative activities 
of SynGAP and Ras-GFR1. The convergence of these GluN2B interactors on the ERK pathway 
is interesting, as increased ERK activation has been observed following sub-anaesthetic 
ketamine administration. Increased levels of phosphorylated ERK were identified in PFC as 
early as 30 min post administration (the earliest time point tested) (Li et al., 2010). Indeed, 
blockade of ERK signalling has been found to prevent the antidepressant action of ketamine 
in the forced swim test (Reus et al., 2014). ERK activation is usually associated with 
transcriptional activation and new protein synthesis which, although it is taking place 
following sub-anaesthetic doses of ketamine (Li et al., 2010), is likely to be too slow to be 
responsible for the hyper-locomotion observed here. However, the Ras-ERK pathway has 
been implicated in the control of synaptic delivery of GluR1 AMPA receptors (Zhu et al., 2002; 
Patterson et al., 2010). This raises the possibility that ketamine-induced alterations in the 
rate of delivery of pre-existing AMPARs to the postsynaptic membrane could play a role in 
the rapid behavioural response, and that this alteration is dependent upon the presence of 
one or more specific GluN2B CTD interactors at the NMDAR. Indeed, a link between GluN2B- 
containing NMDA receptor activity, SynGAP, Ras-ERK signalling, and synaptic weakening via 
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removal of AMPA receptors has been established (Kim et al., 2005; Rockliffe & Gawler, 2006). 
However, as ketamine is a known NMDAR antagonist, blocking Ca2+ influx through the 
NMDAR the activation of this pathway in this context still appears counter-intuitive. Some 
relevant hypotheses as to how ketamine is able to increase neuronal activity were discussed 
in sections 1.3.4.5 & 1.3.4.7 of the introductory chapter and are also covered in several 
reviews (Seamans, 2008; Miller et al., 2016). Perhaps the hypothesis most relevant to the 
finding reported here, is that of tonic GluN2B-specific suppression of protein synthesis in 
response to activation by ambient glutamate. It is suggested that upon ketamine binding to 
GluN2B-containing NMDARs this tonic suppression is lifted, resulting in the increased levels 
of synaptic proteins observed following sub-anaesthetic ketamine administration. Evidence 
to support this hypothesis consists of the observation that protein synthesis is upregulated 
following both knockout of GluN2B and genetic replacement of GluN2B with GluN2A in vitro. 
Ketamine application was able to increase protein synthesis in wild-type but not GluN2B 
knockout cultures. Similar results were found in vivo, with ketamine unable to induce 
increases in BDNF, SAP-102, GluA1 or p-mTOR in animals where GluN2B has been selectively 
removed from principal cortical neurons (Miller et al., 2014) 
Although the NMDAR is considered to be an ionotropic glutamate receptor, there is recent 
evidence that glutamate binding is able to induce LTD in the absence of ion flux (Nabavi et 
al., 2013; Stein et al., 2015; Carter & Jahr, 2016). Further to this, an ion flow independent 
reduction in FRET between GluN1 subunits within individual NMDARs has been identified. 
This can be prevented with intracellular infusion of an antibody targeting the GluN1 CTD 
(Dore et al., 2015). This suggests that the GluN1 subunit is able to alter conformation and 
induce signalling changes in response to agonist binding, in the absence of ion flux. It remains 
to be seen whether the same is true for the GluN2B CTD, however it is an interesting 
possibility. A conformational change to the GluN2B CTD in response to ketamine binding 
within the pore could, in theory, reveal or conceal binding sites for interacting proteins and 
control activation/inactivation of interacting molecules. For example, alterations in the 
ability of SynGAP or Ras-GRF1 to bind to the CTD could potentially lead to alterations in ERK 
signalling independent to changes in Ca2+ influx. Indeed, a Ca2+-independent activation of 
SynGAP has been observed in response to the binding of APV in cortical neurons. This was 
hypothesised to be induced via a conformational change to the CTD, although no direct 
evidence of this was provided (Rockliffe & Gawler, 2006). APV binds to the glutamate binding 
site on the NMDAR and competes with glutamate to produce an antagonistic effect, which is 
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a different mechanism of action to the channel pore blocking effect of ketamine. It also 
appears to have an opposite effect on ERK activation to ketamine. However, the concept of 
Ca2+-independent alterations to SynGAP activity is an interesting one. Further investigations 
planned to test the hypothesis of GluN2B CTD conformational change induced by ketamine 
binding are outlined in section 3.6.4. 
CTD identity has also been found to influence excitotoxicity independently of the identity of 
the other receptor domains. The GluN2B CTD promotes neuronal death better in response 
to NMDA application than the GluN2A CTD. This was determined from experiments on 
neuronal cultures, and in vivo using the same GluN2B2A(CTR) mouse line used for the 
experiments presented here. NMDA application promoted more cell death in wild type than 
GluN2B2A(CTR) animals (Martel et al., 2012). Evidence suggests that this enhanced vulnerability 
to excitotoxicity could be via the GluN2B CTD coupling more strongly to PSD95 and NMDAR 
activity-dependent nitric oxide (NO) production (Martel et al., 2012). NO release is able to 
modulate neurotransmitter release and has been implicated in the regulation of neuronal 
excitability and firing (Prast & Philippu, 2001). There is some evidence to suggest that 
ketamine is acting to reduce NO production and that this is important for its antidepressant 
effects (Zhang et al., 2013; Liebenberg et al., 2015). Reduced NO production has the 
downstream effect of stimulating mTOR signalling (Harraz et al., 2016). NO donor therapy 
has been reported to reduce short-term ketamine hyper-locomotion in mice (Kandratavicius 
et al., 2015). Taken together, this raises the possibility that ketamine could be acting via 
reduced NO production, that this is predominantly via the GluN2B CTD, and is therefore not 
taking place in the GluN2B2a(CTR) mutant animals. 
Overall, the finding that the GluN2B CTD is important for ketamine’s short-term hyper-
locomotive effect builds upon the existing literature to point us towards several possible 
mechanisms by which ketamine may be acting. However, there is much further work 
required to take us forward, some of which is outlined in section 3.6 below.   
3.5.3 Ketamine-induced hyper-locomotion in the absence of the NMDAR 
supercomplex  
Further to the striking effects of the CTD replacement mutations on ketamine-induced hyper-
locomotion, PSD95 knockout also reduced the response to ketamine administration. This 
effect was only significant at 5-10 min post-administration. The ketamine hyper-locomotive 
response was preserved in PSD93 knockout animals, and the duration of this response was 
greater than that of wild type animals. There is a tripartite requirement for PSD93, PSD95 
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and the GluN2B CTD for the formation of NMDAR 1.5MDa supercomplexes (Frank et al., 
2016). Therefore, the presence of the ketamine hyper-locomotive response in PSD93 KO 
animals suggests that it is not the formation of the supercomplex itself that is required for 
ketamine action, because that complex formation would also be disrupted in PSD93 KO. The 
increased duration of hyper-locomotion observed in PSD93 KO animals is also interesting, as 
an increase in PSD95 levels at the synapse has previously been observed in the same PSD93 
KO line as used here (Dr Melissa Cizeron, PhD thesis). This raises the possibility that the 
exaggerated ketamine response observed in the PSD93KO animals could be a result of 
increased PSD95 levels, which would provide further evidence for a requirement of PSD95. 
This is consistent with the upregulation of PSD95 expression following sub-anaesthetic 
ketamine administration (Li et al., 2010; Lisek et al., 2017). Taken together with the findings 
discussed in section 3.5.2, this suggests a role of both PSD95 and the GluN2B CTD in ketamine 
action which is independent of NMDAR 1.5MDa supercomplex formation. Interestingly, 
SynGAP associates with NMDAR complexes via PSD95 and SAP102 (Kim et al., 1998; Wang et 
al., 2013), therefore the potential role for PSD95 in ketamine hyper-locomotion adds more 
weight to the idea that SynGAP could also be involved. Perhaps the less dramatic phenotype 
in PSD95 KO, as compared with the GluN2B2A(CTR) animals, could be due to the ability of 
SynGAP to continue to associate with NMDARs via SAP102 in the absence of PSD95 (Kim et 
al., 1998). Further to that, there is evidence that SynGAP can bind to the GluN2B CTD 
independently of the MAGUKs altogether, via its interaction with CAMKIIa (Li et al., 2001). 
Diminished hyper-locomotive response in the absence of PSD95 is also consistent with the 
suggestion that the NO-related mechanism, thought to be responsible for the role of GluN2B 
NMDARs in excitotoxicity, may also be involved in the ketamine response. There is evidence 
that PSD95 is coupling GluN2B to nNOS, and PSD95 knockdown or disruption of the PSD95-
nNOS interface both have anti excitotoxic effects (Sattler et al., 1999; Cao et al., 2005; Zhou 
et al., 2010).  We now know that PSD95 knockout disrupts ketamine-induced hyper-
locomotion, however it remains to be seen whether disrupting the PSD95-nNOS interface 
has an effect on ketamine response.  
3.5.4 Ketamine’s action in the forced-swim test 
Although the short-term hyper-locomotive response to ketamine is a useful assay of its rapid 
effect, it is the long-lasting antidepressant effect which is currently of particular clinical 
interest. It is still unknown whether these two different responses are mediated by the same 
molecular mechanism. The aim will be to establish whether the GluN2B CTD and PSD95 are 
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also involved in ketamine’s long-term antidepressant effects. Regardless of the findings this 
will be a critically important experiment. If the antidepressant effect of ketamine is not 
dependent upon GluN2B and PSD95, then it will provide an important distinction between 
the mechanism underlying the desirable, and the undesirable, effects of ketamine. If it is 
dependent on GluN2B and PSD95, it opens up the possibility of targeting their downstream 
signalling molecules during further investigation into treatments for depression. Although 
the scope of this PhD project was not sufficient to complete this work, two pilot studies were 
carried out to investigate the effect of ketamine administration on wild type mice in the 
forced-swim test. There are some reports of greater antidepressant potency of ketamine in 
female mice (Carrier & Kabbaj, 2013; Zanos et al., 2016), although no such gender specific 
effect was seen in the first FST pilot study (see appendix 1). There were not sufficient animal 
numbers for a meaningful comparison of gender in the second FST pilot study. The results 
from these pilot studies highlight the importance of thorough preliminary work ahead of any 
behavioural study, and lay the ground work for the testing of mutant cohorts, which is 
ongoing.  
3.6 Future directions  
The evidence presented here raises some interesting suggestions as to how ketamine could 
be acting at the molecular level, however it is incomplete, and further avenues of 
investigation will need to be followed before further conclusions can be drawn.  
3.6.1 Additional control experiments 
An important next step for this work will be to confirm the observation of increased 
ketamine-induced hyper-locomotion in GluN2A(2BCTR) by repeating the experiment with the 
inclusion of saline control groups. This is essential to ensure that the increased locomotion 
observed in the GluN2A(2BCTR) is indeed an exaggerated response to ketamine administration, 
and not simply due to a generally higher level of locomotion in these animals. This is of 
additional importance as a trend towards increased locomotion was observed in 
GluN2A(2BCTR) animals in the habituation sessions. Although this additional experiment is 
important, the primary evidence for the involvement of GluN2B CTD in ketamine action 
comes from the absence of a hyper-locomotive effect of ketamine in GluN2B(2ACTR) mutant 
animals, and all appropriate saline controls were included in that experiment. For similar 
reasons, it will be important to repeat the PSD95 knockout hyper-locomotion experiment 
with saline controls. Homozygous PSD95 mutant animals displayed reduced levels of 
locomotion at two time points during the habituation sessions, although no significant 
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difference in total distance travelled during habituation was observed (appendix 2). 
However, it will be important to ensure that these animals are physically capable of levels of 
locomotion above those observed here. One option for this could be to include a cocaine-
stimulated positive control group, cocaine induces hyper-locomotion in mice but acts at the 
dopamine transporter, not the NMDA receptor (Giros et al., 1996).  
Although basal synaptic NMDA current is normal in swap mutants, which suggests that 
receptors are localized to synapses in the usual way, there is some literature suggesting that 
CTD is important in receptor trafficking, and that GluN2B subunit-containing NMDARs are 
more likely to be found extra-synaptically (Stocca & Vicini, 1998; Tovar & Westbrook, 1999; 
Martel et al., 2009). Therefore, it could be argued that the alteration of the CTD in 
GluN2B2A(CTD) and GluN2A2B(CTD) mutants could be affecting NMDAR targeting to the synapse, 
and thus altering the ketamine response in that way. In order to address this potential 
concern, electron microscopy could be used to establish the ratio of synaptic to extra 
synaptic NMDARs in GluN2B2A(CTD) and GluN2A2B(CTD) mutants, in comparison with control 
animals. Further to this, basic immunostaining for GluN1, GluN2A and GluN2B extracellular 
domains will confirm whether or not the brain wide distribution of NMDAR subtypes is 
perturbed in GluN2B2A(CTD) and GluN2A2B(CTD) mutants.  
Ketamine is known to bind to the PCP site within the NMDAR channel pore (Macdonald et 
al., 1987; Zeilhofer et al., 1992), which is formed by the transmembrane domains of the 
receptor subunits. The genetic manipulations in the GluN2B2A(CTD) and GluN2A2B(CTD) mutants 
are specific to the CTD. However, it could be suggested that this modification of the CTD is 
having an allosteric effect on pore structure which could prevent ketamine binding in the 
GluN2B2A(CTD) mutants. Especially as binding at extracellular receptor domains has been found 
to induce conformational change in the NMDAR CTD (Dore et al., 2015), it is not impossible 
that the inverse may be taking place. This theory can be tested by establishing with 
hippocampal slice electrophysiology whether ketamine can still block ion flow through 
NMDARs in GluN2B2A(CTD) and GluN2A2B(CTD) mutants. This work is ongoing.  
3.6.2 Long-term ‘antidepressant’ action of ketamine  
As discussed in section 3.5.4 it will be essential to know whether the GluN2B CTD is also 
required for the long-term antidepressant effect of ketamine. The pilot studies described in 
section 3.4 have begun this work. A reduction in immobility time is the key measurement of 
antidepressant effects in this assay. A power calculation based on the second pilot study 
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carried out suggests that, if the trend towards a reduction in immobility time in the second 
pilot study represents a true effect, 4 animals per group would be required for it to be 
statistically significant with an alpha error level of 0.05 and a beta error level of 0.2 (power 
0.8). This suggests a small increase in sample size would be sufficient to detect the effect of 
ketamine. Using this information repeat FST experiments are being carried out to test for the 
presence or absence of a ketamine-induced antidepressant effect in GluN2B2A(CTD), 
GluN2A2B(CTD) and other mutant lines.  
3.6.3 Biochemical analysis  
Although it is possible to speculate on the potential signalling cascades involved in ketamine 
action from what we know about GluN2B and PSD95 interactors, it will be important to 
investigate this further experimentally. There are a host of signalling molecules and synaptic 
proteins previously identified as having a role in ketamine action. These include: BDNF, p-
mTOR, p-4E-BP1, p-p70S6K, p-ERK, Synapsin, PSD95, Arc, GluR1, Rheb and others (Li et al., 
2010; Haile et al., 2014; Harraz et al., 2016). The simple next step will be to establish whether 
these changes can be detected in western blot of protein extracts from wild type ketamine- 
and saline-treated animals, and whether those changes are still detectable in the mutant 
lines in which ketamine-induced behaviour is diminished. Of particular interest will be the 
ratio of ERK to phosphor-ERK as discussed in section 3.5.2. This work has already begun, see 
appendix 3 for characterisation of antibodies. Further to this, the question of whether the 
effect on the ketamine response in GluN2B2A(CTR) and PSD95KO animals is due to loss of 
SynGAP at the NMDAR can be addressed with some immunoprecipitation experiments. This 
would establish whether SynGAP is able to interact with the NMDAR in the absence of the 
GluN2B CTD or PSD95.  
3.6.4 Metabotropic action of GluN2B 
The most convincing data for a metabotropic effect of the NMDAR to date has come from 
measuring FRET between fluorescently tagged cytoplasmic domains of GluN1 subunits 
expressed in cultured neurons (Dore et al., 2015). The potential metabotropic action of the 
GluN2B CTD in response to ketamine could be investigated in a similar way by fluorescently 
tagging the GluN2B CTD and measuring FRET in response to ketamine binding.  
3.6.5 Action of other non-competitive NMDAR antagonists  
Another interesting question to answer will be whether or not this GluN2B CTD-specific 
action is a unique characteristic of ketamine, or whether other non-competitive NMDAR 
antagonists can act in the same way. For example, MK-801 is able to induce hyper-
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locomotion (Liljequist et al., 1991) and only a short-term antidepressant response (Autry et 
al., 2011). Therefore, measuring the behavioural responses to MK-801 in WT and 
GluN2B2A(CTR) mice would be an informative next step. Further to this, memantine does not 
produce antidepressant responses, despite also being a non-competitive NMDAR antagonist 
(Gideons et al., 2014).  
3.6.6 Role of SynGAP 
To test the hypothesis that SynGAP action is underlying both the requirement of GluN2B and 
PSD95 for ketamine action, SynGAP1 mutant animals could be tested in the hyper-
locomotion protocol. Several SynGAP1 mutant lines are available (Komiyama et al., 2002), 
including a knockout line and a line with a loss of enzymatic function only (unpublished), 
which would be useful in determining the role of SynGAP action on Ras specifically. 
3.6.7 PSD95-nNOS interface  
The potential role of PSD95-nNOS interaction in the ketamine response could be probed 
using existing molecules generated to disrupt that interaction in vivo (Florio et al., 2009; 
Carey et al., 2017). Absence of ketamine-induced hyper-locomotion in the presence of these 




Chapter 4 Ketamine-induced alterations to the 




Sub-anaesthetic doses of the NMDA receptor antagonist ketamine have been found to 
increase levels of the synaptic proteins Synapsin I, PSD95, GluR1 and Arc during the 72 hours 
following administration (Li et al., 2010; Tang et al., 2015). Protein synthesis is required for 
both the short-term psychotomimetic and long-term antidepressant effects of ketamine 
(Autry et al., 2011). Generation of new dendritic spines has also been identified in the medial 
prefrontal cortex and hippocampus 24h after a sub-anaesthetic dose of ketamine (Li et al., 
2010; Ardalan et al., 2017). This suggests that alteration of the protein composition of 
synapses, and/or generation of new synapses may play a role in the mechanism of ketamine 
action. However, it is still not known which brain regions are involved in this synaptic 
response to ketamine. The dose dependency of synaptic protein changes is also yet to be 
established. There is existing evidence that it is only sub-anaesthetic doses of ketamine that 
are able to induce an antidepressant response (Li et al., 2010). The activation of mTOR and 
ERK signalling by ketamine administration also seems to be specific to doses below 80mg/kg 
(Li et al., 2010). Therefore, it remains to be seen if changes in synaptic protein levels follow 
the same pattern. The results presented in this chapter focus on the investigation of two of 
the synaptic proteins previously identified as part of the ketamine response, Arc and PSD95 
(Li et al., 2010; Autry et al., 2011; Tang et al., 2015). In order to do this, two reporter mouse 
lines were used, in which the endogenous PSD95 or Arc protein is tagged with a fluorescent 
marker (PSD95eGFP and ArcVENUS, respectively). In addition to both being upregulated by sub-
anaesthetic ketamine administration (Li et al., 2010), PSD95 and Arc are both incorporated 
into the 1.5MDa NMDA receptor supercomplex at the postsynaptic density (Frank et al., 
2016). They also interact with each other, PSD95 is Arc’s most abundant interacting protein 
and this interaction appears to be essential for the targeting of Arc to the synapse (Fernandez 
et al., 2017). Both proteins play important roles in brain function and cognition as 
demonstrated by the effect of knockout on animal behaviour. Knockout of Arc impairs long 
term memory (Plath et al., 2006), and loss or reduction of PSD95 has been found to impair 
learning of a spatial memory task and increase anxiety-like behaviour (Migaud et al., 1998; 
Nagura et al., 2012). However, Arc differs from PSD95 in that its levels are highly dynamic 
and regulated by neuronal activity (Link et al., 1995; Lyford et al., 1995). Arc transcription can 
be induced by NMDAR activation (Steward et al., 1998; Steward & Worley, 2001; Rao et al., 
2006), AMPAR inhibition (Rao et al., 2006), BDNF (Ying et al., 2002; Yasuda et al., 2007; 
Benekareddy et al., 2013) and forskolin application in culture (Waltereit et al., 2001). In 
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addition to this, Arc translation can be induced by activation of mGluRs (Waung et al., 2008) 
and NMDARs (Bloomer et al., 2007). Although Arc and PSD95 are both upregulated following 
10mg/kg ketamine administration, the change in Arc is transient  and detected only at 1 & 
2h post-administration, whereas the change in PSD95 is detected at 2, 6, 24 & 72h (Li et al., 
2010).  
4.1.1 Activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) 
There is previous evidence that Arc protein is able to accumulate at synapses, at the nucleus, 
and more diffusely in the cytoplasm (Moga et al., 2004; Korb et al., 2013; Fernandez et al., 
2017). The circumstances under which Arc is directed to these different subcellular 
compartments, and the function of its presence there, is still under investigation (Bramham 
et al., 2010; Nikolaienko et al., 2017). However, Arc is known to be essential for several forms 
of experimentally-induced synaptic plasticity. It is thought that Arc is able to modify synaptic 
strength by increasing AMPA receptor endocytosis (Chowdhury et al., 2006) and is also able 
to stabilize F-actin during structural plasticity (Messaoudi et al., 2007). Constitutive levels of 
Arc expression are low, but increase in response to synaptic activity (Link et al., 1995; Lyford 
et al., 1995) and there is evidence that Arc is directed specifically to recently-activated 
synapses (Steward et al., 1998; Steward & Worley, 2001; Farris & Steward, 2010). However, 
it has proven difficult to visualize this synaptic Arc accumulation in brain tissue at the level of 
the single synapse, although this has been successfully done in cultured neurons (Okuno et 
al., 2012; Fernandez et al., 2017). Previously published Arc reporter mouse models contain a 
fluorescent construct under the control of the Arc promoter and do not tag the endogenous 
protein itself (Guzowski et al., 1999; Wang et al., 2006). There is also an existing transgenic 
mouse model in which a construct, containing the 7kb promoter of Arc and an mEGFP-tagged 
form of Arc, has been inserted into the genome. This model has proved extremely useful and 
provided important insights into the synaptic targeting of Arc, and its interaction with 
CAMKIIb (Okuno et al., 2012). However, in the mEGFP-Arc Tg mice the tagged form of Arc 
which has been inserted is additional to endogenous Arc, and has been randomly inserted 
into the genome, both of which could have functional consequences. In contrast, the ArcVENUS 
mouse line is a ‘knock-in’, containing the coding sequence for Venus (form of YFP) inserted 
at the c-terminal end of the Arc open reading frame (ORF), before the stop codon. This results 
in the production of Venus-tagged endogenous Arc protein, in homozygous ArcVENUS/VENUS 
mice 100% of Arc protein will contain the tag. Therefore, the ArcVENUS mouse line has the 
potential to provide new information about the synaptic accumulation of Arc protein in vivo. 
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The ArcVENUS mouse line is novel (Fernandez et al., 2017). When combined with the 
synaptome mapping method, first described by Dr Melissa Cizeron in her PhD thesis and in 
(Zhu et al., 2018), it is possible to quantify Arc accumulations at single synapse resolution 
across an entire coronal slice of mouse brain. This method consists of imaging the individual 
synaptic accumulations of the tagged protein using a high-throughput spinning disk confocal 
microscope, which is able to take a grid of many thousands of individual images to cover a 
coronal section of mouse brain. The synaptic accumulations of tagged protein, or ‘puncta’, 
are then detected and quantified from the images, creating a map of the synaptic distribution 
of that protein across the brain. This map was termed the ‘synaptome’ due to the potential 
to use this method to map all the post-synaptic densities in the brain, and the nature of their 
composition at the protein level. This is based on the existing use of the term ‘connectome’ 
to describe a map of the structural connectivity within the brain (Oh et al., 2014). This chapter 
contains the characterisation of the ArcVENUS signal and an Arc synaptome map at baseline 
levels of stimulation, before going on to describe the modifications to this map by ketamine. 
4.1.2 Post-synaptic density protein 95 (PSD95) 
PSD95 is present at glutamatergic synapses and is an essential component of the 1.5MDa 
NMDA receptor supercomplex (Frank et al., 2016). Within these complexes PSD95 is much 
more abundant than Arc (20-fold), indicating that ~5% of PSD95 complexes contain Arc. ~58% 
of Arc was found to be within PSD95 complexes (Fernandez et al., 2017). Although PSD95 
expression can be upregulated by mGluR activation in neuronal culture (Todd et al., 2003), 
and at the whole brain level by electroconvulsive seizure (ECS) (Dyrvig et al., 2014), this 
activity-regulation is not as rapid or as dramatic as that of Arc and the other immediate early 
genes (IEGs). For example, mRNA levels of the IEG c-Fos are over 2000% of sham control at 
1h post-ECS, whereas PSD95 mRNA levels peak at 120% of sham at 16h post-ECS (Dyrvig et 
al., 2014). The PSD95 synaptome map has already been characterized by Dr Cizeron and was 
generated using the PSD95eGFP mouse line described in the methods section of this thesis. 
The majority of PSD95eGFP puncta were found to be at postsynaptic sites and the brain regions 
with the highest puncta density were the hippocampus and the neocortex. The hippocampus 
and the fiber tracts were the regions with the most diverse range of punctum characteristics, 
which included size, shape, density and intensity. Within hippocampal sub-regions gradients 
of change in puncta intensity, density and size were identified and quantified (Dr Melissa 
Cizeron PhD thesis;(Zhu et al., 2018)). It was found that the PSD95 synaptome map was 
reorganized during development, and in the presence of null mutations of other MAGUK 
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proteins (Dr Melissa Cizeron PhD thesis; (Zhu et al., 2018)). However, is not yet known 
whether this map is able to be modified on a shorter time scale, for example by 
pharmacological intervention or changes in neuronal activity.  
4.1.3 Experimental aims 
The aim of the first set of experiments, described in sections 4.3 and 4.4, was to utilize the 
ArcVENUS mouse line and the synaptome mapping pipeline to generate the first Arc synaptome 
map. The aim of the second set of experiments, described in sections 4.5-4.7, was to utilise 
the ArcVENUS and PSD95eGFP mouse lines combined with the synaptome mapping pipeline to 
investigate the effect of two different doses of ketamine on synaptic protein levels. This will 
build on the existing literature in two main ways. Firstly, the use of a low ‘antidepressant’ 
and a high dose of ketamine will investigate the dose dependency of the response of these 
two synaptic proteins. Secondly, the use of the synaptome mapping method will allow the 
screening of multiple brain regions for changes in levels of Arc and PSD95 at the synapse.  
4.2 Summary of methods used in this chapter  
4.2.1  Animals 
In order to detect ketamine-induced changes in synaptic protein levels, two different knock-
in mouse lines were used. The ArcVENUS mouse line contains the coding sequence for Venus, 
a variant of yellow fluorescent protein, at the end of the Arc coding region. Similarly, the 
PSD95EGFP line contains the sequence for enhanced green fluorescent protein (eGFP) at the 
end of the PSD95 coding region. Both of these knock-ins result in the fluorescent tagging of 
the endogenous protein product. All animals used in the following experiments were 
homozygous for either the ArcVENUS or the PSD95eGFP tag and therefore 100% of the relevant 
protein in these animals is tagged. Please see appendix 4 for western blots showing addition 
of tag to endogenous Arc protein, similar characterisation of PSD95EGFP line can be found in 
Dr Fei Zhu’s PhD thesis. 
4.2.2 Immunohistochemistry 
A primary antibody against VGlut1 (cat no. 75-066, Neuromab) was used at a concentration 
of 1:250. An anti-mouse IGg1 Alexa Fluor 555 secondary antibody (cat no. A21127, 
ThermoFisher Scientific) was then applied at a concentration of 1:500. 4’,6-Diamidino-2-
Phenylindole (DAPI) was used at a concentration of 1:1000 to visualise nuclei. Please see 
section 2.3.3 for full IHC protocol.  
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4.2.3  Ketamine treatment & sample preparation 
Ketamine (Vetalar, Boehringer Ingelheim) was administered at either 10mg/kg or 100mg/kg, 
at a volume of 10ml/kg, via subcutaneous injection. Sterile saline at a volume of 10ml/kg was 
administered via the same route to the control groups. ArcVENUS animals were culled by 
perfusion fixation at 1h, 6h or 24h post-administration of ketamine. PSD95eGFP animals were 
culled by perfusion fixation at 24h post-administration. Each group contained 4-5 animals. 
For the baseline Arc synaptome map animals were taken from their home cages and 
immediately culled by perfusion fixation. Brains were processed as described in sections 
2.4.1 - 2.4.4 and coronal sections were taken on a cryostat at a thickness of 18µm. Two 
representative Bregma levels were selected for imaging, these were Bregma 2.10mm and -
1.70mm. These regions were chosen to enable study of the prefrontal cortex and 
hippocampus, both previously implicated in the ketamine response (Li et al., 2010; Fuchikami 
et al., 2015), alongside the screening of multiple other regions that have not yet been studied 
in this context.  
4.2.4  Imaging & analysis 
Sections were imaged on a spinning disk (50 nm) confocal microscope (Revolution XDi, 
Andor), using a 100X, oil immersion lens with an NA of 1.4. The pixel size produced by this 
microscope is 84nm. Please see table 4 in section 2.3.6 for information on the imaging 
parameters used for each of the datasets presented here. Fluorescent puncta were detected 
from the resulting TIFF images and their density, size and intensity were quantified using the 
Ensemble method (Ricky Qiu). Sections were manually divided into previously defined 
anatomical regions and average values for each punctum parameter were calculated for each 
region. For comparison of left and right hemispheres in baseline Arc synaptome map a two-
way ANOVA followed by Sidak’s multiple comparisons was used. For comparison of saline 
groups, a two-way ANOVA followed by Tukey’s multiple comparisons was used to compare 
the 1h groups with both the 6h and 24h groups independently. For the ketamine study 
individual t-tests, one per region, were carried out to compare control and ketamine-treated 
animals and screen for regions with statistically significant changes. No correction for 
multiple comparisons was applied, however, results are interpreted with consideration of 
the increased likelihood of false positives resulting from this method. The effect size of the 
two ketamine doses, as compared to the appropriate saline control group, was calculated 
using the Cohen’s d equation and presented in the form of a blue to white to red colour scale 
on an anatomical brain map.  
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Figure 20 - Summary of the ketamine synaptome mapping protocol. 
For generation of the basal Arc synaptome map step 2 was omitted and animals were culled 
by perfusion fixation immediately upon removal from home cage. Only section B (bregma -
1.70) was analysed for basal map, whereas both A and B were analysed for ketamine 
synaptome. 
4.3 Characterisation of subcellular distribution of Arc-Venus signal     
4.3.1 Synaptic accumulations of Arc 
When imaged at high resolution (SDM confocal, 100X, NA1.4, 50µm pinhole) the fluorescent 
signal in ArcVENUS mice is visible both as small (~0.4µm diameter) punctate accumulations and 
larger (~7µm diameter) oval-shaped accumulations. In hippocampus these small puncta are 
primarily situated in dendritic layers such as the stratum radiatum and stratum moleculare, 
whereas the larger oval-shaped accumulations are located within cell body layers, such as 
the granule cell layer of the dentate gyrus. The left-hand panels in figure 21 show 
representative images of the small punctate accumulations of Arc in several hippocampal 
sub-regions. For comparison the corpus callosum is also shown, this area of fiber tracts is 
known to have few synapses and therefore provides a useful negative control for imaging 
synaptic proteins. The vesicular glutamate transporter 1 (VGlut1), a marker of the 
presynaptic terminals of excitatory neurons (Liguz-Lecznar & Skangiel-Kramska, 2007), has 
been used in figure 21 to show the location of these Arc puncta. There are clear differences 
in Arc puncta density, intensity and size between hippocampal sub regions. The dentate gyrus 
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molecular layer (DGmo) shows relatively few Arc puncta, sparsely distributed (figure 21 A1). 
This is not due to a low number of synapses however, as there are considerably more VGlut1 
puncta than Arc puncta in this area (A2 & A3). In the polymorphic layer of the dentate gyrus 
(DGpo) larger Arc-Venus puncta are visible, these have more varied shapes than the round 
puncta of the molecular layer (B1). These large puncta are tightly juxtaposed with the large 
VGlut1 puncta visible in this area (B3). It is in the DGpo that large ring-shaped PSDs can be 
observed at specialised dendritic spines known as thorny excrescences, these receive input 
from the large synaptic boutons of the mossy fibers which project from DG granule cells 
(Amaral et al., 2007). In the CA1 stratum radiatum (CA1sr) a high density of both Arc and 
VGlut1 puncta can be observed, again Arc puncta are situated close to VGlut1, although the 
high density in this region does make it harder to be certain of this (C1-3). In the CA1 stratum 
lucidum (CA1slu) a similar pattern of puncta as the dentate gyrus polymorphic layer can be 
observed (D1-3). This area also contains large thorny excrescence synapses (Amaral et al., 
2007). As expected there were very few Arc or VGlut1 puncta in the corpus callosum (E1-3). 
The juxta-positioning of Arc puncta with VGlut1 puncta in these different areas of the 
hippocampus is consistent with Arc protein being situated at the postsynaptic side of the 
synapse. The ability to image synaptic accumulations of Arc here demonstrates the utility of 
this knock-in reporter mouse over some previously published Arc reporters which only allow 
the detection of Arc expressing cells, not individual synapses (Guzowski et al., 1999; Vousden 





Figure 21 - Arc signal can be detected close to presynaptic terminals in the hippocampus. 
Immunohistochemistry with antibody for VGlut1 (column 2 & red), Arc-Venus endogenous 
signal (column 1 & green). Scale bars = 5µm. See appendix 5 for antibody control images. 
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4.3.2 Nuclear accumulations of Arc 
Figure 22 contains representative images from two hippocampal cell body layers, and from 
the isocortex, which show the larger (~7µm) accumulations of Arc. 4’,6-Diamidino-2-
Phenylindole (DAPI) has been used to visualise cell nuclei. It is clear from the composite 
images on the right of figure 22, that the large accumulations of Arc (see filled arrow for 
example) are co-localised with the nuclear stain, suggesting that this Arc protein is present 
either in the nucleus, or clustered close to its surface. Arc protein has been observed in nuclei 
previously using immunohistochemistry with an Arc antibody (Korb et al., 2013). In some 
cases, there is also visible Arc-Venus accumulation around the edge of the nucleus and in 
processes extending outwards, (see outline arrow in figure 22 for example), which also 
indicates the occasional presence of detectable levels of Arc protein in the cytoplasm. Again 
this has been reported with antibody staining previously (Korb et al., 2013).  
 
Figure 22 - Arc can be co-localised with nuclei in the hippocampus. 
Immunohistochemistry with DAPI (column 2 & blue), ArcVENUS endogenous signal (column 1 
& green). Scale bars = 5µm. See appendix 5 for antibody control images. 
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It is clear from the DAPI staining in figure 22 that, in the regions sampled here, Arc is not 
present at high levels in every single nucleus. This fits with the existing literature which 
showed a sparse distribution of Arc positive nuclei in hippocampus at baseline levels of 
stimulation (Korb et al., 2013).   
4.4 Characterisation of Arc synaptome map     
4.4.1 Inter-regional diversity  
In order to characterise the diversity in Arc synaptic puncta characteristics further, and to 
provide quantification, entire ArcVENUS brain sections were imaged with a high throughput 
spinning disk confocal microscope. The images acquired were then quantified using the 
ensemble method, as described, to generate average punctum density, intensity and size 
values for different anatomically defined brain regions. This quantification excludes the large 
nuclear accumulations based on their size. The Allen brain atlas was used to delineate 
recognised anatomical regions in order to compare punctum characteristics across brain 
areas. Six main regions were initially analysed to determine the overall pattern of punctate 
Arc protein expression, and to compare the left and right hemispheres, these regions are 
illustrated in figure 23B. As the bar charts in figure 23 C-E show, there was no difference in 
punctum density, intensity or size between the left and right hemispheres of the brain in the 
main regions analysed. An ordinary two-way ANOVA found no significant effect of 
hemisphere overall (density p = 0.1134, size p = 0.1723, intensity p = 0.7633), and Sidak’s 
multiple comparisons testing found no significant difference between hemispheres in any 
one of the main regions. There was, however an overall effect of brain region on all three 
punctum parameters (density p <0.0001, size p <0.0001, intensity p <0.0001). This 
demonstrates the diversity in the nature of Arc accumulation at the synapse between 
anatomically-defined brain regions.  By far the area with the densest distribution of Arc 
puncta was the isocortex, which contained around two times more puncta per 100µm2 than 
the second densest region which was the olfactory areas. At the other end of the scale, the 
fiber tract regions contained fewer than 3 puncta per 100µm2 (figure 23C). The cortex was 
also the area with the brightest puncta on average, and the fiber tracts the dimmest (D). The 
hypothalamus had the largest puncta, despite having relatively few of them (E). The colour 
maps in figure 23 show this diversity of puncta density, size and intensity across different 
brain regions in more detail, and allow us to make several observations about the Arc 
synaptome map at baseline levels of stimulation. Firstly, looking at the hippocampus on these 
brain maps it is possible to see that the trends observed in the representative images 
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presented in figure 21 hold true when the entire area is analysed quantitatively. There is a 
higher density of puncta in the CA1sr as compared with the DGmo (CA1sr = Left m:53.39 per 
100µm2 & sd:4.12, Right m:55.58 & sd:2.67; DGmo inf = Left m:17.03 & sd:2.50, Right 
m:17.92 & sd:2.37)(figure 23C). The same is true for puncta intensity (CA1sr = Left m:8824 & 
sd:580, Right m:8988 & sd:425; DGmo inf = Left m:6044 & sd:420, Right m:6136 & sd:527)(D). 
The DGpo and CA3slu contain larger puncta than other dendritic regions of the hippocampus 
(DGpo = Left m:0.110µm2 & sd:0.003, Right m:0.109 & sd:0.002, CA3slu = Left m:0.009 & 
sd:0.002, Right m:0.088 & sd:0.001, for reference CA1sr = Left m:0.084 & sd:0.001, Right 
m:0.088 & sd:0.001)(E). Indeed, of the main anatomical regions highlighted in figure 23B the 
hippocampus appears to show most puncta diversity in terms of the density and size 
measurements. There is also considerable diversity within the isocortex, with a gradual 
decrease in puncta density visible from the most superficial to the deeper cortical layers (e.g. 
SSp lyr1 = Left m:53.55 & sd:6.16, Right m:56.93 & sd:2.47, lyr6b = Left m:18.40 sd:6.40, Right 
m:20.70 sd:3.36). A similar trend can be observed in the puncta intensity measurement, 
although layer 4 appears to have particularly bright puncta. The somatosensory cortex is the 
area of isocortex with the highest density and intensity of Arc puncta. There is a gradual 
decline in both parameters as distance from the somatosensory cortex increases, with the 
lowest density and intensity found in the most ventral region of the isocortex (ENTI) and the 
most medial region (RSPv). Raw density, intensity and size mean values and standard 
deviation for each brain region can be found in the tables in appendix 11. The thalamus was 
excluded from this analysis due to a technical artefact, which consisted of a dark area in the 
thalamus of some brain sections, visible in figure 23A. This was not present in the ketamine 
synaptome mapping cohorts presented in the rest of this results chapter and did not appear 





Figure 23 - (previous page) Density, intensity and size of Arc puncta across multiple brain 
regions at baseline. 
A. Example montage image showing basal Arc-Venus signal in bregma -1.70mm coronal 
section. One hemisphere shown, montage of ~15,000 individual tile images. B. Diagram 
showing regions delineated for quantification, based on Allen Brain Atlas, please see 
appendix 8 for list of brain region abbreviations. For initial analysis, presented in bar charts 
in C, D and E, main regions (denoted by colour code) were delineated. For secondary analysis, 
presented in colour maps, all outlined regions were delineated. C, D & E Arc-Venus punctum 
quantification. Puncta detected and quantified using Ensemble method, n = 4 mice, all 
ArcVENUS/VENUS. Bar charts show the average values for the main regions as defined in B. Bars 
represent the mean value for the defined region, error bars = SEM, comparison is made 
between left and right hemispheres. ns = not significant, 2-way ANOVA with Sidak’s multiple 
comparisons. Brain maps show the mean value for each smaller anatomical region as a colour 
scale from blue-green-red. 
 
4.4.2 Intra-regional diversity 
Within hippocampal sub-regions it is possible to visually observe gradients of Arc puncta 
distribution in montage images. By delineating smaller areas within the CA1sr, CA1so and 
CA3sr it is possible to carry out a quantification of the nature of these gradients. Two kinds 
of gradient were identified using this method: tangential gradients which run parallel to 
pyramidal cell body layers and radial gradients which run perpendicular to pyramidal cell 
body layers, see figure 24. The tangential gradients follow the same axis as the CA subfield 
classification (CA1-CA2-CA3). The radial gradients follow the dendritic projections of principal 
neurons from proximal to the cell body, out to the most distal.  
 
Figure 24 - Tangential and radial axes in hippocampus 
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The tangential axis was investigated in the CA1 field, where a gradient in Arc was most visible 
from the montage images. Puncta density was found to decrease along this axis in the CA1sr, 
with a dramatic drop in the last two segments before the start of the CA2 field (figure 25A). 
A similar gradient was seen in the CA1so but here there was also a lower density in the first 
segment, closest to the FC, giving the graph an ‘inverted u’ shape. Intensity of detected 
puncta also decreased along this axis in both CA1so and CA1sr and punctum size decreased 
slightly. Identification of gradients along the tangential axis suggests that there are 
differences between the dendritic trees of pyramidal cells situated at different points along 
the CA1 field. Changes along the radial axis were also identified in the CA1sr, with puncta 
density increasing as distance from the pyramidal cell body layer increased and then rapidly 
decreasing again in the last segment before the start of the CA1slm (figure 25B). Punctum 
intensity followed a similar pattern. Punctum size gradually increased along this axis and 
reached its highest level in the final segment before the CA1slm. In the CA3sr a gradual 
increase in puncta density can be seen as distance from the pyramidal cell body layer 
increases, although this flattens out in the last segment before the start of the CA3slm (figure 
25C). There is also a small increase in punctum intensity along this axis, and a small u-shaped 
trend in punctum size. Alterations along the radial axis suggest differences between the 
proximal and distal branches of the dendritic tree of the same pyramidal cell. This is a basic 
quantification of some of the visible trends within the hippocampus, but they highlight the 
potential for the Arc-Venus reporter mouse line, combined with the synaptome mapping 
pipeline to identify subtle alterations in Arc distribution within anatomically defined brain 




Figure 25 - Tangential and radial hippocampal gradients in Arc synaptome map. 
n = 1, average of two hemispheres. Delineations used to generate this data are illustrated in 
bottom panel. Schematic diagram of tangential and radial gradients in relation to 
hippocampal anatomy can be found in figure 24. 
4.5 Effect of saline injection on Arc synaptome map  
Novel experiences and stressful experiences have both been reported to increase Arc 
expression levels (Ramirez-Amaya et al., 2005; Grinevich et al., 2009; Jakkamsetti et al., 
2013). The control group for the ketamine study described here received a single saline 
injection 1h, 6h or 24h pre-sacrifice. This itself was a novel, and mildly stressful experience, 
which therefore has the potential to induce changes in Arc expression. In order to investigate 
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this further, and to provide background information for the interpretation of the ketamine 
results presented in section 4.6, the Arc synaptome map was compared at 1h, 6h and 24h 
post saline administration. The results of this comparison are presented in figure 26. 
Although there is no home cage (baseline) control group included in this data, an overall 
effect of time point was identified for both the density and size parameters (density: 
p<0.0001, intensity: p=0.0586, size: p=0.0003. Ordinary 2-way ANOVA, type III sum of 
squares).  This suggests that injection of saline is having an effect on these parameters during 
the 24h following administration. Tukey’s multiple comparisons testing was used to compare 
the 1h time point with the 6h and 24h time points individually to identify which brain regions 
may be responsible for this effect. No significant changes were identified in any regions 
contained within the bregma 2.10mm section (figure 26A). In the bregma -1.70mm section 
several regions within the hippocampus displayed significantly greater puncta density at 6h 
or 24h than at 1h post-administration (figure 26B). This included the stratum lucidum in all 
CA fields, the molecular and polymorphic layers of the DG, and the CA2 stratum oriens and 
radiatum. The molecular layer of the DG showed an increase in both puncta density and 
puncta size (density: DGmolinf p=0.0002, DGmolsup p<0.0001; intensity: DGmolinf p=0.0046, 
DGmolsup p=0.0146). Several fiber tract regions also showed increased size of detected 
puncta at 6h and 24h as compared with 1h post-saline. Taken together, these observations 
show that it is possible to modify the Arc synaptome map with a brief novel, and mildly 
stressful, experience such as administration of a saline injection, and that in this case those 
modifications are limited to specific anatomical regions. This is interesting because it gives 
an indication of the sensitivity of this method and provides important information for the 
interpretation of the ketamine results presented in the following sections.  
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Figure 26 - Effect of saline injection on Arc synaptome map. 
A. Bregma 2.10mm. B. Bregma -1.70mm. Bars represent mean of 3-5 animals per group. 
Asterisks represent significant change from 1h group as determined by 2-way ANOVA 
followed by Tukey’s multiple comparisons testing.  
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4.6 Ketamine-induced modification of the Arc synaptome map  
4.6.1 Changes in number of Arc puncta detected  
Following on from the characterisation of the basal Arc synaptome map, and the 
modifications induced by novel experience, this section describes the results of an 
experiment investigating the effect of two different doses of ketamine on the Arc synaptome 
map across the 24h following administration. The density of Arc puncta (number of detected 
puncta per 100µm2) was quantified in 89 individual brain regions per hemisphere, across two 
bregma levels, as illustrated in figure 27. For each region one value was generated per mouse 
by taking an average of the two hemispheres. 
 
Figure 27 - Sub-regions delineated for analysis of ketamine-treated brain sections. 
Main region classification based on Allen Brain Atlas. A = bregma 2.10mm, B = bregma -
1.70mm. See appendix 8 for list of abbreviations of brain region names.  
In order visualise changes induced by ketamine administration, the effect size (Cohen’s d) of 
the change from saline control group was calculated for both the low- and high-dose 
ketamine groups, for each of the 89 brain regions. These values are presented as a colour 
scale, in which blue is a decrease from saline control and red is an increase, applied to the 
corresponding regions in the brain maps in figure 28. The Cohen’s d effect size gives a value 
based on the number of standard deviations which separate the means of the two groups. 
Please see appendix 17 for examples of the spread of data underlying different Cohen’s d 
values.   
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Multiple t-tests (one per region) were used to screen brain regions for significant changes, 
the asterisks in figure 28 denote regions in which a significant change was found. It is clear 
from viewing figure 28 that the majority of the ketamine-induced alterations are taking place 
in the bregma -1.70mm section (section B). Indeed, only one region within the bregma 
2.10mm section reached a significant level of change (TTv2: saline = 115.8, low-dose = 49.31, 
p=0.0381). At the 1h time-point there is a general trend towards increases in puncta density 
following both low- and high-doses across many of the main regions contained within the 
bregma -1.70mm section. In the low-dose group there is a cluster of regions with significant 
increases in the olfactory areas, hippocampus and cortical subplate. In the high dose group 
there are fewer significantly-increased regions and these are almost all contained within the 
hippocampus. At 6h post-administration high- and low-doses of ketamine appear to be 
having opposing effects on Arc-Venus puncta density. There is still a general trend towards 
an increase in the low-dose group, with significantly-increased regions clustered within the 
isocortex, hippocampus, cortical subplate, cerebral nuclei, thalamus and hypothalamus. Only 
the olfactory areas and fiber tracts are left unaltered. Conversely, the high-dose group is now 
showing a general decrease in puncta density, as compared with the saline control group, 
with significant decreases seen predominantly in the hippocampus. At 24h post-
administration, a similar trend as the 6h time point can be observed, with the high dose 
inducing a general decrease and the low dose producing a general increase, however fewer 
individual regions are significantly altered. The low-dose group shows a clustering of 
significant increases in regions within the hippocampus, thalamus and fiber tracts. These 
results show that both low- and high-doses of ketamine are able to induce changes in the 
density of Arc puncta. These changes follow the general pattern of a short-term increase 
induced by both doses, followed by a low-dose induced increase and a high-dose induced 
decrease at 6h and 24h. They also show highly brain-region specific effects, with the 
hippocampus affected throughout and the isocortex altered specifically at 6h post-





Figure 28 - Ketamine-induced changes in the density of Arc puncta. 
(continued on next page) Colour scale represents effect size of change in puncta number from 
relevant saline control group (Cohen’s d). Blue indicates decrease, red indicates increase. 
Asterisks represent regions with a statistically significant change from saline control p<0.05 
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(multiple t-tests). N=3-5 depending upon brain region. Grey = brain region not included due 
to damage in one or more sections resulting in n<2 for that region.  
4.6.2 Changes in intensity of detected Arc puncta  
The same analysis was carried out for the average puncta intensity measurements for each 
of the 89 brain regions. It is clear from a comparison of figure 28 and figure 29 that the effects 
of ketamine on the average intensity of detected Arc puncta are much less pronounced than 
its effects on puncta density. There are only a few individual regions showing significant 
change, despite the relatively low stringency of the multiple t-test approach. These regions 
are all contained within the bregma -1.70mm section and the low dose groups. There is a 
decrease in puncta number in the dentate gyrus granule cell layers at 1h (DGgrsup p=0.02, 
DGgrinf p=0.044), an increase in hypothalamus at 6h (p=0.02) and increases in SSp-tr 
(p=0.03), CA1R (p=0.048) and opt (p=0.003) at 24h. There was no pattern of change in 
anatomically-related regions and no individual regions reached the Bonferroni-corrected 
threshold for this experiment, which was p<0.00056. Therefore, it seems that ketamine is 
not having an effect on the mean fluorescence intensity of detected ArcVENUS puncta at these 
doses or time-points.  
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Figure 29 - Ketamine-induced changes in the average intensity of Arc puncta. 
(continued on next page) Colour scale represents effect size of change in average puncta 
intensity from relevant saline control group (Cohen’s d). Blue indicates decrease, red indicates 
increase. Asterisks represent regions with a statistically significant change from saline control 
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(multiple t-tests). N=3-5 depending upon brain region. Grey = brain region not included due 
to damage in one or more sections resulting in n<2 for that region. 
4.6.3 Changes in size of detected Arc puncta  
Again, from viewing figure 30 the alterations in the size of detected puncta appear to be less 
dramatic than those in puncta density, visible in figure 28. There were very few changes 
taking place in the bregma 2.10mm section. At 1h post-administration the low dose induced 
decreases in TTv2 & 3 (p= 0.028 & 0.034), and the high dose induced an increase in motor 
cortex (p=0.047). However, these changes did not reach the Bonferroni corrected p value for 
this experiment (p<0.00056) and were not part of a pattern of changes in anatomically-
related regions. Therefore, from this data it appears that ketamine is not having an effect on 
the mean size of detected Arc puncta at bregma 2.10mm. In the bregma -1.70mm section 
there is some clustering of significant changes in hippocampus. At 1h post-administration 
this takes the form of increase size of detected puncta in the low-dose group in DGmolsup 
(p=0.035) and CA2O (p=0.019), and both molecular layers of the DG are increased in the high-
dose group (DGmolsup p=0.011, DGmolinf p=0.031). This is followed by decreases in multiple 
hippocampal sub-regions in the high-dose group only at 6h and 24h post-administration. This 
includes regions from CA1, CA3 and dentate gyrus. At 24h post-administration significant 
decreases in the high-dose group were also detected in several fiber tract regions (cing 
p=0.048, CC p=0.035, df p=0.030), thalamus (thal p=0.035, LH p=0.047), stn (p=0.008) and 
COApl2 (p=0.026). At 24h post-administration there were also significant changes detected 
in the low dose group in opt (p=0.019) and stn (p=0.021) however these were isolated 
changes, unlike the pattern of changes induced by the high dose.   
Overall this indicates that a high dose of ketamine is able to alter the mean size of detected 
Arc puncta, predominantly in the hippocampus, and that this takes the form of an increase 
in the dentate gyrus at 1h post-administration, followed by a more widespread decrease 
which lasts until at least 24h post-administration.  
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Figure 30 - Ketamine-induced changes in the average size of Arc puncta. 
(continued on next page) Colour scale represents effect size of change in average puncta size 
from relevant saline control group (Cohen’s d). Blue indicates decrease, red indicates increase. 
Asterisks represent regions with a statistically significant change from saline control (multiple 
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t-tests). N=3-5 depending upon brain region. Grey = brain region not included due to damage 
in one or more sections resulting in n<3 for that region. 
4.6.1 Summary  
In summary, both low- and high-doses of ketamine are able to rapidly modify the synaptome 
map of Arc. This modification is predominantly in the form of alterations to the density of Arc 
puncta present. The alterations in Arc puncta density show an interesting dose- and region- 
dependency. At 1h post-administration, both doses increase puncta density above saline 
control levels, whereas at 6h and 24h the low dose is able to induce an increase, but the high 
dose results in a general decrease. Most changes take place in the more rostral section 
(section B, -1.70mm), the hippocampus is affected at all time points but many other regions 
have time- and dose- specific effects. The most striking of these is the increased density in 
isocortex specifically in the low-dose 6h group. Such dramatic effects are not seen in the 
other puncta measurements, however there is a reduction in puncta size following high-dose 
ketamine in the hippocampus at 6h and in additional regions at 24h.  
4.7 Ketamine-induced modification of the PSD95 synaptome map 
The PSD95 synaptome was mapped at 24h post ketamine administration only, the results of 
which are presented in figure 31. In the bregma 2.10mm section in the low dose group there 
was a decrease in puncta density in alv (p=0.003) and ald (p=0.01) and a decrease in size in 
lot (p=0.032). In the high dose group there were significant decreases in density and intensity, 
and increases in size, seen in multiple regions within the olfactory areas including parts of 
the piriform cortex (PIR) and the anterior olfactory nucleus (AON). There are no significant 
changes in density or intensity in the bregma -1.70mm section, with the exception of an 
isolated increase in density in COApl2 (p=0.031). There were decreases in puncta size in 
several regions of isocortex (RSPd p=0.034, MOs p=0.014, MOp p=0.022, SSp-tr p=0.036) and 
the CP (p=0.033) in the low dose group.  
Overall, there do seem to be some effects of ketamine on the PSD95 synaptome at 24h post-
administration, predominantly in the high-dose group and the olfactory areas. These effects 
do not mimic those seen in the Arc synaptome in terms of the regions affected.  
 109 
 
Figure 31 - Ketamine-induced changes in PSD95 synaptome map at 24h. 
(continued on next page) Colour scale represents effect size of change in average puncta size 
from relevant saline control group (Cohen’s d). Blue indicates decrease, red indicates increase. 
Asterisks represent regions with a statistically significant change from saline control (multiple 
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t-tests). N=3-5 depending upon brain region. Grey = brain region not included due to damage 
in one or more sections resulting in n<2 for that region. 
4.8 Chapter discussion  
4.8.1 Basal Arc synaptome map 
Immunohistochemical staining has so far provided most information on the brain-wide and 
subcellular distribution of endogenous Arc protein (Nishimura et al., 2003; Gao et al., 2015). 
However, despite the availability of various antibodies raised against the Arc protein, 
individual accumulations of Arc at synaptic sites have been historically difficult to visualise 
with sufficient clarity in brain tissue. Several reporter mouse lines have been developed by 
placing fluorescent reporters under the control of the Arc promoter (Eguchi & Yamaguchi, 
2009; Grinevich et al., 2009; Susaki et al., 2014), but they are not a direct measure of 
endogenous protein levels. Therefore, the ArcVENUS reporter line is the first method, to our 
knowledge, which enables the clear and reproducible visualization of synaptic and nuclear 
accumulations of endogenous Arc protein in brain tissue. Further to this, the basal Arc 
synaptome map presented here is the first time that the distribution of endogenous Arc 
protein has been imaged and quantified at single synapse resolution across an entire brain 
slice. Whilst interesting in itself, this map also provides a dataset of ‘baseline’ Arc distribution 
for reference purposes. The baseline Arc synaptome map showed a great deal of inter-
regional and intra-regional diversity in all three punctum characteristics. Puncta density 
values varied from 58 per µm2 in layer 1 of the motor cortex down to 0.05 in some fiber tract 
regions. The highest levels of Arc puncta density and intensity were seen in the isocortex and 
the CA1 field of the hippocampus, where Arc mRNA levels are also known to be highest (Link 
et al., 1995; Lyford et al., 1995). The areas with the lowest puncta density were fiber tract 
regions and cell body layers of the hippocampus, which both contain few synapses. Particular 
diversity in Arc punctum characteristics was observed in the hippocampus and isocortex, 
therefore these regions are discussed in more detail below.  
4.8.1.1 Synaptic accumulations of Arc 
Prior to synaptome mapping, co-staining with both a pre-synaptic (VGlut1) and a nuclear 
marker (DAPI) were used to identify the nature and location of ArcVENUS fluorescence at the 
subcellular level. The hippocampus was used as the focus of this investigation as it has a well-
studied structure and connectivity. VGlut1 is a vesicular glutamate transporter situated at 
the pre-synaptic terminals of glutamatergic neurons (Liguz-Lecznar & Skangiel-Kramska, 
2007). There are two other members of the VGlut family (VGlut2 & VGlut3), however in the 
adult mouse VGlut1 is the predominant form expressed in hippocampus (Fremeau et al., 
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2001). ArcVENUS puncta and VGlut1 immunofluorescence puncta were juxtaposed in 
hippocampal sub-regions, which suggests that the majority of the Arc puncta being imaged 
and quantified here are situated at the postsynaptic side of glutamatergic synapses. This fits 
with the proteomic evidence which places Arc at the PSD as part of the NMDA receptor 
supercomplex (Frank et al., 2016), where it interacts with PSD95 (Fernandez et al., 2017). The 
physical co-localisation of tagged PSD95 and Arc has also been observed in neuronal culture 
(Okuno et al., 2012; Fernandez et al., 2017), and EM experiments have detected Arc at 
postsynaptic sites (Moga et al., 2004). This synaptic localization of Arc is known to be activity-
regulated (Steward et al., 1998). In response to experimentally-induced patterned neuronal 
activity, Arc mRNA is rapidly produced and transported out to dendrites, where it 
accumulates close to activated synaptic sites (Steward et al., 1998; Farris & Steward, 2010). 
Arc protein follows a similar pattern of distribution (Moga et al., 2004), and local translation 
has been found to take place in the dendrites. Indeed, application of glutamate is able to 
rapidly (within 15s) induce translation of pre-existing Arc mRNA at dendritic sites (Na et al., 
2016).  However, the picture is complicated by evidence that suggests that, following 
induction by activity, Arc protein is then targeted to inactive synapses (Okuno et al., 2012). It 
may be that Arc is indeed targeted to recently activated synapses, but does not enter the 
spine until cessation of that bout of activity. It is important to remember that all of the 
evidence available so far comes from experimental manipulations of neuronal activity levels 
using HFS and BDNF or TTX application, which may not reflect responses to physiological 
patterns of activity. Uncaging of glutamate at individual spines has enabled the real-time 
observation of rapid glutamate-induced Arc translation events in dendrites (Na et al., 2016). 
A potential future direction would be to apply this method to ArcVENUS neurons to visualise 
the accumulation of Arc protein following activation of a single spine. In the absence of this 
evidence however, it seems likely that Arc-positive synapses are more likely to have recently 
experienced activation than Arc-negative synapses. In the results presented in this thesis, 
VGlut1-labelled presynaptic terminals were often observed without a partner Arc punctum 
juxtaposed, although quantification of nearest neighbour distances would be beneficial to 
confirm this subjective visual observation. This suggests that Arc is not present at detectable 
levels in all synapses. This sparsity of Arc puncta distribution was particularly pronounced in 
the DG. This observation also fits with the previous finding that Arc is much less abundant 
than PSD95 at baseline levels of neuronal activity (Fernandez et al., 2017). Indeed, in the 
PSD95 synaptome map, no such sparse punctum distribution is observed in the DGmo (Dr 
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Melissa Cizeron PhD thesis). Given the importance of the presence of PSD95 for the targeting 
of Arc to synapses (Fernandez et al., 2017), this suggests that in this basal state of the animal 
there are likely to be glutamatergic synapses with a large capacity for increasing their Arc 
content in response to activity. There have been two roles identified for Arc at synaptic sites. 
Arc is able to induce an increase in endocytosis of AMPA receptor subunits through direct 
interactions with parts of the endocytic machinery at the synapse (Chowdhury et al., 2006; 
Vazdarjanova et al., 2006; Okuno et al., 2012; DaSilva et al., 2016), producing a reduction in 
synaptic strength. This function is involved in both translation-dependent LTD (Park et al., 
2008; Waung et al., 2008) and homeostatic scaling (Rial Verde et al., 2006; Shepherd et al., 
2006; Peebles et al., 2010; Beique et al., 2011). There is also evidence that Arc is involved in 
the structural modifications taking place during homeostatic plasticity (Peebles et al., 2010). 
Local Arc expression is also necessary for stabilizing F-actin polymerization associated with 
LTP consolidation, which appears to be via the augmentation of phosphorylated cofilin at 
activated spines (Messaoudi et al., 2007). However, Arc does not interact directly with either 
actin or cofilin (Nair et al., 2017). Although it is not yet clear how Arc is able to facilitate two 
opposing forms of plasticity, there is evidence that post-translational modification of the 
protein could determine its function. For example, SUMOlyated Arc has been found to 
interact with the F-Actin-binding protein Debrin A (Nair et al., 2017). It is impossible to know 
from the data presented in this thesis the function of the synaptic Arc accumulations 
observed in the ArcVENUS mice. However, based on the existing literature, it seems likely that 
Arc presence at the synapse is a response to recent activity at that site and that Arc is acting 
there to alter synaptic strength in response to that activity. Please see section 4.9 for 
suggested future experimental directions to confirm this. 
4.8.1.2 Nuclear accumulations of Arc 
Large, oval-shaped Arc accumulations were found to co-localise with DAPI staining, 
suggesting that they are within, or on the surface of, nuclei. Nuclear Arc localization has been 
observed using other methods of Arc visualization (Lyford et al., 1995; Irie et al., 2000; 
Bloomer et al., 2007; Korb et al., 2013), and there is evidence to suggest that Arc can act in 
the nucleus to increase the expression of PML nuclear bodies, resulting in decreased GluA1 
transcription (Bloomer et al., 2007; Korb et al., 2013). The sparse distribution of Arc-positive 
nuclei in the DG granule cell layer is consistent with previous observations, and the number 
of Arc-positive nuclei can be increased by various kinds of stimulation (Ramirez-Amaya et al., 
2005; Vazdarjanova et al., 2006). Indeed, both kainic acid induced seizure and novel 
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experience were found to increase the amount of nuclear Arc in the hippocampus in ArcVENUS 
mice (Sarah Lemprière MSc dissertation and appendix 12, respectively). The causes and 
effects of Arc protein targeting to different subcellular compartments are still unclear. 
Therefore, the ability to visualise the subcellular distribution of endogenous Arc protein in 
brain tissue slices from ArcVENUS mice clearly, and without the inherent variability of 
immunostaining protocols, is an important tool for future research efforts. Suggested future 
directions for this work can be found in section 4.9. 
4.8.1.3 Diversity between hippocampal sub-regions  
Different hippocampal sub-regions displayed different Arc punctum characteristics, which fit 
with the known size and shape of the postsynaptic terminals within those regions. In CA3slu 
and DGpo large Arc puncta assembled into rosettes were observed. Dendritic spines in these 
regions, known as thorny excrescences, are also particularly large. They synapse on to the 
giant presynaptic boutons of the mossy fibers projecting from the DG granule cell layer and 
contain ring-shaped PSDs (see figure 32). This correlation between known PSD characteristics 
and the nature of Arc puncta provides further evidence for the localization of Arc to the PSD. 
The area with the highest density and intensity of Arc puncta was the CA1sr, which fits with 
the previous evidence showing high levels of Arc mRNA in the CA1 field (Link et al., 1995; 
Lyford et al., 1995). The lowest Arc puncta density was seen in the granule cell and pyramidal 




Figure 32 - Three-dimensional reconstructions of CA3 dendritic segments, thorny 
excresences and postsynaptic densities in wild-type mice. 
Typical examples of dendritic segments (a), presynaptic giant boutons (b) and thorny 
excrescences with their postsynaptic densities shown in red (c-e). Figure taken from (Witton 
et al., 2015).    
4.8.1.4 Diversity within hippocampal sub-regions   
As well as diversity between hippocampal sub-regions, there are also gradients of change in 
Arc punctum measurements within individual sub-regions. Gradients in Arc puncta density, 
intensity and size were observed along both the radial and the tangential axis of the 
hippocampal CA1 field. This suggests both differences in the nature of Arc protein 
accumulation between proximal and distal synapses on the dendritic tree of the same 
pyramidal cell (radial), and differences between the synapses of individual pyramidal neurons 
(tangential), see figure 33. In the Arc basal synaptome map there is a general reduction in 
Arc puncta density, intensity and size from distal to proximal along the tangential axis of CA1. 
Differences in Arc mRNA levels in the nucleus and cytoplasm along the tangential axis of CA1 
have been described previously. Pyramidal cells in distal CA1 are more likely to induce 
overlapping Arc mRNA expression during exposure to two different environments than those 
in proximal CA1, which are more likely to respond to one environment only (Hartzell et al., 
2013).  This fits with other data which identified a higher spatial specificity of place fields in 
proximal CA1 as compared with distal CA1 (Henriksen et al., 2010). Therefore, the Arc 
synaptome gradient could reflect the increasing spatial specificity of cells in the proximal 
direction, thus gradually reducing the likelihood of synaptic activity in any one environment 
along that axis. However, from this initial Arc synaptome data it is difficult to know whether 
this change is indeed due to a reduction in synaptic activity or a more general reduction in 
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synapse number along this axis. Such a gradient was not observed in the PSD95 synaptome 
map (Dr Melissa Cizeron PhD thesis), suggesting that it is likely to be the former.  
 
Figure 33 - Schematic diagram of hippocampal structure and basic circuitry. 
Arrows indicate the direction in which changes across gradients are plotted in figure 25. 
Tangential gradients suggest differences between neighbouring pyramidal neurons, radial 
gradients suggest differences between proximal and distal dendrites of the same pyramidal 
neuron.  
A radial gradient in Arc puncta in the CA1sr was 
also observed. This took the form of increasing 
puncta density, intensity and size with 
increasing distance from the soma. There was 
however, a sharp drop in puncta density in the 
last segment before the beginning of the 
CA1slm. Similar radial gradients were observed 
in the PSD95 and SAP102 synaptome maps (Zhu 
et al., 2018) although direct comparison of 
these datasets with the current one is difficult 
because of differences between analysis methods. The CA1sr contains the proximal regions 
of the apical dendrites of the CA1 pyramidal cells, which receive input primarily from the CA3 
via the Schaffer collateral (Amaral & Laveneux, 2007), see figure 33. Within the CA1sr, both 
the number of perforated synapses and the AMPA content of synapses increases with 
increasing distance from the soma  (Nicholson et al., 2006). Perforated synapses contain 
more NMDA and AMPA receptors than non-perforated synapses, and are therefore expected 
Figure 34 - Schematic diagram showing 
interpretation of tangential and radial 
hippocampal gradients on pyramidal cell 
characteristics. 
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to generate larger synaptic currents when activated (Desmond & Weinberg, 1998; Ganeshina 
et al., 2004a, b). In theory these synapses could therefore be more likely to induce Arc 
expression. Overall these observations of gradients within certain anatomical regions of the 
Arc synaptome map highlight the ability of this method to surpass existing anatomical 
classifications, and allow the study of synapse composition in more depth. Although 
gradients were observed in the PSD95 and SAP102 synaptome maps, this is the first time 
such synaptic gradients have been observed in a protein known to be targeted to recently-
activated synapses. The mapping of Arc and PSD95, with accompanying co-localisation 
analysis, in the same animal would provide important information on the degree to which 
Arc gradients are defined by synapse number vs activity. Mapping Arc gradients in stimulated 
animals (e.g. kainate-induced seizure) would also provide information on their stability and 
underlying mechanisms.  
4.8.1.5 Isocortex 
The existing literature has identified the isocortex as the area containing the highest levels 
of Arc mRNA and protein (Link et al., 1995; Lyford et al., 1995), and a similar observation can 
be made from the Arc synaptome map. The isocortex is the brain region responsible for 
higher cognitive functions such as language, episodic memory and voluntary movement. It 
has a laminar structure which has historically been split into six layers, I being the most 
superficial and VI the deepest (Brodmann, 1909). Each layer contains different cell types and 
has a distinct set of inputs and outputs, see figure 35A. The more superficial (layers I-IV) are 
the main input layers of the cortex and contain mostly localised intracortical connections, 
whereas the deepest (layers V & VI) are the main output layers and form long distance 
projections to subcortical regions and the contralateral hemisphere (Noback et al., 2005; 
Molyneaux et al., 2007). In the Arc synaptome map there was a general decrease in puncta 
density from the superficial to deep layers of isocortex.  A similar pattern of puncta density 
across cortical layers was observed in the PSD95 and SAP102 synaptome maps (Zhu et al., 
2018), suggesting that this is more likely to be a general change in the number of excitatory 
synapses rather than something that is specific to Arc. Indeed, an EM study in human adult 
temporal cortex also found greater densities of synapses (defined as pre- and post-synaptic 
membrane specializations separated by a synaptic cleft) in the more superficial cortical layers 
(DeFelipe et al., 1999), see figure 35B. In addition to this there is a particularly high intensity 
of Arc puncta in layer 4, which is not observed in the PSD95 or SAP102 synaptome maps, or 
human EM data. This is interesting as layer 4 receives the majority of inputs from outside the 
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cortex and is thought to be the main recipient of incoming sensory information (Noback et 
al., 2005). A high level of Arc protein in layer 4 has been observed at lower resolution with 
IHC. In that experiment auditory deprivation was able to reduce this increased staining in 
layer 4 of the auditory cortex and instead shift it to layer 4 in other areas, including the visual 
cortex (Pernia et al., 2017). Taken together this suggests that, in addition to differences in 
general synapse number between cortical layers there are also Arc-specific differences, 
perhaps due to differences in patterns of synaptic input onto cells in those regions.  
 
Figure 35 - Representative column of neocortex showing layers 1-6 & synapse density per 
layer of human temporal cortex. 
A. Representative column of neocortex showing layers 1-6. Golgi stain shows a subset of 
neurons including their processes, Nissl stain shows cell bodies and Weigert stain shows 
myelinated fiber paths. Taken from (Kandel et al., 2000). B. Synapse density per layer of 
human temporal cortex. Mean and 95% confidence intervals of the total number of synapses 
obtained using 10 photomicrographs per layer (solid circles) or 15 photomicrographs per layer 




Overall, looking at the hippocampus and isocortex as examples enables us to conclude that 
the Arc synaptome map can identify differences in the nature of Arc protein accumulation at 
synapses both between, and within, previously-defined anatomical regions. It is also clear 
that, whilst some of these observed differences are likely to be as a result of diversity in the 
density, size or shape of excitatory synapses in these regions, there are also some interesting 
observations which appear to be specific to Arc. Examples of these are the sparse distribution 
of Arc puncta in the DGmo and the high intensity of Arc puncta in layer 4 of isocortex. Given 
the evidence that Arc protein is targeted to synapses in response to patterned synaptic 
activity (Steward et al., 1998), these observations could be the products of the particular 
patterns of input received at synapses within these anatomical regions in the ‘home cage’ 
environment. A more systematic comparison of the Arc and PSD95 synaptome maps, using 
mice containing knock-in fluorescent reporters for both proteins, would shed more light 
upon these Arc-specific synaptome features. In the future, the Arc synaptome could perhaps 
be used to measure alterations in neuronal activity patterns at the single synapse level on a 
whole-brain scale. See section 4.9 for more detail on these potential future directions.    
4.8.2 Effect of a stressful novel experience on Arc synaptome map  
In order to test the ability of the Arc synaptome map to be modified by pharmacological 
agents, and to investigate the molecular mechanism(s) underlying the action of ketamine, a 
ketamine synaptome mapping study was designed. The design of this study included groups 
of animals injected only with sterile saline and sacrificed at three different time points. The 
data from these animals was presented separately here to investigate the effect of a novel, 
and mildly stressful, experience on the Arc synaptome map. Saline injection induced an 
increase in Arc puncta density at 6h post-administration, as compared with the 1h and 24h 
groups. This increase was specific to a number of hippocampal sub-regions and some areas 
of fiber tracts. Without the inclusion of a naïve control group it is not possible to tell whether 
there are already changes taking place at the 1h time point. However, there does seem to be 
a peak in the hippocampus at 6h. There is considerable literature on the effect of novel 
experiences on Arc mRNA and protein levels. Increased numbers of Arc positive cells have 
been observed in hippocampus and parietal cortex for 30min-2h following a 5 min 
exploration of a novel environment (Ramirez-Amaya et al., 2005). Arc in the dendrites has 
also been observed in the CA1 field of hippocampus 4h following 5 min of novelty 
(Jakkamsetti et al., 2013). The results presented here add to that knowledge by 
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demonstrating that Arc is also increased at the synaptic level, and that this can be detected 
as late as 6h following a novel experience. This experience of SC injection also has the 
potential to be stressful for the animal, however, there is no change in Arc punctum 
measurements in the usual stress-response brain regions. These include the amygdala 
(Ressler, 2010), where Arc mRNA has previously been found to be increased following acute 
restraint stress (Trneckova et al., 2007) and the hypothalamus, which contains the 
hypothalamic paraventricular nucleus (PVN) (Herman et al., 2008). However, increases in Arc 
mRNA have also been observed in some hippocampal regions following acute predator scent 
stress (Kozlovsky et al., 2008). Overall these observations suggest that the Arc synaptome 
mapping method can be used to detect a response of Arc to relatively subtle stimuli, whether 
the response here can be classed as a ‘stress’ or a ‘novelty’ response is less simple and would 
require further experimentation. Given the activity-regulated nature of Arc transport to 
synapses, there is the possibility that this method could be used to map synapses activated 
during the encoding of a novel experience. A pilot experiment to do this was carried out as 
part of this PhD project, however no significant changes were observed in Arc punctum 
measurements between control and novel experience groups. A summary of the results from 
this experiment can be found in appendix 12. 
4.8.3 Effect of ketamine administration on the Arc synaptome map 
Following the characterisation of the baseline Arc synaptome map, and modifications 
induced by the administration of saline injection, the effect of ketamine administration was 
investigated. Understanding the molecular mechanism of ketamine action is of particular 
importance because of the clinical relevance of its rapid-onset, long-lasting antidepressant 
effects. Despite considerable work over the last decade the molecular mechanism underlying 
this response is still not fully understood, and it remains unclear why the antidepressant 
response would be specific only to sub-anaesthetic doses (Raffa et al., 2017; Strasburger et 
al., 2017). Our current understanding of the response of Arc to sub anaesthetic ketamine 
administration comes from western blots showing that Arc levels in synaptoneurosomes of 
the prefrontal cortex are increased 1h and 2h post-administration of 10mg/kg ketamine (Li 
et al., 2010). ISH has also shown increased arc mRNA in isocortex, including somatosensory 
and motor areas, 90 min following 25 or 50 mg/kg ketamine administration (de Bartolomeis 
et al., 2013). However, until now the response of Arc to sub-anaesthetic and anaesthetic 
doses of ketamine has not been compared, and it has not been possible to quantify the 
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accumulation of Arc protein at individual synapses in response to ketamine across entire 
brain sections.  
4.8.3.1 Dose-dependent, two-phase response of Arc to ketamine   
The results presented here in section 4.6 add to our current understanding of the action of 
ketamine on Arc in several ways. Firstly, they have enabled the identification of two distinct 
responses of synaptic Arc to a sub-anaesthetic (low) and an anaesthetic (high) dose of 
ketamine. This can be summarised as a two-phase response. In the first phase, both low and 
high doses induced an increase in Arc puncta density in hippocampus at 1h post-
administration, and the low dose also affected some olfactory and cortical subplate regions 
in the same way. In the second phase (6h + 24h) the two doses had opposing effects on 
puncta density. At 6h the low dose again produced an increase in hippocampus and cortical 
subplate but now also had the same effect on isocortex, cortical nuclei, thalamus and 
hypothalamus. Whereas the high dose produced decreases in puncta density in 
hippocampus, accompanied by reductions in puncta size in this region. At the 24h time point 
there is again a general increase in puncta density above saline control in the low dose group, 
particularly in regions within the hippocampus, thalamus and fiber tracts, but there is no 
longer an effect on isocortex. There is also still a general decrease in puncta density in the 
high-dose group, mostly within hippocampus and fiber tracts, and this is again accompanied 
by a decrease in puncta size in these regions.  
When interpreting the results presented here it is important to take into consideration the 
timeline of ketamine presence in the brain tissue. Ketamine is metabolised rapidly and has 
been found to have a half-life in a laboratory mouse of approximately 13 min (Maxwell et al., 
2006). Ideally measurements of receptor occupancy would have been taken from animals 
within the synaptome mapping cohorts. However, in the absence of that data, published ex 
vivo radiography evidence from the same background strain of mouse (C57/BL6) can provide 
a guide. 30mg/kg ketamine delivered via a subcutaneous route reached a maximum level of 
MK801 binding site occupancy after 15 min and was rapidly cleared, resulting in no significant 
level of occupancy after 1h. The maximum level of occupancy reached by this dose was >50% 
(Lord et al., 2013). This strongly suggests that for the low dose (10mg/kg) group in the Arc 
synaptome mapping study ketamine is likely to have been cleared from NMDAR binding sites 
by the first time point (1h). The same kind of receptor occupancy data does not appear to be 
available for a dose close to the 100mg/kg, used as the high dose for the Arc synaptome 
mapping experiment. However, at 60 min post administration of 100mg/kg ketamine it is 
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possible to detect ketamine in the blood, at a serum concentration of ~2ug/ml, see figure 36 
(Maxwell et al., 2006). Therefore, it is possible that during the first phase at 1h post-
administration there is still some blockade of NMDARs by ketamine in the high-dose group. 
However, during phase two (6h-24h) it is highly unlikely that any ketamine is remaining. 
Taken together this existing evidence suggests that most of the changes seen in the Arc 
synaptome map here are a downstream response to the transient blockade of NMDARs by 
ketamine and not an acute response to the current presence of ketamine at receptor sites. 
 
Figure 36 - Serum half-life of ketamine, average of 4 strains of laboratory mice. 
(t1/2 = 13 min). 100mg/kg ketamine administered intraperitoneally. Strains tested = FVB, C3H, 
C57, DBA.  Figure taken from (Maxwell et al., 2006). 
The most dramatic effect of ketamine administration seen here was on the number of Arc 
puncta detected, rather than their size or fluorescence intensity. This raises the question of 
whether this represents specific changes in the delivery of Arc to synapses, or changes in the 
number of synapses in general. Synaptogenesis has been reported in the PFC 24h following 
administration of 10mg/kg ketamine (Li et al., 2010; Ardalan et al., 2017) and in hippocampus 
24h following a 15mg/kg dose of S-ketamine (Ardalan et al., 2017). The increase in Arc puncta 
number is observed here as early as 1h post-administration, which is a time point not 
assessed in the referenced synaptogenesis studies and could be considered too rapid for this 
kind of response. However, synaptogenesis has been observed in the nucleus accumbens 1h 
following a single administration of cocaine (Dos Santos et al., 2017), showing that in general 
the generation of synapses in response to a pharmacological agent is possible on this 
timescale. Conversely, the reduction in Arc puncta density at 6h and 24h following the 
100mg/kg dose could be the result of the removal of Arc from previously Arc-positive 
synapses, or a loss of synapse number in general. There does not appear to be any previous 
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evidence of anaesthetic doses of ketamine causing a loss of synapses or cell death in adult 
animals, although this has been observed in juveniles (Slikker et al., 2007). Answering the 
question of synaptogenesis vs Arc transport was part of the motivation behind mapping the 
PSD95 synaptome in response to ketamine administration. No widespread changes were 
seen in the density, intensity or size of PSD95 puncta at 24h post-administration in the brain 
regions which were affected in the Arc synaptome map. This argues against changes in 
general excitatory synapse number as being the cause for the alterations in Arc puncta 
number. In the Arc synaptome map only a handful of individual regions had a significant 
alteration in average punctum intensity in response to ketamine. However, there were a 
cluster of regions, predominantly within the hippocampus that had a reduction in average 
punctum size at 6h and 24h post-administration of a high dose. Taken together, this suggests 
that in response to low-dose ketamine administration Arc protein is delivered to synapses 
which previously did not contain it at detectable levels (Arc-negative synapses). It also 
suggests that in response to high-dose ketamine administration Arc is first driven to 
previously Arc-negative synapses, producing an increase in puncta number at 1h. This is 
followed by the depletion of Arc from synapses at 6h and 24h, reducing the number of 
synapses containing detectable levels of Arc and also reducing the average size of those 
detectable puncta. However, it is important to remember that all of these values are the 
mean of a potentially diverse population of synapses and therefore it is possible that subtler 
changes in different subpopulations of synapses within these delineated regions could be 
taking place. A future aim is to analyse this data in more depth to identify these 
subpopulations. See section 4.9 for more details.  
4.8.3.2 Screening of brain regions 
The Arc synaptome results provide a considerable amount of data on the brain regions 
affected by ketamine administration across these two phases of response. The hippocampus 
was affected at all three time points and was the area that displayed the most strikingly 
different response to the low and high doses. The hippocampus has previously been 
implicated in the pathophysiology of depression. Reduced hippocampal volume is observed 
in MDD patients and can be rescued with antidepressant treatment (Malykhin et al., 2010). 
Further to this, microinfusion of R-ketamine specifically into DG and CA3 produces an 
antidepressant response (Shirayama & Hashimoto, 2017), suggesting that the hippocampus 
is functionally involved in ketamine’s antidepressant action. An increase in Arc protein level 
has been detected in western blot of hippocampal tissue 30 min after administration of 
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3mg/kg ketamine (Autry et al., 2011). The evidence from the Arc synaptome map builds upon 
this by showing that alterations of Arc protein levels in the hippocampus are at least partially 
due to alterations in the amount of protein at synaptic sites; that this can last up to 24h; and 
that the hippocampus responds differently to low and high doses of ketamine. The 
hippocampus is involved in information processing which is essential for memory formation 
and retrieval (Squire, 1992; Whitlock et al., 2006). It receives input from widespread areas of 
neocortex via the entorhinal cortex (EC), processes this information and produces output 
which is delivered back to neocortical areas again via the EC (Teyler & Rudy, 2007). An effect 
of ketamine on synaptic Arc levels in the hippocampus suggests that modification of synaptic 
strength is taking place either via increased AMPA receptor endocytosis or remodelling of 
spines, which has the potential to alter the way information is processed as it passes through 
the hippocampus. Indeed, 30mg/kg ketamine has been found to induce AMPAR endocytosis-
dependent synaptic depression at Schaffer collateral synapses in CA1, peaking at 20 min post-
administration and lasting for over 4h (Duan et al., 2013). This synaptic depression was linked 
to the memory impairments caused by ketamine (Moosavi et al., 2012) but could have 
relevance to its antidepressant effects also.  
The isocortex was affected by ketamine administration specifically at 6h post-administration. 
This effect was particularly striking in the low-dose group and involved every sub-region 
within isocortex. There is less existing information on the role of isocortical regions in the 
ketamine response than for the hippocampus. From the data presented here the effects in 
the isocortex seem to be temporally secondary to the onset of effects in hippocampus, and 
more transient in nature. There is some evidence that in MDD patients whose symptoms are 
improved by ketamine administration, stimulus-evoked somatosensory cortical responses 
are also increased at 6.5h post-infusion (Cornwell et al., 2012).  
The synaptome mapping results here also identified clusters of affected areas in the cortical 
subplate, cerebral nuclei, thalamus, hypothalamus, olfactory areas and fiber tracts. These 
were predominantly changes in puncta density induced by the low dose. Some of these 
regions do not have a previously identified role in the response to ketamine, for example 
microinfusion of R-ketamine into the basolateral amygdala does not induce an 
antidepressant response (Shirayama & Hashimoto, 2017). These synaptome map findings 
suggest a widespread alteration of synaptic composition following low-dose ketamine 
administration, involving a diverse network of brain regions. Different members of this 
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network appear to be altered at different time points following administration, with 
alterations in the hippocampus a common feature throughout. Although these results cannot 
tell us which of these altered regions is responsible for the behavioural changes caused by 
ketamine, they do provide a list of areas for further investigation along with a timeline of 
their response. Some potential follow-up experiments based on this list have been described 
in section 4.9. 
The majority of the previous work on ketamine’s antidepressant action has focussed upon 
the prefrontal cortex, and there is some compelling evidence that this region is functionally 
important for ketamine’s antidepressant actions (Shirayama & Hashimoto, 2017). This 
includes the finding that both microinfusion of ketamine into the infralimbic (IL) PFC and 
optogenetic stimulation of the same area are able to induce long-lasting antidepressant 
responses similar to systemic ketamine administration (Fuchikami et al., 2015). Further to 
this, the previous evidence for an increase in Arc protein levels following sub-anaesthetic 
ketamine administration came from synaptoneurosomes taken from the mPFC (Li et al., 
2010). The PFC has been identified as important for the cognitive control of flexible actions, 
with the IL area thought to be specifically involved in the development and expression of 
inflexible reward seeking (Barker et al., 2014). However, in the results described here no 
significant alterations in Arc puncta density, intensity or size were detected in the infralimbic 
area of the PFC, which was unexpected. However, it should be noted that in general the 
bregma level containing these regions (2.10mm) showed greater levels of variation between 
mice, with an average 45% larger standard deviation in the density measurement at 1h post-
administration than the bregma 1.70mm section. This suggests that a greater degree of 
biological variation in Arc levels in prefrontal regions could be masking subtle changes in Arc 
puncta measurements. Therefore, before drawing conclusions on this point, it would be 
beneficial to repeat this experiment with a larger number of animals per group. However, if 
there is indeed no change in the synaptome map of the prefrontal cortex, this would be 
contradictory to previous evidence.  
4.8.3.3 Possible mechanisms underlying response of Arc to ketamine   
As mentioned, these results allow us to identify distinct effects of low- and high-dose 
ketamine on Arc puncta number, which do not follow a conventional dose-response 
relationship. In the second phase of response the low dose induced an increase in Arc puncta 
density across multiple regions, whereas the high dose induced a general decrease 
sometimes in the very same regions. This could be described as an indicator of an ‘inverted 
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u’ dose-response relationship, in which response increases with dose only to a point, after 
which the trend reverses and there is a decrease in response with increasing dose. What is 
particularly interesting about this observation is that the low (10mg/kg) dose has been 
repeatedly reported in the literature as ‘antidepressant’ in mice from 1-24h post-
administration (Li et al., 2010; Beurel et al., 2011; Wang et al., 2015; Can et al., 2016; Zanos 
et al., 2016). Whereas this response has not been observed for doses over 80mg/kg (Li et al., 
2010; Chatterjee et al., 2011), which would include the 100mg/kg high dose used here. This 
suggests a correlation between a sustained (>1h) increase in numbers of Arc-positive 
synapses and the presence of an ‘antidepressant’ response. This conclusion is tentative 
however, as behavioural testing was not carried out on the animals involved in this mapping 
study. It is also interesting to note that increased Arc mRNA and protein have been observed 
in cortical regions and parts of the hippocampus following repeated administration of 
conventional antidepressant treatments (SSRIs, SNRIs and tricyclic antidepressants), and that 
short-term treatments are not able to induce this increase (Pei et al., 2003; De Foubert et al., 
2004; Ferres-Coy et al., 2013). These drugs only show antidepressant effects after repeated 
administration, again linking an increase in Arc levels with antidepressant efficacy. A similar 
‘inverted u’ dose response relationship has been described for the release of glutamate in 
the PFC following ketamine administration. Ketamine doses of between 10-30mg/kg induce 
an increase in glutamate over the first 100 min post-administration, whereas 50mg/kg does 
not and 200mg/kg decreases glutamate levels (Moghaddam et al., 1997). An increase in 
general neuronal activity has also been observed in several regions in response to sub-
anaesthetic doses only.  For example a 35mg/kg dose of ketamine induces an increase in the 
uptake of 14C-2-deoxyglucose (2-DG) in multiple brain regions including PFC and parts of 
hippocampus, but this was not observed with an anaesthetic (100mg/kg) dose  (Duncan et 
al., 1998). This correlation of the dose-response of ketamine-induced neuronal activity, 
glutamate release and Arc puncta density is interesting, as increased glutamate release can 
increase Arc levels via mGluR and NMDAR activation, which induces the translation of 
existing Arc mRNA (Bloomer et al., 2008; Waung et al., 2008; Na et al., 2016) and 
transcription of new Arc mRNA (Steward et al., 1998; Steward & Worley, 2001). Interestingly, 
the IEG c-fos staining showed a different pattern of induction to both glutamate and Arc, with 
increases seen in PFC and other areas of isocortex but not the hippocampus. In the case of c-
fos, 100mg/kg induced a greater response than 35mg/kg, not showing the described 
‘inverted u’ dose-response (Duncan et al., 1998). This suggests that perhaps the patterns of 
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activity produced by this ketamine-induced glutamate ‘surge’ do not activate all IEGs in the 
same way, and that some of the synaptome map response described here may be Arc 
specific.  
Several members of the MAPK and mTOR signalling cascades have also been found to be 
activated by low but not high doses of ketamine. At 1h post-administration 5 and 10 mg/kg 
doses are able to increase levels of p4E-BP1, pmTOR, pp70S6K, pERK and pAkt in 
synaptoneurosomes of PFC, but an 80mg/kg dose does not (Li et al., 2010). The response of 
ERK is particularly interesting as ERK phosphorylation is downstream of NMDAR and mGluR 
activation (Mao et al., 2004; Chen et al., 2017) and Arc transcription and translation are ERK 
dependent (Panja et al., 2009; Pintchovski et al., 2009; Kumar et al., 2012), as is the targeting 
of Arc mRNA to activated synaptic sites (Huang et al., 2007). There is also recent evidence 
that Arc protein itself is directly phosphorylated by ERK, and that this may increase transport 
of Arc into the cytoplasm (Nikolaienko et al., 2017). The ability of glutamate to upregulate 
Arc has been found to depend upon NMDAR-mediated ERK phosphorylation (Chen et al., 
2017). When viewed together with the glutamate response this suggests that increased Arc 
levels in the low dose group could be the result of a ketamine-induced increase in glutamate 
release, inducing NMDAR and/or mGluR activation and ERK phosphorylation. Similarly, the 
reduction of glutamate release in response to an anaesthetic dose provides a potential 
explanation for the reduction in Arc during the second phase in the high dose group. 
However, this hypothesis does not explain why there was first a short-term increase in Arc 
puncta density in the high-dose group. The literature on glutamate increase identified no 
such short term increase in glutamate in PFC following 100mg/kg ketamine  (Moghaddam et 
al., 1997).  
Whether or not the glutamate ‘surge’ is responsible for the observed changes in Arc, it 
remains the case that ketamine is an NMDA receptor antagonist, and that at certain time 
points and dosages it is able to increase the levels of an activity-regulated protein. As 
discussed, Arc transcription and translation is induced by NMDA receptor activity (Steward 
et al., 1998; Steward & Worley, 2001; Bloomer et al., 2008). There is some evidence that at 
low doses ketamine is able to act preferentially at inhibitory interneurons in PFC, thus 
increasing excitability of the principal excitatory neurons in that region (Zhang et al., 2008; 
Quirk et al., 2009). If this is taking place in hippocampus and cortex, then it could explain the 
ability of ketamine to induce glutamate release and the expression of IEGs such as Arc and c-
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fos. At high doses this preference for interneurons would be inconsequential, with ketamine 
also causing blockade of NMDARs on principal excitatory neurons, and would perhaps result 
in the decreased Arc levels seen with anaesthetic doses. However, again this hypothesis does 
not explain the short-term increase in Arc levels seen prior to the decreases induced by an 
anaesthetic dose.  
4.8.4 Effect of ketamine administration on PSD95 synaptome map 
PSD95, an important interactor of Arc (Fernandez et al., 2017), has also previously been 
found to be increased in synaptoneurosomes of PFC following low dose ketamine 
administration (Li et al., 2010). However, the increase in PSD95 began later than Arc, at 2h 
post-administration, and lasted much longer, until 72h. This different timeline of PSD95 
response to ketamine informed the design of the PSD95 synaptome mapping experiment 
presented here and therefore only a 24h time point was investigated. The effect of ketamine 
on PSD95 was less dramatic and less widespread than its effect on Arc. The low dose induced 
a decrease in PSD95 puncta in two isocortical regions, and a decrease in size of PSD95 puncta 
in four other isocortical regions. This is in contrast to the Arc results which did not see a 
pattern of change in the isocortex at 24h. The high dose induced a decrease in density and 
intensity, and an increase in the size of PSD95 puncta. Most of the affected regions were 
clustered within the olfactory areas contained within the ‘prefrontal’ bregma 2.10mm brain 
section. Again, these regions were unchanged in the Arc synaptome. As discussed in section 
4.8.3.1 this lack of correlation between changes taking place in the Arc and PSD95 synaptome 
maps suggests that the observed alterations in Arc puncta number are not simply a reflection 
of a change in excitatory synapse number. One expectation when mapping the PSD95 
synaptome at this time point was that it would be possible to identify increases in the number 
of PSD95 puncta in the medial prefrontal cortex (ILA, ORBm, PL, ACAd) as a result of the 
ketamine-induced synaptogenesis previously reported in the literature (Li et al., 2010; 
Ardalan et al., 2017). This was not the case as no increase in PSD95 puncta density was 
observed in these regions.  
4.9 Future directions  
4.9.1 Further analysis of existing data  
The synaptome mapping datasets presented here contain an immense amount of 
information, which has been analysed and presented in a simple way for the purposes of this 
thesis. The statistical approaches used here are not optimal for understanding the 
complexities of this data and therefore an important future direction of this research will be 
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to apply more complex statistical analyses to this data. These could include Bayesian 
inference approaches. A model based on this kind of approach was designed for Dr Melissa 
Cizeron’s synaptome mapping data by Dr Nathan Skene. Adapting this method to 
accommodate the design of the ketamine study described here could provide a superior 
method of analysis to the multiple t-test approach used for this thesis. Further to this, more 
detailed analysis of the existing data which goes beyond comparison of the mean values per 
region would provide more information about the presence of subpopulations of puncta 
within anatomical regions. Again, steps were made towards this goal by Dr Zhen Qiu in the 
analysis of the PSD95EGFP synaptome maps generated by Dr Melissa Cizeron (Zhu et al., 2018). 
These could be adapted for the Arc ketamine dataset.  
4.9.2 ArcVENUS mice 
As the results presented in this thesis show, the ArcVENUS mouse line can be used in 
conjunction with the synaptome mapping pipeline to study large scale synaptic responses to 
stimuli. However, this mouse line also has a potential use for investigating in more detail the 
regulation of Arc subcellular distribution. Generating primary neuronal cultures from these 
animals could allow the visualization of the response of Arc in different subcellular 
compartments to specific cellular stimuli. For example, when combined with a technique 
which allows the uncaging of glutamate at single spines (Noguchi et al., 2011), the response 
of Arc to activity could be visualised at the single synapse level. This could be combined with 
various other antagonists or specific blockers to establish which receptor types/subtypes are 
involved in the response of Arc to glutamate. This kind of information would also aid in the 
interpretation of the results of Arc synaptome mapping experiments.  
4.9.3 Arc synaptome mapping  
The Arc synaptome mapping method, used for the first time here, has multiple potential 
future applications. One important future direction of this work will be to build upon the 
baseline Arc synaptome map by including additional markers. This could start with the 
mapping of Arc and PSD95 in the same animal. Work towards this goal is already underway 
with the generation of an ArcVENUSxPSD95Mcherry mouse line. The PSD95mCherry mouse line is 
designed in the same way as the PSD95EGFP line described in the methods section of this 
thesis, with the exception that the sequence for mCherry (a form of RFP) has been inserted 
at the end of the PSD95 coding region in the place of EGFP. The excitation and emission 
spectra of mCherry are sufficiently separated from those of Venus to allow simultaneous 
imaging of both fluorophores, whereas this is not the case with EGFP and Venus. Performing 
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synaptome mapping of both Arc and PSD95 in the same animals would enable the 
identification of patterns in the Arc synaptome that can be explained by patterns in excitatory 
synapse number, and type, as well as those which are specific to Arc and therefore more 
likely to be caused by region-specific patterns of synaptic activity. It could be argued that 
these Arc-specific features, for example the sparse distribution of Arc-positive synapses in 
the DGmo already identified, are the most likely to be altered by Arc-modulating stimuli such 
as behavioural stimulation. Further to this, the incorporation of a quantification of the 
nuclear localisation of Arc into the synaptome mapping pipeline would allow a more 
complete view of the brain wide distribution of Arc. The alteration of the Arc synaptome map 
by saline injection described here suggests that this method can be used to map the response 
of synaptic Arc to fairly subtle stimuli. A future aim would be to extend this work to map the 
Arc synaptome response to learning and memory paradigms. A pilot study towards this aim 
was carried out as part of this PhD project, the results of which can be found in appendix 12. 
It is hoped that this method could eventually be used to map the synaptic equivalent of the 
memory ‘engram’.    
4.9.4 Further investigations of ketamine action 
Although the evidence here adds to our understanding of the molecular events following the 
administration of ketamine, there is still much which is not fully clear. The future direction of 
research into ketamine action is too broad to be covered in this thesis, however some 
suggestions are described below. Firstly, it will be essential to confirm the presence of the 
described bi-directional Arc synaptome changes along with the presence or absence of a 
ketamine-induced antidepressant response. This would strengthen the evidence for a 
correlation between sustained increases in Arc positive synapse number and the 
antidepressant response. It may also be possible to correlate the degree of antidepressant 
response with the magnitude of change in Arc, which would be particularly convincing. 
Following on from that correlation it will then be important to test for a causal link between 
presence of Arc at the synapse and antidepressant response. This could be done rather 
bluntly by the testing of Arc knockout, or conditional knock out mice, to allow normal 
development of the animal, followed by behavioural testing. Absence of an antidepressant 
response of ketamine in Arc knockout animals would indicate a functional role for the 
protein. However, it would be important to ensure that these animals did not display any 
other phenotypes which would bias the FST, TST or NSFT tests used. Arc knockout mice have 
been generated previously and displayed an inability to form long term memories and 
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alterations in LTP (Plath et al., 2006). A more elegant way of investigating the functional 
requirement of Arc for ketamine’s antidepressant effects would be to knock down Arc 
expression by infusion of Arc antisense oligodeoxynucleotides (ODNs) into target brain 
regions (for example hippocampus) at various time points following ketamine administration 
before behavioural testing. Thus, identifying if Arc upregulation is required for the 
behavioural response, and whether there is a critical time period during which Arc is acting 
in this way. This kind of technique has already been used to investigate the role of Arc in 
consolidation of LTP (Messaoudi et al., 2007). 
It would be interesting to characterize the functional alterations taking place alongside the 
changes in Arc level observed here. In a very simple way, the functional response to changes 
in Arc could begin to be investigated by performing immunohistochemistry for AMPA 
receptors on the existing brain slices from ketamine-treated ArcVENUS mice. A correlation 
between increased Arc at synapses and decreased AMPA receptors would indicate that 
perhaps Arc is acting to reduce synaptic strength via its ability to increase AMPA receptor 
endocytosis. Further to this, slice electrophysiology could be used to identify changes in 
different properties of synaptic transmission and plasticity following ketamine in the regions 
identified here, the hippocampus being an obvious place to start with this. A particularly 
interesting question, which could be addressed here, would be how the functional response 
to ketamine differs between anaesthetic and sub-anaesthetic doses, which we now know 
produce such different changes at the level of synaptic Arc protein. Further to this, the 
question of whether the responses of Arc described here are specific to ketamine could be 
addressed by using another NMDAR antagonist working at the same site, for example 
memantine. Memantine does not cause the same rapid-acting, long-lasting antidepressant 
effect that ketamine does (Gideons et al., 2014), and therefore comparison of the Arc 
synaptome map changes induced by these two compounds could shed more light on the 
elements of the response required for those antidepressant effects.  
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Chapter 5 Conclusions and future directions  
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5.1 Summary of findings  
5.1.1 Use of synaptome mapping to study Arc   
In the ArcVENUS mouse line fluorescently-tagged Arc was detectable as both punctate 
accumulations situated at the post-synaptic side of glutamatergic synapses, and large oval 
accumulations situated within/around the nuclei of certain cells. The use of the synaptome 
mapping method to quantify these accumulations of fluorescently-tagged Arc protein at 
synapses across a whole coronal brain section is the first time that the subcellular distribution 
of Arc has been studied in this way. It has allowed several observations to be made, including 
the identification of gradients of change within defined anatomical regions. This provides a 
useful reference dataset for future research into the brain-wide functions of synaptic Arc. 
This follows on from the work carried out by Dr Melissa Cizeron, in which she generated the 
first synaptome maps of the MAGUK proteins PSD95 and SAP102. The Arc synaptome map 
presented here is the first time that a dynamic and activity-regulated protein has been 
studied using this technique. It is also the first time this technique has been used to detect 
alterations to a synaptome map on such a short (hours) timescale. In this case these changes 
were pharmacologically-induced, but this proof of principle opens the door to the possibility 
of mapping the effects of more subtle interventions, such as learning experiences.  
5.1.1 Insights into ketamine’s molecular mechanism of action  
The findings presented in this thesis provide two new insights into the molecular mechanism 
of ketamine, which are of interest in the context of its antidepressant actions. Firstly, the 
absence of a low dose ketamine-induced hyper-locomotive response in GluN2B2A(CTR) mutant 
animals suggests a critical involvement of the c-terminal domain of the GluN2B subunit in 
this short-term effect of ketamine. Secondly, there is the observation that low- and high- 
doses of ketamine are able to induce opposite effects on Arc protein accumulation at 
synapses. In this case only the low dose of ketamine was able to induce a sustained increase 
in Arc accumulation at synapses, with the high dose depleting Arc from synapses from 6h 
onwards. This enables us to draws a correlation between synaptic Arc levels and ketamine-
induced antidepressant responses, which have been observed following sub-anaesthetic but 
not anaesthetic doses. Other changes specific to sub-anaesthetic doses of ketamine include 
glutamate release and activation of mTOR and ERK signalling, all of which could be upstream 
from the observed changes in Arc. The PSD95 synaptome map did not change along with the 
Arc map at 24h post-ketamine administration, suggesting that the changes observed in Arc 
puncta number are unlikely to be the result of synaptogenesis. The potential implications of 
these two main findings have been discussed in detail within the respective results chapters, 
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however they do not stand in isolation but are linked by the interaction of Arc with the 
GluN2B CTD, and can therefore also be interpreted in relation to one another. Arc forms part 
of the 1.5MDa NMDA receptor supercomplex, the assembly of which is reliant upon the 
presence of the GluN2B c-terminal domain, PSD95 and PSD93 (Frank et al., 2016). Further to 
this, PSD95 is essential for the transport of Arc to the synapse (Fernandez et al., 2017). If the 
absence of the GluN2B c-terminal domain leads to an alteration in the amount of Arc present 
at the synapse, via its interaction with PSD95, this provides a route by which Arc could be 
involved in the GluN2B-specific actions of ketamine. Future directions to address this 
hypothesis are described in section 5.3. 
5.2 Limitations of work presented here 
The limitations of this work, and future directions designed to address these limitations, have 
been discussed within the individual results chapters. The main limitation of using the two 
approaches discussed here to investigate the action of ketamine is that synaptome mapping 
does not provide functional information, and the behavioural tests used only provide a very 
coarse level of functional information. Therefore, it is impossible for us to tell from the work 
presented here, whether the alterations observed in the Arc synaptome are functionally 
involved in either of the behavioural responses to ketamine action measured in the open-
field or the forced swim test. Likewise, it is unclear what is happening at the molecular level 
at the synapse during the behavioural responses observed. Therefore, it will be important to 
carry out further experiments to attempt to link these two findings together, as described in 
section 5.3.  
5.3 Future directions  
Some specific ideas for future directions of the work presented in chapter 3 and 4 have 
already been discussed within those chapters. However, presented here are some key future 
directions which are inspired by the work in both chapters taken together. 
5.3.1 Effect of GluN2B2A(CTR) and GluN2A2B(CTR) mutations on interaction of Arc with 
PSD proteins  
The question of whether the c-terminal domain replacement mutations are able to alter the 
amount of Arc present at the synapse can be addressed with a biochemical analysis of 
GluN2B2A(CTR) and GluN2A2B(CTR) brains. This could involve several experiments, the simplest of 
which would be to prepare a post-synaptic density fraction of brain homogenate and 
compare levels of Arc in wild-type and mutant animals. Further to this, immunoprecipitation 
could be carried out with antibodies for the n-terminal domains of GluN1, GluN2A and 
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GluN2B to establish whether the CTD replacement mutations alter the amount of Arc and 
PSD95 associating with the general population of NMDARs, or specific subtypes respectively. 
A reduction of synapse- or NMDAR-associated Arc in GluN2B2A(CTR) mutants would provide 
some evidence for the involvement of Arc in ketamine action.  
5.3.2 Synaptome mapping of GluN2B2A(CTR) and GluN2A2B(CTR) mutants  
As discussed in section 5.1, perhaps the most pressing question that links these findings is 
whether the increases seen in Arc protein accumulation at synapses in response to low doses 
of ketamine are in some way regulated by an action of the GluN2B c-terminal domain. This 
could be tested by administering ketamine to mice containing both the GluN2B2A(CTR) genetic 
modification, and the ArcVENUS tag. Generation of this mouse line has already begun. The aim 
of this experiment would be to establish whether the dose-dependent effects of ketamine 
on the Arc synaptome are affected by the GluN2B2A(CTR) modification. If, for example, these 
changes to the synaptome were absent or perturbed in GluN2B2A(CTR) animals, this would 
implicate both the GluN2B CTD in the mechanism underlying the Arc response to ketamine, 
and Arc in the mechanism underlying the behavioural response to ketamine. This experiment 
could be followed up by a similar analysis of the Arc synaptome response in GluN2A2B(CTR) 
mutants to establish whether this is exaggerated in animals in which the behavioural 
response to ketamine is exaggerated.  
5.3.3 Synaptome mapping and behavioural testing in the same animals  
Similarly, it would be interesting to establish whether alterations in the synaptome map can 
be detected at the early time point at which the hyper-locomotive response to ketamine is 
present. This would be most informative if animals were first tested in the open-field to 
establish the amount of hyper-locomotion displayed by each individual, before being 
immediately culled and brains preserved for synaptome mapping. This would provide the 
opportunity to correlate any synaptome changes with the degree of hyper-locomotive 
response to ketamine observed. This could be combined with the experiment suggested in 
section 5.3.1. If the Arc synaptome map is altered during the time period that hyper-
locomotion is observed, this would implicate Arc as having a role in the molecular mechanism 
of this effect, potentially via its interaction with the GluN2B c-terminal domain.  
5.3.4 Testing the behavioural response to ketamine in Arc knockout animals 
The most important experiment to carry out, in order to establish whether the alterations 
observed in the Arc synaptome are functionally relevant for ketamine’s behavioural actions, 
will be to study the behavioural response to ketamine displayed by animals which lack, or 
 135 
have reduced levels of, Arc protein. One option for this experiment would be the use of a 
complete Arc knockout mouse line such as that generated by the laboratory of Prof. Dietmar 
Kuhl and used previously to study the role of Arc in memory (Plath et al., 2006; Ploski et al., 
2008). These animals fail to form lasting memories in several kinds of learning tasks, whereas 
short-term memory was intact. Therefore testing of ketamine’s effect on behaviour in these 
mice would need to avoid tasks which could be affected by this memory impairment. For 
example, if hyper-locomotion in an open field arena is measured, this should not rely upon 
any habituation sessions taking place too far from the time of testing. Further to this, it is 
possible to reduce the amount of Arc protein in an acute way via the infusion of Arc antisense 
ODNs into specific brain regions of interest (Guzowski et al., 2000). In this way, the changes 
in synaptic Arc levels in specific regions seen in the synaptome maps could be tested for a 
functional role in the behavioural action of ketamine. For example, does the infusion of Arc 
antisense ODNs into the hippocampus following a low dose of ketamine prevent the 
antidepressant effects detectable with the forced swim test? Is there a critical period of time 
during which Arc is acting to produce these effects?  
5.3.5 Long-term goals of this area of research 
As described in chapter 1 of this thesis, the current antidepressant treatments available to 
patients have two main limitations. The first of which is that they are not effective for all 
patients, the second is that they take several weeks of repeat dosing before symptoms are 
reduced. Ketamine has been found to be effective in previously treatment-resistant MDD 
patients and is antidepressant in humans and mice after just one dose. In the long-term it is 
hoped that the work presented here, along with the future directions described, will 
contribute significantly to our understanding of the molecular events underlying the 
observed effects of ketamine. This kind of knowledge will be essential for the development 
of a ketamine-based antidepressant treatment which lacks ketamine’s undesirable 
psychotomimetic effects. One important piece of information which will emerge from the 
future experiments described in section 3.6.2 will be whether or not the antidepressant 
effects of ketamine are reliant on the GluN2B CTD, as the psychotomimetic effects appear to 
be. If they are not, and it becomes clear that the psychotomimetic and antidepressant effects 
of ketamine are mediated by different molecular mechanisms, this may provide an 
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Appendix 1: Comparison of male and female groups in open-field and FST 
behaviours, with and without ketamine administration  
 
Appendix.figure 1 – No effect of gender on wild-type ketamine hyper-locomotive response. 
Distance travelled by wild-type animals during ketamine response window. Pooled data from 
all experiments, with the exception of the pilot study which was all-male and is not included 
here. Data points = individual animals, error bars = SEM. One-way ANOVA, Sidak’s multiple 
comparisons.   
 
 
Appendix.figure 2 – No effect of gender on wild-type immobility time in FST. Time spent 
immobile (s), total over whole 4 min scoring period, per mouse in both ketamine and saline 




Appendix 2: Total distance travelled during open-field habituation sessions  
 
 
Appendix.figure 3 – Effect of genotype on baseline distance travelled during all habituation 
sessions. Sum of distance travelled during all periods spent in open field prior to ketamine 
administration. This includes 2x 10 min habituation sessions on day 1 and 1x 15min 
habituation session on day 2. Each data point represents one mouse, line = mean, error bars 
= SEM. **= p<0.01, ***=p<0.001.  
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Appendix 3: Test western blot images using antibodies for proteins previously altered as 
part of ketamine response.  
BDNF Akt Erk   p-Akt p-Erk 













SynGAP p-eEF2 eEF2 








Appendix.figure 4 - Extract from two wild-type mice used to test specificity of antibodies. 
Molecular weight ladder positions shown on left, table contains target protein, molecular 




Appendix 4:  Western blot images showing tagged and untagged forms of Arc in extract 
from wild-type controls, ArcVENUS. 
 
 
Appendix.figure 5 – Western blot showing tagged and un-tagged forms of Arc present in 
protein extract from animals wild-type (WT), heterozygous (HET) and homozygous for 
ArcVENUS tag (HOM), probed with an anti-Arc antibody (A, Santa Cruz, SC-17869) and an anti-
GFP antibody (B, Invitrogen, A-11122). A. Red channel = anti-Arc, Green channel = b-Actin 
loading control and molecular weight ladder. Molecular weight of Arc is 45kDa, WT Arc band 
shown by open arrows in A, this band is strongest in the WT lane and not detectable in the 
ArcVENUS HOM lane. Molecular weight of Venus (YFP) tag is approx. 27kDa, bringing the total 
tagged form of arc to a molecular weight of the tagged form of Arc to approx. 72kDa. A strong 
band in the ArcVNUES HOM lane can been seen just above the 64kDa marker, this is likely to be 
the tagged form of Arc and has been highlighted with filled arrows in A. B. Red channel = Anti-
GFP antibody, Green channel = b-Actin loading control and molecular weight ladder. 
Sequence of GFP and Venus considered sufficiently similar for anti-GFP primary to recognise 
Venus. Some non-specific bands can be observed. However, in ArcVENUS HOM lane a bright 
band can be observed just above 64kDa marker, highlighted with filled arrows, which is where 
tagged form of Arc would be expected to be. A fainter band at the same molecular weight 









Appendix 5: Control images from VGlut1 and DAPI IHC.   
  
Appendix.Figure 6 – Control images from VGlut1 IHC and ArcVENUS co-imaging. Middle 
column shows control in which VGlut1 primary antibody was not applied but all other 
conditions remained the same. Right column shows the result of VGlut1 IHC staining on a 




Appendix.figure 7 (previous page) – Control images from DAPI and ArcVENUS co-imaging. For 
each brain region imaged: top row = mouse homozygous for ArcVENUS tag, bottom row = wild-
type mouse in which no ArcVENUS tag is present.   
 
Appendix 6: Example metadata from VGlut1 and ArcVENUS co-imaging  
 
Name : 2017_11_10_GGV430_CA1_SR_1 10/11/2017 15:24:30  
 
Type : 16 bit grey/pseudo 
Intensity : 1.000000 lux 
x : 512 * 0.084034 : um 
y : 512 * 0.084000 : um 
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[Grab Parameters End] 
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[Tab Device Info End] 
[Tab Exposure] 
Window=512 : 512 
Shutter=Open 
Binning=1 x 1 
Temperature - Actual =-70 
Display Control - Fastest=Checked 
Display Control - Display Rate=1 
Gains - Pre-Amp-Gain=Gain 3 
EM Gain - Enabled=Checked 
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Gains - EMGain=250 
Exposure Time - Frame Transfer=Unchecked 
Exposure Time - unit=ms 
Exposure Time - exposure value=120.0 
Exposure Time - Readout in ms=19.371 
Experiment Control - FLZ=Unchecked 
Experiment Control - Trig Mode=Free Run 
Use Frame averaging=Checked 
Frames to be averaged=2 
Fastest Grab=Unchecked 
Available memory=4095 






TTL High Open=Checked 
Shutter Open Transfer Time=60 
Shutter Close Transfer Time=80 
[Tab Temperature/Shutter End] 
[Tab Speed/Amplifer] 
Horizontal Readout=17.000 
Vertical Readout time=[1.700] 
ADC Channel=0 
Vertical Clock Voltage=Normal 
Output Amplifier=EM Port 
Baseline Clamp=Checked 
[Tab Speed/Amplifer End] 
[Tab Image Orientation] 
Flip=None 
Rotation in Degrees=None 










[Image Info End] 
[First Frame] 
SavedTime=10/11/2017 13:45:22.921 
[First Frame End] 
 
Appendix 7: Example metadata from DAPI and ArcVENUS co-imaging  
 
Name : 2017_11_10_GGV440_CA3_SLU_11 10/11/2017 12:44:56  
 
Type : 16 bit grey/pseudo 
Intensity : 1.000000 lux 
x : 512 * 0.084034 : um 
y : 512 * 0.084000 : um 













Protocol - Sarah venus 
 6D View Compatible - No 
 Image - 2017_11_10_GGV440_CA3_SLU_1 
  Camera Binning - Use Current 
 184 
  Wait Allocation - Off 
  Camera Selection - Use Current 
  Events 
   Keyboard Events - On 
    Default name - Spacebar 
   Triggered Events - Off 
  Repeat T - 1 time (0 ms - fastest) 
   Repeat - Channel (515,561) 
    Channel Description 
     Channel - 515 
      Camera EM Gain - 250 
      Camera Binning X - CURRENT 
      Camera Binning Y - CURRENT 
      Camera Exposure Time (s) - 0.12 
      Camera Exposure Units - 1 
      DSD Imaging Mode - 3 
      LUT - Green 
      Map Min - 621 
      Map Max - 7195 
      Trigger - Pre : X,X,X,X,X,X,X,X, :: Post : X,X,X,X,X,X,X,X, 
      AMH Filter Wheel - Current 
      AMH Intensity - Current 
      AMH Shutter - Current 
      IXBX AFMirror - Current 
      IXBX Analyzer - Current 
      IXBX Condenser - 0 
      IXBX DIC - Current 
      IXBX Fluo Filter 1 - 6 
      IXBX Fluo Filter 2 - Current 
      IXBX Fluo Filter 3 - Current 
      IXBX Fluo Shutter 1 - Current 
      IXBX Polarizer - Current 
      IXBX Port - 1 
      IXBX Trans Filter 1 - Current 
      IXBX Trans Shutter 1 - Current 
      LVPZT - DELTA_Z 0 
      ROTR Shutter 1 - Current 
      ROTR Shutter 2 - Current 
      ROTR Wheel 1 - 4 
      ROTR Wheel 2 - Current 
      ROTR Wheel 3 - Current 
      CSU Aperture - Current 
      CSU Camera Port - Current 
      CSU Lens 1 - Current 
      CSU Lens 2 - Current 
      CSU NIR Shutter - Current 
      CSU PB Mirror - Current 
      CSU PB Shutter - Current 
      CSU Port - Current 
      CSU Shutter - Open 
      Dichroic - 1 
      Emmision - 1 
      Excitation - 1 
      NDFilter - Current 
      AOTF Channel 1 Intensity - -1 
      AOTF Channel 2 Intensity - -1 
      AOTF Channel 3 Intensity - 40 
      AOTF Channel 4 Intensity - -1 
      AOTF Channel 5 Intensity - -1 
      AOTF Channel 6 Intensity - Current 
      AOTF Laser 1 Enabled - 0 
      AOTF Laser 1 External Control - Current 
      AOTF Laser 2 Enabled - 0 
      AOTF Laser 2 External Control - Current 
      AOTF Laser 3 Enabled - 1 
      AOTF Laser 3 External Control - Current 
      AOTF Laser 4 Enabled - 1 
      AOTF Laser 4 External Control - Current 
      AOTF Laser 5 Enabled - 0 
      AOTF Laser 5 External Control - Current 
      AOTF Laser 6 Enabled - 0 
      AOTF Laser 6 External Control - Current 
      AOTF MPD - 0 
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      AOTF Position - 515 
      AOTF Shutter - Open 
     Channel - 561 
      Camera EM Gain - 250 
      Camera Binning X - CURRENT 
      Camera Binning Y - CURRENT 
      Camera Exposure Time (s) - 0.055 
      Camera Exposure Units - 1 
      DSD Imaging Mode - 3 
      LUT - Red 
      Map Min - 1178 
      Map Max - 4858 
      Trigger - Pre : X,X,X,X,X,X,X,X, :: Post : X,X,X,X,X,X,X,X, 
      AMH Filter Wheel - Current 
      AMH Intensity - Current 
      AMH Shutter - Current 
      IXBX AFMirror - Current 
      IXBX Analyzer - Current 
      IXBX Condenser - 0 
      IXBX DIC - Current 
      IXBX Fluo Filter 1 - 6 
      IXBX Fluo Filter 2 - Current 
      IXBX Fluo Filter 3 - Current 
      IXBX Fluo Shutter 1 - Current 
      IXBX Polarizer - Current 
      IXBX Port - 1 
      IXBX Trans Filter 1 - Current 
      IXBX Trans Shutter 1 - Current 
      LVPZT - DELTA_Z 0 
      ROTR Shutter 1 - Current 
      ROTR Shutter 2 - Current 
      ROTR Wheel 1 - 73 
      ROTR Wheel 2 - Current 
      ROTR Wheel 3 - Current 
      CSU Aperture - Current 
      CSU Camera Port - Current 
      CSU Lens 1 - Current 
      CSU Lens 2 - Current 
      CSU NIR Shutter - Current 
      CSU PB Mirror - Current 
      CSU PB Shutter - Current 
      CSU Port - Current 
      CSU Shutter - Open 
      Dichroic - 1 
      Emmision - 1 
      Excitation - 1 
      NDFilter - Current 
      AOTF Channel 1 Intensity - -1 
      AOTF Channel 2 Intensity - -1 
      AOTF Channel 3 Intensity - -1 
      AOTF Channel 4 Intensity - 40 
      AOTF Channel 5 Intensity - -1 
      AOTF Channel 6 Intensity - Current 
      AOTF Laser 1 Enabled - 0 
      AOTF Laser 1 External Control - Current 
      AOTF Laser 2 Enabled - 0 
      AOTF Laser 2 External Control - Current 
      AOTF Laser 3 Enabled - 1 
      AOTF Laser 3 External Control - Current 
      AOTF Laser 4 Enabled - 1 
      AOTF Laser 4 External Control - Current 
      AOTF Laser 5 Enabled - 0 
      AOTF Laser 5 External Control - Current 
      AOTF Laser 6 Enabled - 0 
      AOTF Laser 6 External Control - Current 
      AOTF MPD - 0 
      AOTF Position - 561 
      AOTF Shutter - Open 
    Snap - Frame 
   End - Channel 
  End - T 
 



















[Grab Parameters End] 










Ocx_Time=20:32:52 Jun 14 2016 
Ocx_File=C:\PROGRA~2\ANDORB~1\COMMON~1\KIDAND~1.OCX 
 
[Tab Device Info End] 
[Tab Exposure] 
Window=512 : 512 
Shutter=Open 
Binning=1 x 1 
Temperature - Actual =-70 
Display Control - Fastest=Checked 
Display Control - Display Rate=1 
Gains - Pre-Amp-Gain=Gain 3 
EM Gain - Enabled=Checked 
Gains - EMGain=250 
Exposure Time - Frame Transfer=Unchecked 
Exposure Time - unit=ms 
Exposure Time - exposure value=120.0 
Exposure Time - Readout in ms=19.371 
Experiment Control - FLZ=Unchecked 
Experiment Control - Trig Mode=Free Run 
Use Frame averaging=Checked 
Frames to be averaged=2 
Fastest Grab=Unchecked 
Available memory=4095 






TTL High Open=Checked 
Shutter Open Transfer Time=60 
Shutter Close Transfer Time=80 
[Tab Temperature/Shutter End] 
[Tab Speed/Amplifer] 
Horizontal Readout=17.000 
Vertical Readout time=[1.700] 
ADC Channel=0 
Vertical Clock Voltage=Normal 
Output Amplifier=EM Port 
Baseline Clamp=Checked 
[Tab Speed/Amplifer End] 
[Tab Image Orientation] 
Flip=None 
Rotation in Degrees=None 
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[Image Info End] 
[First Frame] 
SavedTime=10/11/2017 11:19:36.609 
[First Frame End] 
 
Appendix 8: Abbreviations of brain regions included in synaptome mapping analyses. 
 
ACAd Anterior cingulate area 
aco Anterior commissure, olfactory limb  
Ald Agranular insular area, dorsal part 
alv Alveus 
Alv Agranular insular area, ventral part 
AONm Anterior olfactory nucleus, medial part 
AONpv Anterior olfactory nucleus, posteroventral part 
AUDd Dorsal auditory area  
AUDp Primary auditory area 
AUDv Ventral auditory area 
BLAa Basolateral amygdala nucleus, anterior part  
BLAp Basolateral amygdala nucleus, posterior part  
BLAv Basolateral amygdala nucleus, ventral part  
BMAp Basomedial amygdalar nucleus, posterior part   
CA1_slm CA1 field, stratum lacunosum moleculare  
CA1_so CA1 field, stratum oriens 
CA1_sp CA1 field, pyramidal layer  
CA1_sr CA1 field, stratum radiatum  
CA2_slm CA2 field, stratum lacunosum moleculare  
CA2_so CA2 field, stratum oriens 
CA2_sp CA2 field, pyramidal layer  
CA2_sr CA2 field, stratum radiatum  
CA3_s CA3 field, stratum radiatum  
CA3_slm CA3 field, stratum lacunosum moleculare  
CA3_slu CA3 field, stratum lucidum  
CA3_so CA3 field, stratum oriens 
CA3_sp CA3 field, pyramidal layer  
cc Corpus callosum  
CEA Central amydalar nucleus  
cing Cingulum bundle 
COApl1 Cortical amygdalar area, posterior part, lateral zone, layer 1 
COApl2 Cortical amygdalar area, posterior part, lateral zone, layer 2 
COApl3 Cortical amygdalar area, posterior part, lateral zone, layer 3 
CP Caudoputamen  
cpd Cerebral peduncle    
df Dorsal fornix 
DG_mo_inf Dentate gyrus, molecular layer, inferior part 
DG_mo_sup Dentate gyrus, molecular layer, superior part 
DG_po Dentate gyrus, polymorphic layer  
DG_sg_inf Dentate gyrus, granule cell layer, inferior part 
DG_sg_sup Dentate gyrus, granule cell layer, superior part 
DP Dorsal peduncular area   
ECT Ectorhinal area 
ENTI Entorhinal area, lateral part 
EP Endopiriform nucleus 
EPd Endopiriform nucleus, dorsal part   
FC Fasciola cinerea  
fi Fimbria   
Gpe Globus pallidus, external segment    
Hypothalamus Hypothalamus   
ILA Infralimbic area  
int Internal capsule    
LA Lateral amygdalar nucleus  
LH Lateral habenula  
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lot Lateral olfactory tract, body    
MEA Medial amygdalar nucleus  
MH Medial habenula  
Mop Primary motor area 
MOp Primary motor area 
Mos Secondary motor area  
MOs Secondary motor area   
opt Optic tract 
ORBl Orbital area, lateral part 
ORBm Orbital area, medial part 
ORBvl Orbital area, ventrolateral part   
PAA1 Piriform-amygdalar area, molecular layer  
PAA2 Piriform-amygdalar area, pyramidal layer  
PAA3 Piriform-amygdalar area, polymorph layer  
PERI Perirhinal area 
PIR1 Piriform area, molecular layer  
PIR2 Piriform area, pyramidal area 
PIR3 Piriform area, polymorph layer  
PL Prelimbic area   
RSPd Retrosplenial area, dorsal part 
RSPv Retrosplenial area, ventral part   
SEZ Subependymal zone  
SSp Primary somatosensory area 
SSp-bfd Primary somatosensory area, barrel field  
SSp-tr Primary somatosensory area, trunk  
st Stria terminalis 
STN Subthalamic nucleus    
Tea Temporal association areas  
Thalamus  Thalamus  
TTd1 Taemia tecta, dorsal part, layer 1 
TTd2 Taemia tecta, dorsal part, layer 2 
TTd3 Taemia tecta, dorsal part, layer 3 
TTv1 Taemia tecta, ventral part, layer 1 
TTv2 Taemia tecta, ventral part, layer 2 
TTv3 Taemia tecta, ventral part, layer 3 
 
  
Appendix 9: Example metadata from Arc baseline synaptome mapping.  
Name : GGV430_sHC_BASALMAP_28.08.17 29/08/2017 13:04:42  
 
Type : 16 bit grey/pseudo 
Intensity : 1.000000 lux 
x : 512 * 0.084034 : um 
y : 512 * 0.084000 : um 













Protocol - Sarah venus 
 6D View Compatible - No 
 Image - GGV430_sHC_BASALMAP_28.08.17 
  Camera Binning - Use Current 
  Wait Allocation - Off 
  Camera Selection - Use Current 
  Scan - Sarah montage  
  Montage Acquisition 
  Events 
   Keyboard Events - On 
    Default name - Spacebar 
   Triggered Events - Off 
  Repeat T - 1 time (0 ms - fastest) 
   Repeat - Montage 
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    Montage Positions - (33673 ( 223 by 151 )) 
    Repeat - Channel (515) 
     Channel Description 
      Channel - 515 
       Camera EM Gain - 250 
       Camera Binning X - CURRENT 
       Camera Binning Y - CURRENT 
       Camera Exposure Time (s) - 0.12 
       Camera Exposure Units - 1 
       DSD Imaging Mode - 3 
       LUT - Green 
       Map Min - 621 
       Map Max - 7195 
       Trigger - Pre : X,X,X,X,X,X,X,X, :: Post : 
X,X,X,X,X,X,X,X, 
       AMH Filter Wheel - Current 
       AMH Intensity - Current 
       AMH Shutter - Current 
       IXBX AFMirror - Current 
       IXBX Analyzer - Current 
       IXBX Condenser - 0 
       IXBX DIC - Current 
       IXBX Fluo Filter 1 - 6 
       IXBX Fluo Filter 2 - Current 
       IXBX Fluo Filter 3 - Current 
       IXBX Fluo Shutter 1 - Current 
       IXBX Polarizer - Current 
       IXBX Port - 1 
       IXBX Trans Filter 1 - Current 
       IXBX Trans Shutter 1 - Current 
       LVPZT - DELTA_Z 0 
       ROTR Shutter 1 - Current 
       ROTR Shutter 2 - Current 
       ROTR Wheel 1 - 4 
       ROTR Wheel 2 - Current 
       ROTR Wheel 3 - Current 
       CSU Aperture - Current 
       CSU Camera Port - Current 
       CSU Lens 1 - Current 
       CSU Lens 2 - Current 
       CSU NIR Shutter - Current 
       CSU PB Mirror - Current 
       CSU PB Shutter - Current 
       CSU Port - Current 
       CSU Shutter - Open 
       Dichroic - 1 
       Emmision - 1 
       Excitation - 1 
       NDFilter - Current 
       AOTF Channel 1 Intensity - -1 
       AOTF Channel 2 Intensity - -1 
       AOTF Channel 3 Intensity - 40 
       AOTF Channel 4 Intensity - -1 
       AOTF Channel 5 Intensity - -1 
       AOTF Channel 6 Intensity - Current 
       AOTF Laser 1 Enabled - 0 
       AOTF Laser 1 External Control - Current 
       AOTF Laser 2 Enabled - 0 
       AOTF Laser 2 External Control - Current 
       AOTF Laser 3 Enabled - 1 
       AOTF Laser 3 External Control - Current 
       AOTF Laser 4 Enabled - 1 
       AOTF Laser 4 External Control - Current 
       AOTF Laser 5 Enabled - 0 
       AOTF Laser 5 External Control - Current 
       AOTF Laser 6 Enabled - 0 
       AOTF Laser 6 External Control - Current 
       AOTF MPD - 0 
       AOTF Position - 515 
       AOTF Shutter - Open 
     Snap - Frame 
    End - Channel 
   End - Montage 
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  End - T 
 
[Protocol Description End] 
[XYZScan] 































[Grab Parameters End] 










Ocx_Time=20:32:52 Jun 14 2016 
Ocx_File=C:\PROGRA~2\ANDORB~1\COMMON~1\KIDAND~1.OCX 
 
[Tab Device Info End] 
[Tab Exposure] 
Window=512 : 512 
Shutter=Open 
Binning=1 x 1 
Temperature - Actual =-70 
Display Control - Fastest=Checked 
Display Control - Display Rate=10 
Gains - Pre-Amp-Gain=Gain 3 
EM Gain - Enabled=Checked 
Gains - EMGain=250 
Exposure Time - Frame Transfer=Unchecked 
Exposure Time - unit=ms 
Exposure Time - exposure value=120.0 
Exposure Time - Readout in ms=19.371 
Experiment Control - FLZ=Unchecked 
Experiment Control - Trig Mode=Free Run 
Use Frame averaging=Checked 
Frames to be averaged=2 
Fastest Grab=Unchecked 
Available memory=4095 







TTL High Open=Checked 
Shutter Open Transfer Time=60 
Shutter Close Transfer Time=80 
[Tab Temperature/Shutter End] 
[Tab Speed/Amplifer] 
Horizontal Readout=17.000 
Vertical Readout time=[1.700] 
ADC Channel=0 
Vertical Clock Voltage=Normal 
Output Amplifier=EM Port 
Baseline Clamp=Checked 
[Tab Speed/Amplifer End] 
[Tab Image Orientation] 
Flip=Vertical 
Rotation in Degrees=None 










[Image Info End] 
[First Frame] 
SavedTime=28/08/2017 16:45:17.711 
[First Frame End] 
 
Appendix 10: Stitching code used to generate montages for delineation as part of 
synaptome mapping pipeline.  
 
function stitching_Melissa 
root_dir = 'Z:\microscopy\2016-11_GGV_Behaviour_Mapping\'; 
out_dir = 'Z:\users\Sarah\PhD\Arc behaviour mapping\Stitched\'; 
Mouse_id = {'GGV430'}; 
Section_id = {'sHC9'}; 
d = dir(root_dir); 
isub = [d(:).isdir]; %# returns logical vector 
name_Folds = {d(isub).name}'; 
name_Folds(ismember(name_Folds,{'.','..'})) = []; 
down_sampling_factor = 16; 
split_char ='\';% for windows 
%% divide the folder name 
Mouse_list = cell(length(name_Folds)-2,1); 
Section_list = cell(length(name_Folds)-2,1); 
parfor i = 1:length(name_Folds) 
    temp_folder_name_split = strsplit(name_Folds{i},'_'); 
    Mouse_list(i) = temp_folder_name_split(1); 
    Section_list(i) = temp_folder_name_split(2); 
end 
%% select the mouse in the Mouse_id and Section_id. 
  
n = 1; 
for i = 1:length(Mouse_id) 
    for j = 1:length(Section_id) 
        temp_mouse_index = intersect(strmatch(Mouse_id{i},Mouse_list),strmatch(Section_id{j},Section_list)); 
        if ~isempty(temp_mouse_index) 
            select_mouse_path{n} = [root_dir,name_Folds{temp_mouse_index(end)}]; 
            n = n +1; 
        end 
    end 
end 
if size(select_mouse_path,1) == 1 




%% Then reorder the imported data based on the digitsfor i = 1:length(dir1) 
row_num = zeros(length(select_mouse_path),1); 
col_num = zeros(length(select_mouse_path),1); 
for i = 1:length(select_mouse_path) 
    disp(select_mouse_path{i}); 
    %% first get the number of rows and columns from the meta_data 
    dir_meta = dir([select_mouse_path{i},split_char,'*.txt']); 
    if ~isempty(dir_meta) 
        fid = fopen([select_mouse_path{i},split_char,dir_meta(1).name]); 
        montage_meta = textscan(fid,'%s',10 ,'headerlines', 33);%% according to the format of metadata --- CHANGE IF MONTAGE ROW 
COLUMNS ARE AT DIFFERENT LINE 
        col_num(i) = str2num(montage_meta{1}{6}); 
        row_num(i) = str2num(montage_meta{1}{8}); 
        fclose(fid); 
        %% then get the image name and re-order the name 
        dir_image{i} = dir([select_mouse_path{i},split_char,'*.tif']); 
        temp_digits = zeros(length(dir_image{i}),1); 
        parfor j = 1:length(dir_image{i}) 
            temp_file_name = strsplit(dir_image{i}(j).name(1:end-4),'_'); 
            temp_digits(j) = str2num(temp_file_name{end}(2:end)); 
        end 
        digits{i} = temp_digits; 
        [~,ind] = sort(temp_digits); 
         
        %% then load the data and save the downsample image in the memory 
         
        pctRunOnAll warning off; 
        % montage = cell(row_num,1); 
        iminfo = imfinfo([select_mouse_path{i},split_char,dir_image{i}(ind(1)).name]); 
%         pctRunOnAll warning off 
%         im = uint16(rand(iminfo.Height/4,iminfo.Width/4,length(dir1))*100); 
        im = zeros(iminfo(1).Height/down_sampling_factor,iminfo(1).Width/down_sampling_factor,length(temp_digits)); 
        tic 
        parfor j = 1:length(temp_digits) 
%                 tic 
            %     for j = 1:col_num; 
%             j 
            %     montage{i} = [montage{i},imread(dir1(ind).name)]; 
            im(:,:,j) = imresize(imread([select_mouse_path{i},split_char,dir_image{i}(ind(j)).name]),1/down_sampling_factor,'nearest'); 
            %         disp(dir1(ind(i).name)); 
            %     ind = ind +1; 
            %     end 
            %     montage{i} = imresize(montage{i} ,1/down_sampling_factor); 
%                 t = toc 
        end 
        t = toc 
        montage = cell(row_num(i),1); 
        ind = 1; 
        for m = 1:row_num(i) 
            for n = 1:col_num(i) 
                %         i,j 
                %         im(:,:,index) = normaliz(im(:,:,index)); 
                %         ind = (i-1)*col_num+j; 
                montage{m} = [montage{m},(im(:,:,ind))]; 
                ind = ind +1; 
            end 
        end 
        montage_output = cell2mat(montage); 
        temp_name = strsplit(select_mouse_path{i},split_char); 
         
        imwrite(uint16(montage_output),[out_dir,'Montage_',temp_name{end},'.tif']); 
%         temp_montage = reshape(im,[row_num*512/down_sampling_factor,col_num*512/down_sampling_factor]); 
  
        %     filename{end} = sprintf('m%.5d',digits); 
        %         filename = [strjoin(filename,'_'),'.tif']; 
        %     end 
        %     movefile(dir1(i).name,[temp_path,filename]); 
        %     end 




Appendix 11: Tables of raw numbers from basal Arc synaptome map  
 
A. Main regions  
 
 DENSITY  INTENSITY  SIZE  
 MEAN SD MEAN SD MEAN SD 
CN_L 11.68 2.74 8443 1449 0.095 0.002 
CN_R 13.52 1.81 8709 1175 0.094 0.002 
CORTEX_L 40.50 4.94 11101 1293 0.091 0.001 
CORTEX_R 43.69 2.49 11450 996 0.090 0.001 
CS_L 19.14 4.86 8734 1657 0.097 0.002 
CS_R 20.69 2.41 8757 1570 0.096 0.001 
FT_L 0.36 0.25 4564 345 0.093 0.003 
FT_R 0.43 0.18 4433 554 0.091 0.007 
HC_L 19.68 3.51 6896 602 0.090 0.001 
HC_R 20.54 2.55 7094 491 0.090 0.001 
HY_L 11.35 1.02 6809 1367 0.100 0.001 
HY_R 11.35 0.94 6761 1269 0.100 0.001 
OLF_L 23.41 5.66 9244 1661 0.095 0.003 
OLF_R 25.59 2.79 9290 1130 0.094 0.002 
 
B. Detailed regions  
  
DENSITY  INTENSITY  SIZE   
MEAN SD MEAN SD MEAN SD 
alv_L 0.32 0.12 4729 595 0.091 0.012 
alv_R 0.43 0.18 5033 639 0.097 0.007 
AUDd_L 41.74 4.63 11488 1356 0.092 0.002 
AUDd_Layer1_L 52.17 7.91 11742 1320 0.091 0.002 
AUDd_Layer1_R 56.90 2.86 11479 885 0.090 0.002 
AUDd_Layer2-3_L 50.04 5.98 12063 1203 0.095 0.002 
AUDd_Layer2-3_R 52.69 2.56 11901 867 0.094 0.001 
AUDd_Layer4_L 47.60 5.25 12557 1258 0.092 0.002 
AUDd_Layer4_R 52.85 1.32 12944 1028 0.091 0.000 
AUDd_Layer5_L 37.41 4.19 11163 1563 0.092 0.001 
AUDd_Layer5_R 40.52 1.00 11575 1021 0.091 0.001 
AUDd_Layer6a_L 37.55 4.50 10669 1673 0.089 0.001 
AUDd_Layer6a_R 41.39 1.88 11415 1087 0.089 0.001 
AUDd_Layer6b_L 20.60 8.26 8463 1508 0.091 0.002 
AUDd_Layer6b_R 25.74 5.57 9157 1070 0.089 0.001 
AUDd_R 45.79 1.80 11744 968 0.091 0.001 
AUDp_L 41.41 6.09 11022 1349 0.093 0.002 
AUDp_Layer1_L 47.04 6.74 10609 779 0.093 0.001 
AUDp_Layer1_R 54.34 4.06 10956 912 0.092 0.001 
AUDp_Layer2-3_L 45.31 6.85 11280 1096 0.096 0.002 
AUDp_Layer2-3_R 48.50 2.94 11356 675 0.095 0.002 
AUDp_Layer4_L 46.96 6.97 12292 1193 0.093 0.002 
AUDp_Layer4_R 50.79 2.84 12529 861 0.092 0.001 
AUDp_Layer5_L 36.55 5.46 10927 1555 0.093 0.002 
AUDp_Layer5_R 39.63 2.57 11303 955 0.092 0.001 
AUDp_Layer6a_L 39.25 4.35 10697 1618 0.090 0.001 
AUDp_Layer6a_R 42.17 1.52 11343 944 0.089 0.000 
AUDp_Layer6b_L 23.63 9.97 8573 1642 0.091 0.002 
AUDp_Layer6b_R 30.63 8.87 9548 1191 0.090 0.001 
AUDp_R 45.01 2.28 11425 859 0.092 0.001 
AUDv_L 38.93 6.10 10587 1433 0.093 0.002 
AUDv_Layer1_L 46.04 6.84 10402 1168 0.092 0.001 
AUDv_Layer1_R 52.98 4.77 11048 1275 0.091 0.001 
AUDv_Layer2-3_L 40.01 6.20 10501 1247 0.096 0.002 
AUDv_Layer2-3_R 45.23 2.62 11005 821 0.094 0.001 
AUDv_Layer4_L 41.60 7.05 11280 1412 0.093 0.002 
AUDv_Layer4_R 48.06 2.79 11947 994 0.092 0.001 
AUDv_Layer5_L 33.87 5.60 10448 1570 0.094 0.002 
AUDv_Layer5_R 38.17 2.29 10987 1239 0.093 0.001 
AUDv_Layer6a_L 37.79 5.10 10386 1725 0.091 0.002 
AUDv_Layer6a_R 40.66 1.97 11025 1001 0.090 0.001 
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AUDv_Layer6b_L 24.92 7.28 8740 1635 0.091 0.002 
AUDv_Layer6b_R 32.95 10.54 9825 1193 0.090 0.004 
AUDv_R 43.41 2.57 11163 1057 0.092 0.001 
BLAa_L 23.03 7.02 8891 1847 0.097 0.003 
BLAa_R 17.46 12.19 8888 1882 0.072 0.048 
BLAp_L 27.57 6.29 9715 1931 0.098 0.004 
BLAp_R 21.25 14.27 9761 1656 0.073 0.049 
BLAv_L 19.19 4.26 9043 1490 0.098 0.003 
BLAv_R 16.11 10.97 9027 1406 0.073 0.049 
BMAp_L 11.52 3.54 8390 1464 0.098 0.001 
BMAp_R 10.73 7.45 8519 1614 0.073 0.048 
CA1_slm_L 19.79 4.65 6554 462 0.090 0.002 
CA1_slm_R 20.98 3.06 6654 406 0.089 0.001 
CA1_so_L 42.55 5.27 8127 725 0.082 0.001 
CA1_so_R 43.85 3.17 8362 656 0.082 0.001 
CA1_sp_L 5.60 0.94 7262 498 0.092 0.002 
CA1_sp_R 5.70 1.84 7314 401 0.094 0.005 
CA1_sr_L 53.39 4.12 8825 580 0.084 0.001 
CA1_sr_R 55.58 2.67 8988 425 0.084 0.001 
CA2_slm_L 1.49 0.80 5539 714 0.087 0.002 
CA2_slm_R 1.70 0.28 5765 480 0.087 0.002 
CA2_so_L 3.57 1.09 5938 580 0.088 0.001 
CA2_so_R 4.49 0.84 6269 647 0.090 0.004 
CA2_sp_L 1.35 0.60 6923 849 0.158 0.014 
CA2_sp_R 1.51 0.49 6988 576 0.153 0.018 
CA2_sr_L 6.03 1.15 6336 539 0.090 0.001 
CA2_sr_R 7.57 0.53 6396 407 0.090 0.002 
CA3_slm_L 11.27 3.30 6089 752 0.091 0.003 
CA3_slm_R 12.38 1.56 6246 551 0.089 0.001 
CA3_slu_L 17.63 2.58 6701 524 0.112 0.002 
CA3_slu_R 20.00 1.58 6919 331 0.111 0.001 
CA3_so_L 18.98 2.60 6851 567 0.092 0.002 
CA3_so_R 21.03 0.67 7216 459 0.091 0.001 
CA3_sp_L 8.81 3.15 6558 519 0.115 0.002 
CA3_sp_R 10.14 2.99 6757 401 0.113 0.002 
CA3_sr_L 26.47 1.47 7515 610 0.092 0.002 
CA3_sr_R 28.84 2.60 7817 331 0.092 0.002 
cc_L 1.30 0.73 6114 994 0.092 0.003 
cc_R 1.46 0.60 6323 525 0.092 0.003 
CEA_L 9.33 2.79 8215 1626 0.100 0.003 
CEA_R 11.03 2.06 8596 1357 0.098 0.001 
cing_L 6.11 0.57 7670 863 0.089 0.001 
cing_R 4.97 1.76 7456 753 0.090 0.002 
COApl1_L 16.49 2.76 9419 1716 0.094 0.004 
COApl1_R 13.00 8.84 8840 1281 0.071 0.048 
COApl2_L 13.00 3.00 8998 1393 0.099 0.002 
COApl2_R 10.08 6.98 8173 1100 0.073 0.048 
COApl3_L 12.27 0.57 8847 1179 0.099 0.002 
COApl3_R 11.38 8.22 8534 1349 0.073 0.049 
CP_L 27.98 5.12 9674 1672 0.093 0.002 
CP_R 32.39 2.91 10309 1209 0.091 0.001 
df_L 0.11 0.12 2013 2328 0.044 0.053 
df_R 0.05 0.11 966 1931 0.025 0.049 
DG_mo_inf_L 17.03 2.51 6044 420 0.093 0.003 
DG_mo_inf_R 17.92 2.38 6136 527 0.092 0.003 
DG_mo_sup_L 18.17 2.94 6369 625 0.092 0.003 
DG_mo_sup_R 19.00 2.64 6516 543 0.091 0.002 
DG_po_L 10.16 1.80 6078 426 0.111 0.003 
DG_po_R 11.11 1.66 6276 510 0.109 0.002 
DG_sg_inf_L 1.46 0.65 4895 333 0.120 0.008 
DG_sg_inf_R 1.43 0.58 5033 445 0.119 0.009 
DG_sg_sup_L 1.46 0.57 5037 367 0.123 0.003 
DG_sg_sup_R 1.51 0.64 5088 475 0.125 0.002 
ECT_L 34.98 6.81 10118 1599 0.093 0.002 
ECT_Layer1_L 43.23 8.21 10025 1581 0.091 0.002 
ECT_Layer1_R 50.39 6.22 11001 1472 0.089 0.001 
ECT_Layer2-3_L 35.36 7.00 10464 1615 0.095 0.002 
ECT_Layer2-3_R 41.85 4.46 11125 1135 0.093 0.001 
ECT_Layer5_L 31.14 5.87 9937 1600 0.093 0.001 
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ECT_Layer5_R 35.87 1.48 10453 1184 0.092 0.001 
ECT_Layer6a_L 33.01 5.73 9585 1562 0.090 0.002 
ECT_Layer6a_R 38.01 2.06 10182 859 0.090 0.001 
ECT_Layer6b_L 23.36 6.45 8463 1363 0.091 0.002 
ECT_Layer6b_R 30.30 4.72 9691 605 0.090 0.002 
ECT_R 40.58 2.56 10791 1158 0.092 0.001 
ENTI_L 29.87 6.28 9727 1814 0.094 0.003 
ENTI_Layer1_L 38.25 7.36 9937 2042 0.091 0.004 
ENTI_Layer1_R 44.93 5.50 10424 1508 0.088 0.002 
ENTI_Layer2-3_L 28.84 5.76 9815 1685 0.096 0.003 
ENTI_Layer2-3_R 33.12 2.36 10100 1325 0.094 0.001 
ENTI_Layer5_L 28.98 5.46 9569 1641 0.095 0.002 
ENTI_Layer5_R 33.85 1.96 9963 1128 0.093 0.001 
ENTI_Layer6a_L 24.46 9.26 8492 1785 0.092 0.002 
ENTI_Layer6a_R 28.33 0.53 9105 908 0.089 0.002 
ENTI_Layer6b_L 16.63 5.00 8050 1325 0.096 0.006 
ENTI_Layer6b_R 18.06 6.16 8408 1068 0.092 0.003 
ENTI_R 33.85 2.19 10043 1328 0.093 0.001 
EP_L 15.19 4.81 8029 1590 0.093 0.002 
EP_R 17.36 1.84 8230 1185 0.091 0.001 
FC_L 0.97 0.44 5595 539 0.096 0.006 
FC_R 0.76 0.28 5677 413 0.090 0.007 
fi_L 0.11 0.12 1873 2174 0.048 0.055 
fi_R 0.16 0.11 2812 1904 0.067 0.045 
GPe_L 0.54 0.37 4929 3331 0.078 0.052 
GPe_R 0.87 0.47 6593 1351 0.099 0.006 
Hypothalamus_L 2.76 1.02 6809 1367 0.100 0.001 
Hypothalamus_R 2.87 0.94 6761 1269 0.100 0.001 
int_L 0.27 0.27 3209 2185 0.070 0.047 
int_R 0.22 0.18 3316 2231 0.074 0.049 
LA_L 22.17 6.11 8761 1781 0.096 0.002 
LA_R 24.44 3.73 8957 1303 0.095 0.001 
MEA_L 7.08 2.29 7887 1350 0.099 0.002 
MEA_R 7.52 2.04 7732 1324 0.098 0.003 
MOp_L 39.85 3.95 10753 1085 0.090 0.000 
MOp_Layer1_L 51.79 6.28 11322 1200 0.091 0.001 
MOp_Layer1_R 55.20 4.81 11831 1152 0.090 0.001 
MOp_Layer2-3_L 44.14 5.23 11250 1010 0.092 0.001 
MOp_Layer2-3_R 45.77 2.62 11600 898 0.092 0.001 
MOp_Layer5_L 36.82 3.31 10516 1124 0.090 0.000 
MOp_Layer5_R 38.55 1.75 10924 978 0.090 0.001 
MOp_Layer6a_L 34.03 2.42 10130 1164 0.088 0.001 
MOp_Layer6a_R 34.49 2.15 10442 1004 0.087 0.001 
MOp_Layer6b_L 22.82 2.28 8695 962 0.087 0.000 
MOp_Layer6b_R 23.63 2.66 8937 921 0.087 0.002 
MOp_R 40.82 1.99 11099 1017 0.090 0.001 
MOs_L 39.09 2.71 11433 1270 0.091 0.001 
MOs_Layer1_L 55.39 7.46 12249 1785 0.092 0.002 
MOs_Layer1_R 58.26 6.57 12838 1611 0.091 0.001 
MOs_Layer2-3_L 44.25 4.01 11944 1273 0.092 0.001 
MOs_Layer2-3_R 44.63 2.71 12204 1088 0.092 0.000 
MOs_Layer5_L 33.47 2.36 11031 1220 0.092 0.001 
MOs_Layer5_R 33.66 1.53 11399 970 0.092 0.001 
MOs_Layer6a_L 31.98 2.52 10137 1228 0.087 0.000 
MOs_Layer6a_R 31.06 1.31 10379 993 0.087 0.001 
MOs_Layer6b_L 23.49 1.17 8752 918 0.087 0.001 
MOs_Layer6b_R 23.11 2.14 8813 760 0.086 0.001 
MOs_R 38.93 1.45 11727 1069 0.091 0.000 
opt_L 0.05 0.11 875 1750 0.025 0.049 
opt_R 0.05 0.11 884 1768 0.023 0.046 
PAA1_L 20.71 6.89 9530 1546 0.094 0.003 
PAA1_R 15.57 10.61 8998 1172 0.071 0.047 
PAA2_L 16.17 5.61 9067 1486 0.098 0.002 
PAA2_R 10.16 7.62 8463 846 0.074 0.050 
PAA3_L 17.38 5.28 9100 1495 0.098 0.002 
PAA3_R 15.95 11.05 8842 1066 0.072 0.048 
PERI_L 31.09 7.48 9618 1727 0.094 0.002 
PERI_Layer1_L 38.95 7.40 9571 1734 0.091 0.003 
PERI_Layer1_R 47.04 4.93 10294 1651 0.088 0.001 
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PERI_Layer2-3_L 29.79 7.29 9802 1674 0.096 0.002 
PERI_Layer2-3_R 35.74 2.47 10310 1324 0.094 0.001 
PERI_Layer5_L 31.14 6.09 9759 1772 0.094 0.002 
PERI_Layer5_R 35.63 2.36 10153 1155 0.092 0.001 
PERI_Layer6a_L 27.95 7.98 8722 1608 0.091 0.002 
PERI_Layer6a_R 32.44 1.74 9289 726 0.089 0.000 
PERI_Layer6b_L 17.92 9.33 8226 1313 0.093 0.005 
PERI_Layer6b_R 19.44 4.87 8675 601 0.089 0.000 
PERI_R 36.28 1.72 10065 1252 0.092 0.001 
PIR1_L 30.38 7.18 9691 1932 0.093 0.003 
PIR1_R 35.90 2.84 10134 930 0.092 0.002 
PIR2_L 15.46 4.42 8645 1638 0.098 0.002 
PIR2_R 18.30 1.98 9019 710 0.096 0.001 
PIR3_L 26.19 6.41 9277 1655 0.095 0.003 
PIR3_R 29.30 2.91 9517 1019 0.093 0.001 
RSPd_L 35.36 2.50 11194 1215 0.091 0.001 
RSPd_Layer1_L 50.01 6.52 11686 1614 0.091 0.001 
RSPd_Layer1_R 50.25 4.67 11633 1591 0.092 0.002 
RSPd_Layer2-3_L 39.74 4.21 11534 1230 0.092 0.001 
RSPd_Layer2-3_R 39.63 2.74 11402 1001 0.092 0.001 
RSPd_Layer5_L 32.12 2.59 11144 1165 0.093 0.002 
RSPd_Layer5_R 32.20 1.68 11101 799 0.092 0.001 
RSPd_Layer6a_L 29.14 2.20 10352 1150 0.088 0.002 
RSPd_Layer6a_R 29.60 1.78 10496 924 0.088 0.002 
RSpd_Layer6b_L 21.79 3.93 9061 1114 0.085 0.002 
RSPd_Layer6b_R 26.76 4.73 9698 146 0.087 0.003 
RSPd_R 33.95 5.64 10810 1594 0.091 0.001 
RSPv_L 29.84 1.45 10039 1017 0.091 0.001 
RSPv_Layer1_L 35.20 2.78 10161 924 0.091 0.001 
RSPv_Layer1_R 30.82 8.52 9858 1150 0.092 0.002 
RSPv_Layer2-3_L 20.44 2.98 9888 950 0.093 0.001 
RSPv_Layer2-3_R 22.57 3.70 9725 522 0.093 0.001 
RSPv_Layer5_L 31.01 2.40 10390 798 0.089 0.000 
RSPv_Layer5_R 28.76 4.14 9967 1243 0.089 0.001 
RSPv_Layer6a_L 26.03 0.59 9935 936 0.088 0.001 
RSPv_Layer6a_R 24.36 4.21 9677 1448 0.087 0.001 
RSPv_Layer6b_L 23.06 4.86 8968 943 0.086 0.002 
RSPv_Layer6b_R 24.74 2.37 9092 920 0.085 0.002 
RSPv_R 28.17 1.15 10015 764 0.090 0.001 
SSp_L 44.60 4.05 11756 1203 0.090 0.001 
SSp_Layer1_L 53.55 6.16 11929 864 0.090 0.001 
SSp_Layer1_R 56.93 2.47 11902 559 0.089 0.001 
SSp_Layer2-3_L 53.42 5.52 12480 976 0.092 0.001 
SSp_Layer2-3_R 54.88 1.45 12333 604 0.092 0.001 
SSp_Layer4_L 50.55 4.25 12707 1200 0.088 0.001 
SSp_Layer4_R 53.88 2.84 12916 768 0.088 0.001 
SSp_Layer5_L 39.95 3.51 11373 1328 0.090 0.001 
SSp_Layer5_R 42.23 2.14 11764 898 0.089 0.001 
SSp_Layer6a_L 38.39 4.30 10960 1510 0.088 0.001 
SSp_Layer6a_R 41.25 1.44 11373 920 0.087 0.001 
SSp_Layer6b_L 18.41 6.40 8433 1300 0.090 0.001 
SSp_Layer6b_R 20.71 3.38 8921 851 0.089 0.001 
SSp_R 47.44 1.71 11973 744 0.089 0.001 
st_L 0.16 0.11 3110 2101 0.069 0.046 
st_R 0.22 0.18 3361 2277 0.070 0.046 
STN_L 1.62 1.42 6354 1385 0.068 0.046 
STN_R 2.32 1.06 6704 1369 0.093 0.004 
TEa_L 38.44 6.03 10586 1606 0.093 0.002 
TEa_Layer1_L 45.96 8.20 10440 1621 0.091 0.002 
TEa_Layer1_R 52.52 7.05 11171 1772 0.090 0.000 
TEa_Layer2-3_L 40.12 7.13 10669 1517 0.095 0.002 
TEa_Layer2-3_R 45.04 3.97 11210 1391 0.094 0.001 
TEa_Layer4_L 39.90 5.16 11400 1555 0.094 0.002 
TEa_Layer4_R 46.25 3.61 11923 1390 0.092 0.000 
TEa_Layer5_L 33.12 5.54 10197 1533 0.093 0.002 
TEa_Layer5_R 36.82 2.32 10738 1286 0.093 0.001 
TEa_Layer6a_L 38.12 5.45 10370 1671 0.091 0.002 
TEa_Layer6a_R 40.79 1.60 10835 1091 0.089 0.001 
TEa_Layer6b_L 23.65 6.58 9055 1862 0.091 0.002 
 197 
TEa_Layer6b_R 31.63 7.29 9874 1251 0.090 0.002 
TEa_R 42.87 2.69 11132 1382 0.091 0.000 
 
Appendix 12: Preliminary results on nature of nuclear accumulation of Arc 4h following 
open field exploration and rotarod training.  
 
Appendix.figure 8 –  A. Percentage of dentate gyrus area occupied by Arc-positive nuclei. B. 
Average fluorescence intensity of detected Arc positive-nuclei. N=5-6. Data points = 
individual mice, bars = mean, error bars = SEM. C. Representative images of Arc signal in 
dentate gyrus in control and open field exploration exposed animals.  
 
Appendix 13: Example metadata file from Arc ketamine synaptome mapping.  
Name : KET_GGV282_HC_24-09-14 28/11/2014 11:19:55  
 
Type : 16 bit grey/pseudo 
Intensity : 1.000000 lux 
x : 512 * 0.084034 : um 
y : 512 * 0.084000 : um 












Protocol - Montage 1channel no Z 
 Image - KET_GGV282_HC_24-09-14 
  Camera Binning - Use Current 
  Wait Allocation - Off 
  Camera Selection - Use Current 
  Scan - Montage 
  Montage Acquisition 
  Events 
   Keyboard Events - On 
    Default name - Spacebar 
  Move Channel - 488 
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   Camera EM Gain - 250 
   Camera Binning X - CURRENT 
   Camera Binning Y - CURRENT 
   Camera Exposure Time (s) - 0.05 
   Camera Exposure Units - 1 
   LUT - Green 
   Map Min - 143 
   Map Max - 527 
   CoolLED Intensity 1 - Current 
   CoolLED Intensity 2 - Current 
   CoolLED Intensity 3 - Current 
   CoolLED Intensity 4 - Current 
   CoolLED Pulsed Mode - Current 
   CoolLED Shutter - Closed 
   CoolLED Wavelength - Current 
   IX81_BX61 EPI Filter - 6 
   IX81_BX61 BF Shutter - Current 
   IX81_BX61 EPI Shutter - Current 
   IX81_BX61 ND Filter - 5 
   IX81_BX61 Filter 1 - 0 
   IX81_BX61 Filter 2 - 0 
   IX81_BX61 Filter 3 - 0 
   IX81_BX61 Port - 1 
   LVPZT - DELTA_Z 0 
   CSU Aperture - Current 
   CSU Camera Port - Current 
   CSU Lens 1 - Current 
   CSU Lens 2 - Current 
   CSU NIR Shutter - Current 
   CSU PB Mirror - Current 
   CSU PB Shutter - Current 
   CSU Port - Current 
   CSU Shutter - Open 
   Dichroic - 1 
   Emmision - 525 
   Excitation - 1 
   NDFilter - Current 
   AOTF Channel 1 Intensity - 0 
   AOTF Channel 2 Intensity - 70 
   AOTF Channel 3 Intensity - 0 
   AOTF Channel 4 Intensity - 0 
   AOTF Channel 5 Intensity - Current 
   AOTF Channel 6 Intensity - Current 
   AOTF Laser 1 Enabled - 1 
   AOTF Laser 1 External Control - Current 
   AOTF Laser 2 Enabled - 1 
   AOTF Laser 2 External Control - Current 
   AOTF Laser 3 Enabled - 1 
   AOTF Laser 3 External Control - Current 
   AOTF Laser 4 Enabled - 1 
   AOTF Laser 4 External Control - Current 
   AOTF Laser 5 Enabled - 0 
   AOTF Laser 5 External Control - Current 
   AOTF Laser 6 Enabled - 0 
   AOTF Laser 6 External Control - Current 
   AOTF MPD - 1 
   AOTF Position - 488 
   AOTF Shutter - Open 
  Repeat T - 1 time (0 ms - fastest) 
   Repeat - Montage 
    Montage Positions - (16440 ( 120 by 137 )) 
    Snap - Frame 
   End - Montage 
  End - T 
 












Montage=Edge Overlap 0  
Plates= 
MontageOffsets=16440 -1498.5,-3827.544,0 -1455.47478991596,-3827.544,0 -1412.44957983193,-3827.544,0 -
1369.4243697479,-3827.544,  
… 


















[Grab Parameters End] 










Ocx_Time=13:17:04 Jul 26 2013 
Ocx_File=C:\PROGRA~2\ANDORB~1\COMMON~1\KIDAND~2.OCX 
 
[Tab Device Info End] 
[Tab Exposure] 
Window=512 : 512 
Shutter=Open 
Binning=1 x 1 
Temperature - Actual =-70 
Display Control - Fastest=Checked 
Display Control - Display Rate=3 
Gains - Pre-Amp-Gain=Gain 3 
EM Gain - Enabled=Checked 
Gains - EMGain=250 
Exposure Time - Frame Transfer=Unchecked 
Exposure Time - unit=ms 
Exposure Time - exposure value=50.0 
Exposure Time - Readout in ms=19.379 
Experiment Control - FLZ=Unchecked 
Experiment Control - Trig Mode=Free Run 
Use Frame averaging=Checked 
Frames to be averaged=4 
Fastest Grab=Unchecked 
Available memory=4095 






TTL High Open=Checked 
Shutter Open Transfer Time=60 
Shutter Close Transfer Time=80 




Vertical Readout time=[1.700] 
ADC Channel=0 
Vertical Clock Voltage=Normal 
Output Amplifier=EM Port 
Baseline Clamp=Checked 
[Tab Speed/Amplifer End] 
[Tab Image Orientation] 
Flip=None 
Rotation in Degrees=None 










[Image Info End] 
[First Frame] 
SavedTime=24/09/2014 16:24:00.683 
[First Frame End] 
 
Appendix 14: Example metadata file from PSD95 ketamine synaptome mapping.  
Name : 2014-12-11_GKD182_KET_HC 12/12/2014 09:59:03  
 
Type : 16 bit grey/pseudo 
Intensity : 1.000000 lux 
x : 512 * 0.084034 : um 
y : 512 * 0.084000 : um 












Protocol - Montage 1channel no Z 
 Image - 2014-12-11_GKD182_KET_HC 
  Camera Binning - Use Current 
  Wait Allocation - Off 
  Camera Selection - Use Current 
  Scan - Montage 
  Montage Acquisition 
  Events 
   Keyboard Events - On 
    Default name - Spacebar 
  Move Channel - 488 
   Camera EM Gain - 250 
   Camera Binning X - CURRENT 
   Camera Binning Y - CURRENT 
   Camera Exposure Time (s) - 0.05 
   Camera Exposure Units - 1 
   LUT - Green 
   Map Min - 143 
   Map Max - 527 
   CoolLED Intensity 1 - Current 
   CoolLED Intensity 2 - Current 
   CoolLED Intensity 3 - Current 
   CoolLED Intensity 4 - Current 
   CoolLED Pulsed Mode - Current 
   CoolLED Shutter - Closed 
   CoolLED Wavelength - Current 
   IX81_BX61 EPI Filter - 6 
   IX81_BX61 BF Shutter - Current 
   IX81_BX61 EPI Shutter - Current 
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   IX81_BX61 ND Filter - 5 
   IX81_BX61 Filter 1 - 0 
   IX81_BX61 Filter 2 - 0 
   IX81_BX61 Filter 3 - 0 
   IX81_BX61 Port - 1 
   LVPZT - DELTA_Z 0 
   CSU Aperture - Current 
   CSU Camera Port - Current 
   CSU Lens 1 - Current 
   CSU Lens 2 - Current 
   CSU NIR Shutter - Current 
   CSU PB Mirror - Current 
   CSU PB Shutter - Current 
   CSU Port - Current 
   CSU Shutter - Open 
   Dichroic - 1 
   Emmision - 525 
   Excitation - 1 
   NDFilter - Current 
   AOTF Channel 1 Intensity - 0 
   AOTF Channel 2 Intensity - 60 
   AOTF Channel 3 Intensity - 0 
   AOTF Channel 4 Intensity - 0 
   AOTF Channel 5 Intensity - Current 
   AOTF Channel 6 Intensity - Current 
   AOTF Laser 1 Enabled - 1 
   AOTF Laser 1 External Control - Current 
   AOTF Laser 2 Enabled - 1 
   AOTF Laser 2 External Control - Current 
   AOTF Laser 3 Enabled - 1 
   AOTF Laser 3 External Control - Current 
   AOTF Laser 4 Enabled - 1 
   AOTF Laser 4 External Control - Current 
   AOTF Laser 5 Enabled - 0 
   AOTF Laser 5 External Control - Current 
   AOTF Laser 6 Enabled - 0 
   AOTF Laser 6 External Control - Current 
   AOTF MPD - 1 
   AOTF Position - 488 
   AOTF Shutter - Open 
  Repeat T - 1 time (0 ms - fastest) 
   Repeat - Montage 
    Montage Positions - (31439 ( 211 by 149 )) 
    Snap - Frame 
   End - Montage 
  End - T 
 











Montage=Edge Overlap 0  
Plates= 
MontageOffsets=31439 -4969.64705882353,-3088.092,17.268857642086 -4926.62184873949,-3088.092, 
… 
 



















[Grab Parameters End] 










Ocx_Time=13:17:04 Jul 26 2013 
Ocx_File=C:\PROGRA~2\ANDORB~1\COMMON~1\KIDAND~2.OCX 
 
[Tab Device Info End] 
[Tab Exposure] 
Window=512 : 512 
Shutter=Open 
Binning=1 x 1 
Temperature - Actual =-70 
Display Control - Fastest=Checked 
Display Control - Display Rate=3 
Gains - Pre-Amp-Gain=Gain 3 
EM Gain - Enabled=Checked 
Gains - EMGain=250 
Exposure Time - Frame Transfer=Unchecked 
Exposure Time - unit=ms 
Exposure Time - exposure value=50.0 
Exposure Time - Readout in ms=19.371 
Experiment Control - FLZ=Unchecked 
Experiment Control - Trig Mode=Free Run 
Use Frame averaging=Checked 
Frames to be averaged=2 
Fastest Grab=Unchecked 
Available memory=4095 






TTL High Open=Checked 
Shutter Open Transfer Time=60 
Shutter Close Transfer Time=80 
[Tab Temperature/Shutter End] 
[Tab Speed/Amplifer] 
Horizontal Readout=17.000 
Vertical Readout time=[1.700] 
ADC Channel=0 
Vertical Clock Voltage=Normal 
Output Amplifier=EM Port 
Baseline Clamp=Checked 
[Tab Speed/Amplifer End] 
[Tab Image Orientation] 
Flip=None 
Rotation in Degrees=None 











[Image Info End] 
[First Frame] 
SavedTime=11/12/2014 11:23:48.398 
[First Frame End] 
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Appendix 15: Tables of raw numbers from ketamine Arc synaptome maps 
 
 1H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
BREGMA  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
2.10 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
ACAd 30.90 14.03 4632 692 0.251 0.014 27.79 9.65 4172 129 0.249 0.013 41.41 2.62 4803 280 0.263 0.004 
Ald 39.10 4.84 5412 685 0.250 0.009 41.68 0.50 4933 465 0.248 0.006 42.62 0.72 5652 614 0.254 0.003 
Alv 40.55 2.41 5594 791 0.254 0.010 42.12 0.71 5110 548 0.249 0.007 43.17 1.14 5728 520 0.256 0.003 
ILA 21.41 13.80 4208 205 0.251 0.023 14.62 7.71 4117 115 0.238 0.006 29.87 13.30 4191 130 0.263 0.010 
MOp 38.67 3.70 5670 943 0.246 0.007 40.93 1.15 4908 461 0.248 0.009 42.14 1.07 5951 728 0.254 0.004 
MOs 34.06 11.47 5075 760 0.247 0.009 37.92 4.99 4550 418 0.250 0.011 41.23 1.23 5113 403 0.258 0.003 
ORBl 40.46 2.23 5408 670 0.253 0.009 40.33 2.49 4875 377 0.248 0.008 42.44 0.45 5593 417 0.256 0.003 
ORBm 23.28 13.80 4270 386 0.255 0.018 15.06 7.69 4084 90 0.240 0.007 30.95 11.92 4156 139 0.268 0.012 
ORBvl 35.85 6.68 4872 483 0.250 0.011 32.74 8.22 4430 235 0.243 0.005 40.44 1.75 4990 311 0.257 0.008 
PL 30.43 14.32 4558 654 0.252 0.015 24.14 8.60 4133 128 0.248 0.011 38.68 6.04 4533 351 0.266 0.007 
DP 32.71 13.12 4189 151 0.268 0.021 20.61 11.84 4070 144 0.252 0.010 37.49 11.79 4249 204 0.277 0.003 
PIR1 52.08 2.16 5335 774 0.278 0.010 52.12 1.31 4929 731 0.275 0.005 52.04 1.03 5083 502 0.282 0.007 
PIR2 36.70 5.53 4778 484 0.284 0.010 35.44 10.26 4443 533 0.278 0.003 39.02 4.93 4656 457 0.285 0.005 
PIR3 30.38 13.21 4514 532 0.268 0.016 19.87 16.10 4184 298 0.252 0.012 34.60 6.13 4284 288 0.275 0.002 
TTd1 33.04 14.99 4119 115 0.262 0.028 22.84 12.42 4046 152 0.252 0.018 36.97 20.77 4240 293 0.268 0.021 
TTd2 22.71 9.40 4262 172 0.270 0.019 12.29 8.38 4169 94 0.253 0.009 27.24 11.85 4271 86 0.278 0.007 
TTd3 20.11 8.37 4140 102 0.260 0.018 13.17 10.02 4117 132 0.244 0.011 25.21 13.52 4141 112 0.269 0.009 
TTv1 44.49 9.80 4612 436 0.276 0.015 33.20 11.78 4235 348 0.263 0.004 45.55 7.21 4633 758 0.287 0.008 
TTv2 25.03 9.15 4307 234 0.277 0.014 10.66 7.30 4172 137 0.255 0.009 26.19 14.20 4412 271 0.283 0.009 
TTv3 27.15 11.34 4139 179 0.265 0.013 13.53 9.49 4088 199 0.244 0.012 25.59 17.02 4204 390 0.266 0.014 
AONm 14.48 8.27 4150 128 0.252 0.017 7.69 6.25 4096 77 0.236 0.005 18.49 10.83 4101 124 0.263 0.005 
AONpv 34.79 6.88 4581 492 0.275 0.012 25.44 14.93 4254 320 0.258 0.006 33.03 10.00 4398 440 0.277 0.006 
EPd 12.02 6.30 4163 149 0.245 0.014 6.46 6.17 4100 196 0.228 0.008 12.38 7.23 4091 44 0.247 0.007 
aco 0.78 0.81 3111 1752 0.148 0.097 0.70 0.97 2038 2355 0.106 0.123 0.81 0.69 3365 995 0.164 0.069 
lot 3.78 5.38 3077 1061 0.189 0.080 0.78 1.03 1928 2227 0.117 0.135 0.73 0.63 2868 1913 0.180 0.120 
SEZ 2.36 1.56 4006 95 0.233 0.014 1.23 1.43 2731 1602 0.137 0.094 2.68 2.08 4081 168 0.240 0.028 
 
 6H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
BREGMA DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
2.10 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
ACAd 32.62 14.90 4584 335 0.253 0.012 21.97 9.25 4262 216 0.240 0.014 35.79 7.09 5213 1410 0.254 0.008 
Ald 31.57 10.60 4928 1409 0.246 0.006 39.91 2.02 4905 658 0.246 0.009 41.33 0.76 6374 1409 0.244 0.008 
Alv 37.85 6.37 5115 1593 0.251 0.006 41.70 1.81 5064 514 0.250 0.010 40.98 1.23 6528 1635 0.248 0.010 
ILA 26.06 20.28 4357 322 0.252 0.023 10.03 3.76 4091 59 0.230 0.009 32.01 13.46 5053 1040 0.250 0.007 
MOp 34.58 9.50 5286 1270 0.246 0.003 37.53 3.77 5205 815 0.241 0.009 40.44 0.97 6307 1662 0.245 0.009 
MOs 26.44 19.45 4774 860 0.241 0.013 32.20 10.09 4554 270 0.242 0.012 37.74 3.31 5597 1820 0.251 0.013 
ORBl 37.02 4.63 4900 1235 0.252 0.004 40.78 2.19 4735 199 0.251 0.010 41.29 1.58 6400 1741 0.246 0.010 
ORBm 26.65 19.91 4293 309 0.256 0.024 9.95 2.92 4073 57 0.232 0.007 31.90 14.07 4878 1018 0.254 0.005 
ORBvl 32.69 14.40 5058 860 0.247 0.011 34.90 5.20 4551 376 0.244 0.009 39.58 2.57 5893 1702 0.248 0.008 
PL 28.68 19.05 4548 609 0.252 0.019 23.40 6.61 4141 89 0.248 0.012 31.82 9.52 5046 1373 0.251 0.007 
DP 28.42 21.68 4474 530 0.257 0.024 17.45 5.21 4019 63 0.248 0.014 35.71 10.22 4976 1253 0.261 0.012 
PIR1 46.42 9.98 5517 1678 0.278 0.007 52.95 1.18 4809 191 0.276 0.004 47.83 7.57 6169 1909 0.269 0.020 
PIR2 32.39 15.57 5099 1180 0.284 0.008 36.64 4.42 4363 213 0.280 0.005 38.85 5.21 5783 1544 0.272 0.022 
PIR3 27.95 21.18 4663 846 0.265 0.019 23.46 7.42 4165 88 0.259 0.013 33.33 10.70 5342 1446 0.260 0.013 
TTd1 32.94 27.80 4611 859 0.247 0.047 19.05 8.08 4036 62 0.248 0.021 31.79 17.67 5080 1347 0.253 0.018 
TTd2 26.60 22.54 4460 580 0.269 0.017 11.23 5.85 4152 78 0.249 0.021 28.71 15.29 5039 839 0.263 0.014 
TTd3 27.61 22.81 4301 331 0.264 0.022 9.62 3.85 4096 92 0.239 0.015 28.11 16.14 4972 936 0.253 0.011 
TTv1 35.68 28.11 5086 1160 0.264 0.023 N/A N/A N/A N/A N/A N/A 37.97 14.54 5653 2125 0.265 0.019 
TTv2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 28.98 17.95 5697 1187 0.268 0.021 
TTv3 29.23 22.39 4511 782 0.265 0.025 16.42 11.61 4061 63 0.252 0.018 28.93 18.34 5397 1584 0.254 0.016 
AONm 29.23 24.68 4250 341 0.266 0.026 5.98 4.02 4100 43 0.232 0.023 25.87 20.23 5058 866 0.251 0.010 
AONpv 31.79 23.04 4796 803 0.265 0.021 28.62 11.79 4274 153 0.263 0.015 31.49 17.34 5636 1561 0.260 0.014 
EPd 17.92 17.68 4118 218 0.245 0.028 7.28 3.06 4168 96 0.228 0.017 25.11 18.06 4941 913 0.250 0.007 
aco 2.42 3.07 3174 1784 0.165 0.104 0.50 0.17 3809 68 0.164 0.009 19.67 21.72 4492 856 0.235 0.034 
lot 8.11 14.93 3078 1723 0.196 0.111 1.50 1.56 3193 1201 0.194 0.088 22.49 24.20 4198 1737 0.228 0.075 




 24H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
 DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
Bregma 
2.10 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
ACAd 29.91 12.96 4632 622 0.254 0.021 28.27 12.20 4553 599 0.246 0.014 36.20 7.45 4908 659 0.247 0.013 
Ald 33.44 10.92 5374 1396 0.244 0.014 36.59 10.96 5117 998 0.246 0.010 40.79 1.21 5560 576 0.246 0.012 
Alv 38.52 5.21 5493 1345 0.252 0.017 37.56 9.89 5339 1153 0.249 0.010 41.07 1.20 5889 673 0.248 0.012 
ILA 21.41 15.73 4392 238 0.251 0.029 16.67 15.43 4258 326 0.236 0.018 25.42 10.05 4481 418 0.240 0.016 
MOp 37.17 7.26 5501 1289 0.248 0.017 38.99 4.52 5529 1202 0.244 0.010 39.64 1.44 5782 841 0.242 0.012 
MOs 36.72 6.61 5107 869 0.250 0.019 35.07 8.52 4804 1037 0.248 0.010 37.26 4.62 5442 936 0.241 0.010 
ORBl 40.29 3.23 5426 973 0.253 0.019 35.14 11.55 5180 1010 0.244 0.013 40.18 1.72 5657 443 0.246 0.012 
ORBm 22.41 16.55 4385 333 0.252 0.029 10.00 4.59 4100 170 0.231 0.009 28.32 10.41 4616 713 0.244 0.016 
ORBvl 37.10 4.31 5156 816 0.252 0.020 30.11 12.60 4808 837 0.239 0.013 38.19 2.61 5394 897 0.241 0.009 
PL 30.06 12.74 4587 568 0.255 0.023 26.25 13.15 4459 547 0.244 0.011 35.38 9.56 4827 671 0.248 0.015 
DP 30.79 14.10 4322 323 0.267 0.017 22.18 14.81 4293 561 0.251 0.013 34.60 8.93 4546 574 0.255 0.014 
PIR1 47.81 4.29 5069 1149 0.277 0.012 42.67 19.45 4961 920 0.272 0.013 51.06 1.51 5730 925 0.273 0.009 
PIR2 32.51 7.57 4997 1127 0.281 0.016 31.80 16.74 4612 660 0.277 0.014 40.87 3.12 5065 682 0.280 0.010 
PIR3 31.14 10.52 4560 598 0.269 0.013 23.10 16.43 4435 647 0.258 0.016 35.53 8.79 4757 564 0.267 0.013 
TTd1 31.71 18.30 4281 295 0.261 0.022 23.71 16.70 4232 467 0.255 0.019 37.09 12.83 4674 610 0.256 0.016 
TTd2 26.07 13.76 4585 258 0.270 0.022 18.25 15.60 4258 291 0.259 0.013 N/A N/A N/A N/A N/A N/A 
TTd3 23.59 15.46 4390 272 0.262 0.023 17.21 16.60 4209 311 0.247 0.016 28.87 15.46 4531 397 0.252 0.021 
TTv1 37.52 20.70 4732 786 0.270 0.016 30.53 24.14 4325 697 0.267 0.028 N/A N/A N/A N/A N/A N/A 
TTv2 25.97 15.10 4695 747 0.274 0.022 16.51 19.09 4128 235 0.267 0.012 N/A N/A N/A N/A N/A N/A 
TTv3 25.74 19.40 4510 206 0.267 0.022 17.08 21.77 4066 320 0.247 0.033 32.93 13.86 4658 591 0.260 0.014 
AONm 16.30 17.79 4565 352 0.254 0.032 14.79 18.33 4141 236 0.242 0.020 26.25 17.15 4312 219 0.252 0.026 
AONpv 31.07 11.93 5053 1068 0.275 0.020 25.93 17.07 4352 396 0.264 0.015 38.34 7.67 4910 620 0.267 0.015 
EPd 16.94 15.14 4415 243 0.248 0.026 12.07 14.92 4154 258 0.232 0.019 20.69 12.52 4377 270 0.245 0.020 
aco 1.84 2.32 3100 2073 0.167 0.114 1.61 3.04 2018 2053 0.107 0.110 1.78 1.56 4038 269 0.203 0.037 
lot 6.58 12.30 2920 1948 0.183 0.126 0.76 0.75 2290 1635 0.137 0.100 6.19 11.14 3886 143 0.244 0.023 
SEZ 10.03 16.83 4366 211 0.241 0.041 2.45 4.22 3329 1046 0.156 0.095 6.40 9.52 4177 164 0.227 0.026 
 
 
 1H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
 DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
BREGMA -1.70 
MEA
N SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
alv 1.43 1.76 2912 1908 0.164 0.112 3.22 3.73 3492 403 0.214 0.072 1.54 0.57 3989 211 0.219 0.045 
AUDd 40.26 1.14 6348 609 0.254 0.007 41.33 0.67 6615 655 0.248 0.003 40.95 1.32 6570 96 0.252 0.013 
AUDp 40.22 0.87 6247 548 0.255 0.007 41.09 0.57 6430 686 0.250 0.004 40.73 0.90 6528 182 0.254 0.011 
AUDv 40.74 0.95 6120 348 0.258 0.006 41.23 0.33 6263 529 0.253 0.005 41.47 0.99 6376 433 0.258 0.009 
BLAa 38.78 4.17 4871 561 0.278 0.006 43.27 2.14 5292 959 0.272 0.006 41.01 2.79 5260 650 0.273 0.004 
BLAp 38.42 2.38 5102 736 0.273 0.007 41.53 2.86 5207 22 0.269 0.006 40.77 1.84 5464 447 0.270 0.005 
BLAv 35.24 6.59 4560 707 0.274 0.004 44.89 2.69 4833 83 0.276 0.009 41.34 4.54 4770 347 0.274 0.005 
BMAp 36.65 7.10 4831 845 0.282 0.010 46.97 1.98 4789 742 0.282 0.008 42.87 2.38 4934 596 0.281 0.004 
CA1O 36.79 8.60 4729 670 0.229 0.010 48.31 1.09 4961 953 0.239 0.002 42.73 5.04 4668 341 0.240 0.013 
CA1R 38.78 4.54 4859 704 0.221 0.006 46.57 1.86 5360 1149 0.224 0.002 46.09 4.24 5371 149 0.227 0.010 
CA1SLM 33.47 14.77 4124 321 0.256 0.022 57.13 1.12 4367 1004 0.269 0.005 56.40 5.14 4506 253 0.275 0.012 
CA1sp 23.97 10.42 5104 555 0.286 0.019 38.47 2.13 4658 775 0.292 0.003 33.74 5.81 4925 319 0.289 0.015 
CA2O 27.82 13.98 4399 387 0.277 0.005 47.66 5.46 4156 790 0.285 0.001 36.42 12.28 4268 219 0.278 0.011 
CA2R 17.21 13.80 4267 342 0.265 0.023 39.27 13.01 4040 695 0.279 0.011 35.05 13.96 4332 179 0.281 0.011 
CA2SLM 30.82 13.65 4090 323 0.282 0.009 54.19 3.32 4133 814 0.286 0.001 50.89 10.18 4327 238 0.287 0.008 
CA2sp 29.64 7.17 6851 1715 0.310 0.008 39.26 1.50 5473 785 0.311 0.004 34.48 2.51 5747 670 0.307 0.008 
CA3O 16.20 9.06 4368 307 0.236 0.018 30.57 11.43 4108 620 0.253 0.017 30.44 12.54 4534 329 0.250 0.018 
CA3R 17.15 6.74 4511 339 0.224 0.010 32.34 8.15 4303 630 0.241 0.017 29.94 8.78 4588 63 0.245 0.020 
CA3SLM 22.25 11.56 4106 253 0.249 0.019 43.34 14.47 3966 582 0.265 0.014 42.66 11.25 4267 229 0.268 0.014 
CA3SLU 15.30 7.77 4359 309 0.249 0.015 29.64 7.65 4323 841 0.264 0.017 28.91 7.89 4573 145 0.269 0.022 
CA3sp 12.27 3.46 5945 1234 0.282 0.018 24.14 7.34 4545 545 0.280 0.008 21.82 8.23 5038 111 0.278 0.022 
CC 1.38 0.97 4069 382 0.204 0.053 2.60 1.98 3570 340 0.228 0.020 1.54 1.33 3529 1012 0.199 0.060 
CEA 30.00 8.11 4700 521 0.281 0.007 42.22 4.04 4396 787 0.285 0.007 31.90 12.54 4697 344 0.278 0.016 
cing 5.28 4.07 4220 302 0.237 0.017 15.78 14.54 3749 317 0.247 0.018 7.23 6.26 4124 143 0.234 0.019 
COApl1 45.70 9.30 4885 802 0.281 0.008 48.96 2.97 4778 1061 0.280 0.007 50.89 1.14 5150 336 0.280 0.005 
COApl2 37.12 6.09 4817 654 0.289 0.007 45.46 2.68 4707 914 0.284 0.007 42.12 1.20 5109 507 0.285 0.006 
COApl3 38.20 7.36 4834 2190 0.287 0.009 48.72 3.24 5012 273 0.281 0.009 43.69 1.89 4878 471 0.283 0.007 
CP 35.55 2.16 5341 449 0.261 0.005 38.31 1.74 5280 926 0.260 0.005 35.76 2.09 5343 323 0.257 0.007 
cpd 0.58 0.74 2220 2366 0.132 0.132 N/A N/A N/A N/A N/A N/A 1.08 1.41 3840 314 0.206 0.064 
df 0.24 0.31 2070 2401 0.107 0.124 1.12 0.89 2724 1830 0.179 0.120 0.57 0.71 3336 1034 0.156 0.074 
 206 
DGgrInf 3.91 2.03 6175 1383 0.285 0.015 10.53 8.37 4430 310 0.287 0.005 10.71 7.47 5204 534 0.286 0.019 
DGgrSup 5.28 3.13 6084 1084 0.288 0.017 13.78 9.91 4459 313 0.287 0.005 14.49 9.06 5033 355 0.290 0.020 
DGmolinf 4.54 2.37 4194 294 0.199 0.006 23.49 19.17 3799 461 0.235 0.034 22.36 17.58 4189 120 0.239 0.033 
DGmolsup 8.80 4.13 4195 275 0.216 0.011 30.41 18.33 3882 467 0.247 0.024 32.95 14.18 4194 114 0.257 0.024 
ECT 41.27 1.71 6104 504 0.260 0.008 42.93 2.23 5989 759 0.255 0.003 42.20 1.57 6183 409 0.259 0.008 
ENTI 41.47 2.26 6009 694 0.265 0.006 44.71 3.03 5675 938 0.262 0.004 42.71 1.98 5610 598 0.266 0.009 
EPd 29.32 8.20 4503 460 0.270 0.008 45.67 1.56 4578 829 0.272 0.005 38.41 7.90 4706 362 0.267 0.013 
fi 0.17 0.12 2671 1775 0.101 0.097 0.41 0.41 2201 1740 0.134 0.104 0.22 0.29 1891 1596 0.098 0.098 
Hypothalamus 32.16 16.41 4623 708 0.294 0.013 47.35 2.61 4317 705 0.294 0.007 37.85 8.91 4609 628 0.295 0.007 
int 0.45 0.44 2439 1801 0.146 0.104 1.00 1.07 2642 1790 0.172 0.115 0.59 0.76 2856 1111 0.158 0.072 
LA 36.21 4.34 4614 500 0.278 0.006 43.26 1.70 4954 876 0.275 0.003 39.35 4.06 4949 360 0.275 0.006 
LH 22.45 17.16 4302 376 0.278 0.026 39.32 17.43 3890 636 0.286 0.010 35.55 9.10 4217 305 0.290 0.009 
MEA 36.09 11.14 4682 687 0.289 0.006 49.07 2.37 4634 812 0.287 0.007 40.68 7.21 4762 501 0.287 0.006 
MH 35.51 7.94 4584 523 0.302 0.011 43.73 12.50 4385 860 0.296 0.009 45.93 3.08 4859 397 0.302 0.008 
MOp 41.54 1.68 6470 1325 0.255 0.011 42.41 1.25 7005 1126 0.252 0.006 43.23 0.60 6585 400 0.261 0.011 
MOs 41.33 1.55 6828 1518 0.257 0.010 42.06 1.10 7338 1373 0.253 0.007 42.78 0.97 6845 753 0.263 0.011 
opt 0.09 0.12 1550 2132 0.066 0.092 0.05 0.06 763 881 0.034 0.041 0.08 0.16 934 1868 0.054 0.108 
PAA1 42.46 8.06 4671 527 0.278 0.007 50.64 1.27 4938 500 0.276 0.006 43.21 7.98 4668 511 0.278 0.005 
PAA2 27.29 8.91 4515 489 0.279 0.010 43.91 1.66 4488 668 0.280 0.004 32.41 11.08 4605 470 0.280 0.004 
PAA3 34.59 7.40 4674 596 0.278 0.003 44.61 0.38 4719 725 0.277 0.007 37.93 8.02 4725 343 0.277 0.005 
PERI 41.70 2.66 5912 490 0.263 0.006 44.05 3.15 5968 528 0.257 0.001 42.50 2.00 5865 378 0.263 0.010 
PIR1 38.86 5.82 4895 444 0.267 0.001 47.64 3.45 5466 599 0.262 0.004 43.55 6.28 5139 619 0.268 0.006 
PIR2 27.88 2.81 5262 546 0.281 0.006 41.03 1.43 4806 452 0.278 0.002 29.97 11.50 5044 452 0.276 0.010 
PIR3 36.22 2.20 4687 361 0.270 0.004 43.42 2.31 5097 784 0.265 0.004 38.77 6.07 4984 454 0.266 0.006 
PML 6.55 1.75 4437 312 0.242 0.017 20.46 14.50 3888 447 0.261 0.021 20.61 13.52 4363 54 0.263 0.029 
RSPd 42.14 1.22 6788 1318 0.263 0.011 42.66 0.73 7234 1363 0.258 0.006 43.32 0.41 6796 894 0.269 0.011 
RSPv 42.58 1.10 6239 1061 0.270 0.011 43.70 1.29 6458 1276 0.267 0.004 43.69 2.24 6272 609 0.273 0.010 
SSp-bfd 41.50 1.37 6725 962 0.252 0.010 42.23 1.20 7135 787 0.247 0.004 41.96 1.68 7927 1620 0.249 0.010 
SSp-tr 42.13 1.48 6841 1101 0.252 0.011 42.28 1.53 7110 1138 0.248 0.003 42.77 2.49 7052 447 0.253 0.010 
stn 38.64 3.76 5293 1194 0.294 0.017 N/A N/A N/A N/A N/A N/A 41.85 1.63 5205 1360 0.296 0.004 
stSup 0.14 0.10 1897 1467 0.076 0.055 0.22 0.43 970 1940 0.053 0.105 0.08 0.10 1362 1737 0.048 0.059 
TEa 40.52 1.47 6068 633 0.260 0.008 41.74 0.22 6027 613 0.257 0.005 41.68 1.33 6297 440 0.258 0.008 
Thalamus 16.22 13.72 4135 362 0.278 0.020 25.80 17.23 3615 343 0.280 0.008 17.52 17.42 4093 290 0.279 0.016 
 
Appendix 15 (cont.): Tables of raw numbers from ketamine Arc synaptome maps 
 6H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
 DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
BREGMA -1.70 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
alv 4.46 3.79 4001 42 0.254 0.012 2.50 0.76 4038 28 0.242 0.006 1.11 1.14 3447 1006 0.215 0.060 
AUDd 42.71 1.34 6590 845 0.259 0.008 49.00 0.96 6709 838 0.249 0.010 40.98 0.50 6346 847 0.261 0.012 
AUDp 42.58 1.41 6326 867 0.262 0.008 49.00 1.67 6469 769 0.251 0.008 41.23 0.76 6070 615 0.264 0.013 
AUDv 42.41 1.14 6136 743 0.263 0.007 48.86 1.31 6296 750 0.252 0.007 41.16 0.98 5913 577 0.266 0.012 
BLAa 42.53 3.64 5148 440 0.281 0.013 49.77 3.26 5845 890 0.270 0.008 38.66 4.31 4923 557 0.277 0.009 
BLAp 39.98 0.75 5297 555 0.274 0.008 48.02 2.92 5822 504 0.267 0.005 37.01 2.48 5088 699 0.271 0.010 
BLAv 40.79 3.96 4776 319 0.273 0.008 51.85 3.12 5556 783 0.270 0.010 33.29 9.65 4628 511 0.273 0.008 
BMAp 45.26 5.54 4799 199 0.285 0.012 53.79 1.78 5410 668 0.276 0.008 36.16 9.21 4480 404 0.282 0.005 
CA1O 46.51 3.56 4934 741 0.239 0.003 55.61 2.00 5029 518 0.234 0.009 34.06 8.42 4305 427 0.234 0.008 
CA1R 46.26 1.38 5212 676 0.224 0.002 53.87 2.00 5294 652 0.220 0.007 33.95 6.20 4404 538 0.217 0.006 
CA1SLM 52.84 6.18 4480 478 0.274 0.004 61.94 5.77 4469 373 0.267 0.007 18.00 13.92 3892 136 0.234 0.037 
CA1sp 32.34 4.92 5134 409 0.291 0.006 40.04 2.71 4952 242 0.288 0.011 20.36 6.28 4844 522 0.286 0.019 
CA2O 40.75 7.49 4521 380 0.283 0.007 52.02 6.43 4333 205 0.280 0.010 25.28 10.04 4157 265 0.276 0.007 
CA2R 32.85 10.10 4334 285 0.278 0.006 39.19 11.85 4222 151 0.271 0.012 17.87 10.41 4084 181 0.267 0.021 
CA2SLM 46.62 7.67 4451 495 0.286 0.005 54.53 12.82 4254 305 0.283 0.008 25.40 16.38 3956 155 0.272 0.025 
CA2sp 34.20 4.00 6623 1292 0.307 0.008 44.71 2.75 5820 551 0.308 0.007 28.38 3.73 6098 1432 0.308 0.007 
CA3O 26.52 10.69 4439 356 0.250 0.011 35.75 7.75 4467 221 0.250 0.006 12.81 6.51 4179 240 0.232 0.005 
CA3R 27.76 9.45 4661 438 0.242 0.011 32.51 7.90 4675 403 0.239 0.007 10.94 2.88 4171 89 0.221 0.003 
CA3SLM 40.55 10.17 4399 518 0.270 0.006 45.83 15.76 4241 342 0.263 0.010 18.31 10.50 3985 158 0.255 0.024 
CA3SLU 24.62 8.48 4399 237 0.266 0.009 33.91 6.11 4445 192 0.262 0.006 13.45 6.44 4158 134 0.254 0.003 
CA3sp 21.02 5.23 5665 1139 0.284 0.017 27.87 4.89 5087 155 0.282 0.012 11.77 2.69 5772 1308 0.279 0.028 
CC 2.67 2.24 4047 84 0.241 0.006 1.48 0.95 4059 106 0.223 0.021 1.33 1.16 3998 221 0.232 0.030 
CEA 36.03 4.00 4529 166 0.287 0.008 46.91 8.08 4885 409 0.282 0.005 28.30 10.63 4597 223 0.281 0.008 
cing 10.19 8.99 4184 55 0.249 0.010 6.99 2.92 4287 94 0.235 0.012 2.70 1.73 4096 148 0.241 0.012 
COApl1 41.79 22.97 4860 707 0.275 0.012 62.68 2.34 6009 1139 0.271 0.006 44.89 10.79 4649 613 0.282 0.008 
COApl2 44.75 7.72 4848 358 0.284 0.012 52.72 6.74 5563 932 0.278 0.007 32.60 13.84 4526 347 0.284 0.006 
COApl3 39.68 13.99 4751 488 0.277 0.007 55.35 1.82 5425 908 0.272 0.011 34.64 11.97 4507 472 0.278 0.007 
CP 37.91 2.01 5299 406 0.267 0.005 45.69 2.02 5612 624 0.259 0.006 35.17 3.61 4944 312 0.268 0.009 
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cpd 0.78 0.49 3925 222 0.234 0.034 7.06 7.85 3951 152 0.220 0.024 0.81 0.76 3405 1068 0.209 0.070 
df 0.67 0.22 3900 148 0.217 0.031 0.47 0.40 3097 1736 0.167 0.100 0.25 0.23 2565 2223 0.144 0.126 
DGgrInf 8.39 3.41 5536 1132 0.287 0.017 9.57 4.06 5284 371 0.283 0.007 3.95 2.10 6099 1118 0.292 0.021 
DGgrSup 9.71 3.37 5419 857 0.291 0.015 13.42 5.33 5209 294 0.286 0.009 4.85 2.99 6014 969 0.293 0.020 
DGmolinf 23.63 15.46 4199 263 0.241 0.026 25.81 16.10 4204 127 0.230 0.024 4.19 2.08 4042 255 0.206 0.012 
DGmolsup 29.93 16.62 4185 237 0.253 0.019 34.88 14.16 4225 193 0.244 0.019 6.60 3.42 4041 243 0.219 0.019 
ECT 42.87 1.89 6124 649 0.262 0.005 50.27 2.46 6132 654 0.256 0.004 41.16 1.44 5682 353 0.265 0.008 
ENTI 43.10 2.41 5860 743 0.266 0.005 51.30 0.77 5751 689 0.263 0.003 40.59 1.07 5177 137 0.267 0.008 
EPd 39.58 9.87 4529 154 0.277 0.014 48.66 6.87 4860 439 0.269 0.007 31.60 13.87 4415 199 0.271 0.008 
fi 0.37 0.24 2663 1033 0.153 0.056 0.39 0.47 1980 1986 0.118 0.119 0.16 0.21 1850 2139 0.088 0.109 
Hypothalamus 37.89 8.18 4311 112 0.295 0.010 54.76 1.95 4663 241 0.291 0.008 17.59 16.62 4312 53 0.292 0.005 
int 0.45 0.33 2345 1643 0.140 0.097 1.37 1.21 3856 226 0.179 0.089 0.65 0.60 3239 1186 0.200 0.079 
LA 40.14 5.13 4793 312 0.281 0.010 49.59 3.41 5163 563 0.273 0.006 34.91 6.68 4603 393 0.276 0.006 
LH 31.46 18.18 4257 161 0.280 0.030 54.31 3.51 4262 221 0.295 0.007 20.17 6.19 4111 44 0.292 0.023 
MEA 41.40 10.21 4564 173 0.292 0.010 55.77 1.05 4976 491 0.287 0.008 32.66 14.02 4428 224 0.289 0.007 
MH 44.09 5.83 5495 943 0.305 0.008 56.02 4.84 4743 462 0.304 0.007 33.43 5.96 4772 563 0.307 0.022 
MOp 43.04 1.67 6597 776 0.257 0.008 49.92 2.08 6801 766 0.248 0.007 41.58 0.62 5945 980 0.267 0.013 
MOs 42.93 1.55 7102 910 0.257 0.008 49.44 2.22 7191 951 0.249 0.008 41.16 0.88 6277 972 0.270 0.013 
opt 0.04 0.10 711 1589 0.027 0.060 0.08 0.12 1104 1655 0.051 0.079 0.11 0.12 1838 2122 0.097 0.112 
PAA1 39.36 17.03 4597 630 0.281 0.015 55.95 7.19 5456 1228 0.273 0.006 38.39 16.70 4696 700 0.278 0.008 
PAA2 28.61 12.16 4508 408 0.284 0.007 41.67 10.32 5137 1067 0.278 0.007 26.37 15.08 4717 274 0.280 0.009 
PAA3 38.63 15.06 4460 361 0.284 0.013 51.12 3.00 5267 876 0.273 0.008 29.67 13.51 4463 462 0.271 0.004 
PERI 43.41 1.99 5937 547 0.266 0.005 50.96 1.82 5982 631 0.259 0.005 41.31 1.08 5382 278 0.266 0.010 
PIR1 42.00 11.84 5097 865 0.271 0.010 54.80 2.07 5757 1193 0.261 0.003 42.36 7.47 5153 817 0.271 0.012 
PIR2 33.01 10.65 5116 373 0.283 0.009 42.07 5.55 5375 756 0.273 0.006 29.40 11.99 5122 58 0.282 0.009 
PIR3 37.98 10.97 4755 545 0.275 0.014 48.91 2.34 5480 801 0.261 0.004 33.68 9.03 4778 616 0.265 0.005 
PML 21.39 10.32 4323 143 0.264 0.015 21.17 12.55 4372 210 0.252 0.013 7.27 3.20 4207 207 0.242 0.019 
RSPd 43.51 1.55 7164 1049 0.263 0.008 50.07 2.49 7067 986 0.255 0.007 41.45 0.72 6229 802 0.275 0.011 
RSPv 44.44 1.80 6530 833 0.270 0.008 51.66 0.98 6357 815 0.264 0.008 41.52 1.19 5763 726 0.281 0.008 
SSp-bfd 42.47 1.28 6786 585 0.255 0.006 49.60 1.51 7273 966 0.245 0.011 41.77 0.65 6461 984 0.260 0.010 
SSp-tr 43.19 1.53 6916 903 0.253 0.008 50.20 1.86 7291 787 0.241 0.009 N/A N/A N/A N/A N/A N/A 
stn 38.82 1.41 5427 597 0.297 0.009 54.70 2.94 5952 524 0.295 0.008 37.32 3.34 5044 437 0.301 0.013 
stSup 0.27 0.27 2778 1858 0.109 0.103 0.26 0.26 2489 2159 0.088 0.107 0.29 0.31 2492 1180 0.117 0.092 
TEa 42.68 1.43 6102 640 0.262 0.006 49.11 1.21 6243 790 0.253 0.006 40.84 1.68 5817 668 0.266 0.009 
 
Thalamus 15.55 12.73 4077 181 0.272 0.029 39.63 17.16 4192 217 0.284 0.008 15.93 5.52 4107 44 0.289 0.018 
 
Appendix 15 (cont.): Tables of raw numbers from ketamine Arc synaptome maps 
 24H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
BREGMA DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
-1.70 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
alv 1.30 0.77 3790 331 0.231 0.031 9.25 9.18 3680 264 0.261 0.014 0.54 0.47 3130 1303 0.154 0.077 
AUDd 41.59 1.53 6522 577 0.259 0.009 41.90 1.86 7272 702 0.250 0.009 42.06 0.67 7377 1057 0.247 0.005 
AUDp 41.33 2.32 6259 587 0.255 0.014 42.08 1.99 6883 841 0.254 0.007 42.09 0.44 6956 771 0.249 0.004 
AUDv 41.20 1.89 5991 613 0.257 0.013 41.85 2.06 6648 886 0.256 0.007 42.17 0.46 6630 653 0.251 0.005 
BLAa 40.25 3.78 5217 956 0.273 0.008 42.23 2.54 5880 509 0.272 0.007 38.71 4.46 5335 984 0.265 0.010 
BLAp 39.09 2.28 5401 921 0.268 0.009 39.79 0.99 6099 580 0.266 0.004 39.74 2.88 6012 1268 0.267 0.005 
BLAv 39.37 5.81 4780 794 0.270 0.007 42.94 2.01 5699 736 0.265 0.005 38.84 6.47 5301 1236 0.264 0.012 
BMAp 38.79 8.43 4826 950 0.275 0.010 45.09 2.21 5406 513 0.278 0.013 38.34 10.73 5067 1091 0.270 0.012 
CA1O 45.33 6.08 3872 1211 0.242 0.015 48.51 1.80 5340 931 0.236 0.012 39.29 7.23 4729 429 0.222 0.016 
CA1R 44.31 2.51 3947 1228 0.229 0.009 46.97 1.66 5533 899 0.220 0.010 41.44 3.72 4903 421 0.213 0.009 
CA1SLM 47.62 13.10 3514 1032 0.270 0.022 51.46 13.07 4558 869 0.263 0.023 25.62 12.46 4189 314 0.234 0.025 
CA1sp 24.01 7.27 5073 814 0.295 0.016 34.62 7.04 5409 937 0.291 0.009 19.38 6.65 4953 171 0.275 0.009 
CA2O 34.40 13.29 4033 448 0.284 0.010 48.44 5.00 4612 873 0.282 0.008 22.09 12.79 4332 424 0.272 0.013 
CA2R 22.79 12.67 3940 317 0.275 0.023 40.59 13.91 4472 905 0.277 0.018 9.72 4.77 4394 284 0.248 0.018 
CA2SLM 34.57 26.23 3909 581 0.284 0.016 48.71 16.82 4435 1155 0.284 0.013 15.71 7.86 4085 338 0.266 0.012 
CA2sp 29.14 5.88 7471 2966 0.315 0.008 34.27 6.25 7409 2529 0.309 0.004 29.50 4.59 5256 394 0.304 0.010 
CA3O 20.50 7.00 4069 344 0.246 0.020 35.73 8.52 4361 500 0.252 0.016 14.23 9.45 4570 383 0.218 0.023 
CA3R 18.87 5.88 4182 445 0.232 0.017 34.93 9.55 4635 625 0.242 0.021 14.26 4.43 4740 398 0.210 0.010 
CA3SLM 28.52 16.40 3888 373 0.261 0.024 45.62 17.79 4338 989 0.264 0.028 11.15 4.18 4264 308 0.225 0.012 
CA3SLU 15.99 7.28 4010 380 0.254 0.027 33.36 9.59 4506 630 0.261 0.019 10.99 5.52 4484 365 0.231 0.006 
CA3sp 14.08 7.09 6179 1561 0.297 0.021 26.50 8.13 5517 998 0.283 0.013 10.07 3.28 5605 389 0.273 0.019 
CC 1.68 1.29 3889 311 0.235 0.024 3.96 0.47 3697 268 0.247 0.010 0.54 0.34 4201 297 0.192 0.024 
CEA 31.95 9.38 4614 504 0.278 0.015 41.98 3.24 5040 484 0.284 0.009 32.74 9.43 4982 368 0.273 0.005 
cing 7.34 6.87 3584 1028 0.247 0.017 20.63 5.81 3800 258 0.261 0.007 3.14 1.59 4489 274 0.224 0.015 
COApl1 50.78 3.80 5052 1155 0.274 0.002 52.89 2.98 5815 811 0.274 0.014 48.05 6.73 5657 1916 0.269 0.008 
COApl2 42.13 3.14 5044 1107 0.278 0.004 45.91 2.66 5503 626 0.279 0.013 38.52 8.89 5411 1562 0.270 0.004 
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COApl3 43.06 3.49 4848 892 0.277 0.007 45.86 2.41 5682 469 0.271 0.005 38.24 8.52 5612 1856 0.268 0.007 
CP 36.30 2.42 5065 558 0.263 0.017 38.54 1.57 5871 544 0.260 0.006 34.52 3.15 5442 749 0.249 0.010 
cpd 0.89 0.55 2795 1880 0.208 0.116 2.19 0.36 3636 53 0.257 0.011 0.28 0.30 2124 2346 0.131 0.121 
df 0.61 0.51 2943 1296 0.169 0.098 1.54 0.43 3616 286 0.236 0.018 0.10 0.10 1194 1772 0.044 0.044 
DGgrInf 7.65 4.73 4790 1987 0.298 0.008 15.92 10.29 4956 702 0.292 0.018 3.20 0.92 5822 402 0.282 0.011 
DGgrSup 8.88 5.17 4963 2068 0.304 0.009 19.21 10.59 5060 805 0.291 0.020 3.23 1.20 5713 444 0.287 0.014 
DGmolinf 11.49 8.94 3303 1085 0.226 0.029 29.71 17.36 3996 599 0.242 0.028 8.45 5.97 4413 318 0.207 0.022 
DGmolsup 16.46 8.09 3480 1027 0.238 0.023 37.64 16.96 4137 771 0.252 0.030 8.85 4.60 4416 296 0.208 0.010 
ECT 41.04 1.81 5949 684 0.257 0.013 42.15 1.87 6371 739 0.257 0.007 41.79 0.81 6323 1104 0.253 0.006 
ENTI 42.13 2.14 5514 569 0.262 0.012 43.66 1.86 6129 788 0.263 0.007 42.96 1.81 5552 1092 0.259 0.004 
EPd 36.22 11.13 4618 751 0.267 0.018 44.80 2.50 5027 402 0.272 0.007 36.44 10.54 4904 773 0.259 0.016 
fi 0.43 0.42 2886 1930 0.162 0.119 0.89 0.40 3525 280 0.237 0.020 0.05 0.06 961 1115 0.026 0.030 
Hypothalamus 41.16 6.03 4108 1853 0.295 0.003 44.25 4.22 4642 209 0.293 0.008 23.55 15.21 4554 488 0.280 0.014 
int 0.65 0.77 2874 1921 0.160 0.112 2.11 0.71 3571 291 0.250 0.020 0.13 0.18 1998 2194 0.069 0.095 
LA 36.85 6.64 4828 917 0.273 0.015 42.67 2.77 5358 500 0.274 0.005 38.52 7.45 5240 920 0.269 0.007 
LH 29.70 13.33 3627 1420 0.289 0.015 46.42 5.09 4191 706 0.291 0.007 12.65 9.45 4318 302 0.265 0.012 
MEA 35.58 12.54 4614 762 0.283 0.009 46.22 3.01 5003 402 0.289 0.008 32.22 11.20 4838 750 0.277 0.013 
MH 43.25 3.62 4354 2070 0.308 0.006 47.29 3.76 5334 892 0.303 0.008 33.03 7.63 4813 935 0.293 0.013 
MOp 42.39 2.13 5851 1903 0.256 0.014 42.99 1.31 7302 582 0.253 0.008 42.51 2.10 6595 706 0.250 0.007 
MOs 42.13 2.68 6372 2241 0.257 0.012 42.50 1.72 7629 838 0.255 0.006 41.74 2.00 6827 747 0.253 0.008 
opt 0.04 0.10 382 855 0.026 0.059 0.24 0.14 2614 869 0.169 0.092 0.00 0.00 N/A N/A N/A N/A 
PAA1 48.15 3.59 5591 1127 0.275 0.005 49.08 2.19 5376 1118 0.278 0.018 46.56 1.38 5695 1649 0.265 0.010 
PAA2 33.49 9.83 5057 1549 0.277 0.011 41.72 4.42 5111 803 0.282 0.011 35.79 9.66 5268 1271 0.270 0.006 
PAA3 40.54 3.13 4779 974 0.272 0.006 43.26 1.99 5396 754 0.274 0.015 41.04 3.61 5433 1279 0.266 0.005 
PERI 41.93 1.57 5542 659 0.261 0.012 43.12 2.05 6279 721 0.260 0.007 43.20 1.42 6245 1007 0.258 0.006 
PIR1 45.82 2.85 4982 676 0.263 0.012 47.43 2.42 5755 630 0.267 0.011 44.90 4.39 6037 1615 0.257 0.007 
PIR2 32.74 3.81 5189 1134 0.275 0.014 40.05 3.22 5413 402 0.280 0.010 36.57 7.23 5730 1329 0.271 0.006 
PIR3 40.68 3.13 4815 646 0.263 0.010 43.58 1.92 5625 614 0.265 0.010 40.83 3.09 5615 1303 0.259 0.008 
PML 7.03 3.60 3454 1201 0.251 0.017 25.78 13.23 4143 592 0.262 0.025 5.49 2.01 4491 318 0.227 0.008 
RSPd 42.45 2.32 6450 2199 0.261 0.011 42.44 2.03 7727 1037 0.259 0.007 42.53 1.97 6649 736 0.260 0.007 
RSPv 43.17 2.18 5629 1878 0.271 0.009 43.54 1.94 7247 1106 0.267 0.007 42.84 2.49 5854 829 0.267 0.006 
SSp-bfd 42.53 1.37 6892 331 0.258 0.010 42.41 2.06 7747 925 0.248 0.010 42.11 1.61 7377 1277 0.243 0.008 
SSp-tr 42.52 1.76 6856 210 0.251 0.017 42.82 1.34 7605 523 0.246 0.009 42.99 2.24 7173 1033 0.243 0.009 
stn 39.15 4.67 4524 1562 0.297 0.002 41.17 4.12 5672 210 0.289 0.006 36.71 6.80 4749 549 0.290 0.004 
stSup 0.36 0.12 3783 145 0.196 0.057 0.73 0.55 3082 1008 0.192 0.070 0.07 0.12 1227 2126 0.060 0.105 
TEa 41.14 1.99 5928 639 0.258 0.012 41.98 1.97 6433 877 0.257 0.008 41.63 0.51 6396 885 0.253 0.006 
Thalamus 14.30 11.44 3459 1296 0.281 0.012 33.22 11.98 3967 774 0.284 0.012 5.41 6.35 4275 373 0.263 0.005 
 
Appendix 16: Tables of raw numbers from ketamine PSD95 synaptome mapping  
 
 24H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
BREGMA DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
2.10 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
ACAd 107.19 9.99 14462 170 0.083 0.001 101.95 7.35 13619 1962 0.084 0.002 101.41 4.69 13616 1976 0.084 0.002 
aco 9.50 1.94 9170 19 0.088 0.000 7.33 2.58 8653 924 0.089 0.002 6.24 2.04 8745 757 0.090 0.000 
Ald 107.32 1.97 15312 814 0.083 0.001 97.59 4.51 13659 1669 0.083 0.002 103.28 4.23 15165 907 0.083 0.001 
Alv 100.60 1.15 15167 615 0.084 0.001 91.63 3.13 13407 1865 0.084 0.001 93.72 4.73 14497 905 0.084 0.001 
AONm 96.96 3.24 9594 172 0.078 0.000 91.81 10.48 8992 1480 0.079 0.002 88.36 2.03 8817 327 0.080 0.001 
AONpv 87.24 6.91 10917 607 0.083 0.001 84.72 3.97 10542 995 0.082 0.001 67.33 10.82 9732 466 0.086 0.001 
CTX1 124.39 3.88 16791 570 0.084 0.001 116.25 8.07 16078 1773 0.084 0.001 120.76 10.68 16894 1884 0.084 0.001 
CTX5 91.08 4.33 13742 205 0.083 0.001 88.80 3.65 12884 1989 0.084 0.001 89.64 1.93 13139 1640 0.084 0.001 
CTX6a 82.90 5.32 11419 355 0.083 0.000 82.03 3.80 11038 1844 0.083 0.002 82.04 5.02 11011 1593 0.084 0.002 
DP 96.18 9.32 13592 927 0.083 0.001 96.91 7.56 12845 2423 0.084 0.001 92.60 4.35 12829 862 0.085 0.002 
EPd 61.42 7.19 9733 293 0.086 0.001 58.47 7.76 9618 699 0.085 0.001 54.73 5.57 8982 614 0.087 0.001 
ILA 96.72 5.79 12710 128 0.081 0.000 97.05 4.19 12022 1969 0.082 0.001 92.99 3.08 11702 1596 0.083 0.002 
lot 1.12 0.06 8322 296 0.091 0.001 0.89 0.33 7961 1057 0.089 0.001 0.76 0.29 7779 572 0.088 0.005 
MOp 98.94 3.47 15481 643 0.084 0.000 95.98 6.19 14696 1893 0.084 0.001 98.75 3.26 15182 1217 0.084 0.001 
MOs 103.52 9.44 15141 1298 0.084 0.001 102.05 8.95 14600 2135 0.084 0.001 102.43 9.36 14652 2518 0.085 0.002 
ORBl 95.70 6.12 15004 144 0.084 0.001 92.37 2.90 13694 2015 0.084 0.001 90.60 4.38 13935 961 0.085 0.001 
ORBm 103.54 7.59 13193 437 0.081 0.001 100.24 5.50 12361 1838 0.082 0.002 98.78 5.65 12291 2056 0.083 0.003 
ORBvl 95.28 8.88 13934 261 0.082 0.000 95.09 6.35 12948 2237 0.083 0.002 91.99 3.30 12992 1173 0.084 0.001 
OT N/A N/A N/A N/A N/A N/A 66.61 12.82 10723 700 0.085 0.002 61.67 11.61 9917 698 0.085 0.001 
PIR1 89.66 2.17 11973 291 0.084 0.001 84.23 5.64 10992 1632 0.084 0.002 84.54 1.98 11281 136 0.084 0.000 
PIR2 75.84 7.33 10986 50 0.084 0.000 70.58 8.53 10187 1419 0.084 0.001 68.19 2.41 10549 362 0.085 0.000 
PIR3 73.82 2.33 10327 461 0.086 0.000 69.83 7.87 10083 827 0.085 0.001 66.68 3.73 9747 497 0.087 0.001 
PL 106.91 7.14 13836 406 0.082 0.000 102.53 6.93 13035 1873 0.083 0.002 101.48 4.55 13193 2218 0.084 0.003 
SEZ 25.41 2.72 8838 262 0.083 0.001 20.57 9.24 8253 907 0.083 0.002 21.84 0.94 8053 460 0.084 0.001 
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TTd1 109.23 5.38 12749 180 0.081 0.001 104.70 10.20 11540 2214 0.082 0.002 102.78 8.18 12324 1079 0.082 0.001 
TTd2 89.30 5.16 11212 382 0.081 0.000 83.64 9.77 10250 1872 0.082 0.002 87.50 8.12 10946 747 0.083 0.001 
TTd3 95.41 0.47 11011 418 0.081 0.001 92.77 5.91 10040 1749 0.081 0.002 89.60 2.03 10328 476 0.083 0.001 
TTv1 96.07 5.21 11417 582 0.082 0.001 91.67 11.68 10396 1599 0.082 0.002 97.12 3.19 11526 684 0.081 0.001 
TTv2 72.99 9.73 9917 245 0.083 0.001 64.71 11.62 9094 1101 0.083 0.002 74.43 11.90 10343 1194 0.083 0.002 
TTv3 96.16 3.70 10984 32 0.081 0.000 91.28 4.77 9807 1389 0.082 0.002 93.16 6.42 10331 764 0.081 0.002 
 
 
 24H POST-ADMINISTRATION  
 SALINE CONTROL LOW DOSE KETAMINE (10mg/kg) HIGH DOSE KETAMINE (100mg/kg) 
BREGMA DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  DENSITY  INTENSITY  SIZE  
-1.70 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
alv 1.41 1.35 6002 763 0.094 0.003 2.50 1.49 7036 580 0.093 0.002 1.55 1.16 6472 1783 0.088 0.009 
AUDd 89.97 4.44 14659 1674 0.090 0.001 94.90 9.27 16308 2788 0.087 0.002 95.73 6.62 18309 3275 0.088 0.003 
AUDp 93.66 4.84 15442 1316 0.089 0.001 97.37 7.76 16707 2370 0.087 0.002 N/A N/A N/A N/A N/A N/A 
AUDv 95.97 7.46 15580 1099 0.089 0.001 98.87 9.01 16364 2285 0.087 0.002 N/A N/A N/A N/A N/A N/A 
BLAa 88.91 2.43 13898 2004 0.090 0.003 93.71 7.03 14224 1556 0.087 0.003 92.74 3.14 14502 282 0.088 0.002 
BMAp 75.56 4.66 11355 1875 0.089 0.002 82.33 11.83 12330 2292 0.087 0.002 86.79 7.86 12468 81 0.087 0.001 
CA1O 109.79 52.29 12805 2284 0.086 0.003 121.00 50.16 14081 3097 0.085 0.003 132.42 23.80 14582 3264 0.086 0.007 
CA1R 136.21 11.34 15514 849 0.087 0.002 142.04 14.02 16376 1733 0.085 0.004 131.45 23.71 16011 3509 0.088 0.006 
CA1SLM 113.86 22.31 12314 3791 0.088 0.001 118.21 20.27 13702 2827 0.086 0.003 96.03 17.85 11169 3106 0.090 0.006 
CA1sp 49.55 43.58 9083 1826 0.090 0.002 50.44 41.29 10295 2239 0.088 0.003 25.54 16.11 9309 3143 0.091 0.005 
CA2O 90.30 51.76 8049 1367 0.086 0.008 107.41 26.33 9837 1474 0.083 0.004 106.79 18.02 9295 2119 0.085 0.005 
CA2R 106.92 16.29 8615 958 0.085 0.002 111.60 8.31 9445 835 0.083 0.001 94.67 18.95 8769 2112 0.087 0.006 
CA2SLM 109.02 12.91 8598 1031 0.085 0.002 113.13 5.68 9479 740 0.083 0.002 96.47 18.31 8185 1767 0.086 0.006 
CA2sp 34.09 50.88 6718 1457 0.098 0.010 25.15 25.27 7051 635 0.097 0.006 7.61 4.70 6405 936 0.105 0.002 
CA3O 76.22 25.70 8571 825 0.094 0.008 85.33 30.41 9391 670 0.091 0.008 76.67 22.36 8403 1546 0.092 0.007 
CA3R 97.82 6.36 9334 556 0.092 0.002 104.76 7.89 10001 1009 0.089 0.002 91.24 23.19 9667 1875 0.093 0.007 
CA3SLM 111.43 8.81 8867 1429 0.088 0.004 119.11 9.52 9569 953 0.085 0.002 99.99 24.14 8326 1481 0.088 0.007 
CA3SLU 71.61 32.12 10223 662 0.100 0.009 73.10 28.67 11242 1707 0.098 0.009 53.66 9.85 10883 2718 0.106 0.005 
CA3sp 36.44 19.33 8836 1544 0.107 0.003 37.04 18.28 9583 1735 0.104 0.003 24.47 9.31 8692 2439 0.108 0.006 
CC 0.65 0.09 6650 764 0.089 0.001 0.97 0.39 7906 1108 0.088 0.001 0.49 0.41 6366 2138 0.080 0.015 
CEA 66.16 8.06 10478 924 0.089 0.001 69.34 11.82 10921 1212 0.087 0.002 69.49 13.40 11007 1638 0.088 0.003 
cing 6.39 1.75 7256 1044 0.093 0.003 8.67 2.32 8686 1216 0.091 0.001 4.00 3.56 5911 4587 0.071 0.047 
COApl1 82.04 5.95 13404 2412 0.087 0.001 82.21 8.47 12302 2147 0.087 0.002 86.65 6.91 12659 2123 0.087 0.001 
COApl2 72.30 3.92 11825 2107 0.090 0.001 75.18 8.65 11716 1778 0.088 0.002 82.90 5.62 11927 1487 0.088 0.002 
CP 82.07 5.03 12404 802 0.089 0.001 83.28 6.59 13407 1918 0.087 0.002 80.50 3.34 12385 2088 0.088 0.003 
df 0.00 0.00 N/A N/A N/A N/A 0.01 0.02 230 514 0.002 0.006 0.05 0.11 1175 2349 0.019 0.039 
DGgrInf 6.83 2.85 6273 167 0.094 0.002 9.29 3.63 6906 676 0.094 0.001 7.35 7.31 6641 1477 0.095 0.003 
DGgrSup 7.96 2.82 6347 150 0.095 0.001 11.50 5.44 6966 566 0.094 0.002 7.68 6.37 6449 1356 0.095 0.004 
DGmolinf 128.95 8.22 11664 1060 0.086 0.002 133.78 15.34 12306 1691 0.084 0.004 121.09 24.43 11799 2691 0.088 0.007 
DGmolsup 129.58 5.93 12215 1099 0.087 0.002 134.45 16.65 12835 1670 0.085 0.004 123.95 27.62 12025 2728 0.088 0.007 
ECT 103.83 5.55 16523 1264 0.086 0.001 100.55 2.27 15706 1678 0.085 0.002 N/A N/A N/A N/A N/A N/A 
ENTI 103.16 7.44 16104 1728 0.085 0.002 99.40 4.67 15091 1529 0.085 0.002 100.89 3.63 15152 2809 0.086 0.003 
EPd 86.15 4.61 11244 1110 0.085 0.001 89.52 6.18 12106 1673 0.083 0.002 82.25 8.03 10861 1997 0.085 0.003 
FC 65.80 15.08 6345 389 0.084 0.001 74.23 8.46 6868 236 0.083 0.002 45.59 30.05 6758 2209 0.085 0.005 
fi 0.00 0.00 N/A N/A N/A N/A 0.00 0.00 N/A N/A N/A N/A 0.00 0.00 N/A N/A N/A N/A 
GPe 7.43 1.31 7119 318 0.103 0.002 9.74 1.88 7826 708 0.102 0.001 7.34 2.66 7319 1216 0.105 0.002 
GPi 4.70 1.62 7006 717 0.098 0.001 5.01 1.29 7101 450 0.098 0.001 3.03 3.27 6360 1340 0.098 0.005 
Hypothalamus 22.82 1.20 8861 1847 0.099 0.001 25.09 2.08 9008 1047 0.097 0.001 22.92 1.32 8516 1172 0.099 0.001 
int 0.08 0.10 1824 2322 0.029 0.037 0.06 0.10 1480 2263 0.019 0.029 0.03 0.05 654 1307 0.011 0.021 
LA 92.99 5.67 15191 1425 0.090 0.001 92.68 7.61 15679 1894 0.087 0.002 90.90 4.49 14850 1133 0.088 0.003 
LH 13.26 2.55 7557 438 0.096 0.002 13.70 2.61 7911 756 0.095 0.001 8.43 6.29 7580 1940 0.097 0.003 
MEA 64.93 4.23 10724 1201 0.091 0.001 68.50 7.13 10712 1083 0.089 0.002 66.83 5.64 10582 854 0.090 0.001 
MH 12.68 3.77 7304 566 0.089 0.002 15.11 2.37 8003 988 0.087 0.001 9.03 5.68 7169 2196 0.088 0.003 
MOp 86.75 2.58 14132 675 0.090 0.001 94.15 7.47 17554 3091 0.087 0.002 91.08 5.57 15633 4645 0.089 0.003 
MOs 75.89 2.33 13485 682 0.093 0.001 78.53 2.14 17015 3224 0.090 0.001 76.77 2.19 14940 5091 0.092 0.002 
opt 0.00 0.00 N/A N/A N/A N/A 0.00 0.00 N/A N/A N/A N/A 0.00 0.00 N/A N/A N/A N/A 
PAA1 82.63 9.66 11966 670 0.087 0.001 92.48 14.89 12979 2028 0.086 0.003 88.70 7.83 12503 1464 0.086 0.002 
PAA2 81.15 4.68 12718 2504 0.088 0.002 83.48 7.90 12135 2226 0.087 0.003 84.61 2.79 12226 2234 0.086 0.001 
PAA3 81.57 11.08 13086 2751 0.088 0.002 88.45 12.19 13113 2263 0.087 0.002 91.59 6.86 12944 483 0.086 0.001 
PERI 105.67 4.82 16554 1341 0.086 0.001 101.51 3.27 15529 1510 0.085 0.002 106.91 7.59 15969 2875 0.086 0.003 
PIR1 97.83 5.28 14630 819 0.085 0.001 96.21 6.72 13500 1883 0.085 0.002 95.55 1.00 12970 1798 0.087 0.001 
PIR2 66.01 1.58 11920 1272 0.087 0.000 65.11 7.72 10941 1596 0.086 0.001 68.70 2.50 10840 1158 0.087 0.001 
PIR3 96.83 10.37 14505 2253 0.086 0.001 98.89 8.35 14182 1989 0.085 0.002 94.24 2.36 13086 1818 0.087 0.002 
PML 49.46 7.83 8523 415 0.103 0.001 52.05 7.88 9141 926 0.102 0.004 44.62 12.47 8603 1945 0.106 0.007 
RSPd 74.22 3.47 12864 523 0.093 0.001 74.45 1.27 15337 2991 0.091 0.002 74.83 2.97 14577 5105 0.092 0.002 
RSPv 64.73 4.09 10939 910 0.093 0.001 65.59 2.19 12629 2591 0.091 0.002 63.40 9.06 12117 5017 0.092 0.003 
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SI 18.14 4.11 8064 1009 0.099 0.001 16.20 1.98 8233 643 0.098 0.002 9.93 7.94 8139 1288 0.098 0.004 
SSp-bfd 88.45 5.59 14259 1934 0.089 0.002 91.34 6.79 17131 3287 0.087 0.001 90.59 2.63 15427 2947 0.089 0.003 
SSp-tr 96.56 4.52 15303 949 0.088 0.001 102.77 6.11 18784 3166 0.085 0.002 99.21 2.95 16252 3231 0.088 0.002 
stSup 0.07 0.06 1660 1449 0.026 0.023 0.14 0.05 3398 1575 0.048 0.024 0.04 0.06 785 1360 0.013 0.022 
TEa 99.29 6.53 16199 987 0.087 0.001 101.74 4.52 16256 1955 0.086 0.002 N/A N/A N/A N/A N/A N/A 
Thalamus 60.55 3.25 8021 652 0.084 0.001 65.94 4.62 8554 654 0.082 0.001 46.75 21.44 7663 2423 0.086 0.005 
 




Appendix.figure 8 – Example plots of individual data points underlying different Cohen’s d 
effect size values. Data points = individual mice, line = mean, error bars = SD. A. Cohen’s d = 
0, p = 0.903, data from the thalamus at 1h post-administration. B. Cohen’s d = +2.5, p = 0.008, 
data from DGmolsup at 1h post-administration. C. Cohen’s d = -3.5, p = 0.001, data from 
CA1slm 6h post-administration. D. Cohen’s d = +5, p < 0.0001, data from RSPv at 6h post-
administration. E. Cohen’s d +6.8, p < 0.0001, data from stn at 6h post-administration.  
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